Document:

EX-10.1

 Exhibit 10.1 

SHARE PURCHASE AGREEMENT 

BY AND AMONG 

HYPERION THERAPEUTICS, INC., 

HYPERION THERAPEUTICS ISRAEL HOLDING CORP. LTD.

 ANDROMEDA BIOTECH LTD., 

AND 

CLAL BIOTECHNOLOGY INDUSTRIES LTD. 

April 23, 2014 
 [*] Certain
information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
		
	ARTICLE 1 THE SHARE PURCHASE	  	 	1	  
			
	 1.1
	  	 Closing
	  	 	1	  
	 1.2
	  	 Closing Deliveries.
	  	 	2	  
	 1.3
	  	 The Share Purchase
	  	 	4	  
	 1.4
	  	 Payment and Exchange Procedures
	  	 	5	  
	 1.5
	  	 No Further Ownership Rights in the Company Ordinary Shares
	  	 	6	  
	 1.6
	  	 Lost, Stolen or Destroyed Certificates
	  	 	6	  
	 1.7
	  	 Tax Consequences
	  	 	7	  
	 1.8
	  	 Certain Taxes
	  	 	7	  
	 1.9
	  	 Withholding Rights
	  	 	7	  
	 1.10
	  	 Taking of Necessary Action; Further Action
	  	 	8	  
	 1.11
	  	 Contingent Payments
	  	 	8	  
	 1.12
	  	 Payment of Contingent Payments.
	  	 	14	  
		
	ARTICLE 2 REPRESENTATIONS AND WARRANTIES OF THE COMPANY	  	 	18	  
			
	 2.1
	  	 Organization, Standing, Power and Subsidiaries
	  	 	18	  
	 2.2
	  	 Capital Structure
	  	 	18	  
	 2.3
	  	 Authority; Noncontravention
	  	 	21	  
	 2.4
	  	 Financial Statements
	  	 	21	  
	 2.5
	  	 Absence of Certain Changes
	  	 	23	  
	 2.6
	  	 Litigation
	  	 	24	  
	 2.7
	  	 Restrictions on Business Activities
	  	 	25	  
	 2.8
	  	 Compliance with Laws; Governmental Permits
	  	 	25	  
	 2.9
	  	 Title to, Condition and Sufficiency of Assets
	  	 	25	  
	 2.10
	  	 Intellectual Property Rights
	  	 	26	  
	 2.11
	  	 Confidentiality Agreements
	  	 	30	  
	 2.12
	  	 Environmental Matters
	  	 	30	  
	 2.13
	  	 Taxes
	  	 	31	  
	 2.14
	  	 Employee Benefit Plans and Employee Matters
	  	 	34	  
	 2.15
	  	 Interested Party Transactions
	  	 	35	  
	 2.16
	  	 Insurance
	  	 	35	  
	 2.17
	  	 Books and Records
	  	 	35	  
	 2.18
	  	 Material Contracts
	  	 	36	  
	 2.19
	  	 Certain Regulatory Matters
	  	 	37	  
	 2.20
	  	 Accounts Receivable and Payable
	  	 	39	  
	 2.21
	  	 Inventory
	  	 	39	  
	 2.22
	  	 Transaction Fees
	  	 	39	  
	 2.23
	  	 Data Protection and Privacy
	  	 	40	  
	 2.24
	  	 Anti-Corruption
	  	 	40	  
	 2.25
	  	 Representations Complete
	  	 	40	  
		
	ARTICLE 3 REPRESENTATIONS AND WARRANTIES OF THE COMPANY SHAREHOLDER	  	 	40	  
			
	 3.1
	  	 Power and Capacity
	  	 	40	  
	 3.2
	  	 Enforceability; Non-contravention
	  	 	40	  
	 3.3
	  	 Title to Shares
	  	 	41	  
	 3.4
	  	 Litigation
	  	 	41	  

  
 i 

							
	 3.5
	 	 Solvency
	  	 	41	  
	 3.6
	 	 Tax Withholding Information
	  	 	41	  
		
	ARTICLE 4 REPRESENTATIONS AND WARRANTIES OF PARENT AND PURCHASER	  	 	41	  
			
	 4.1
	 	 Organization and Standing
	  	 	41	  
	 4.2
	 	 Authority; Noncontravention
	  	 	42	  
	 4.3
	 	 Capitalization
	  	 	42	  
	 4.4
	 	 Litigation
	  	 	43	  
	 4.5
	 	 No Israeli Presence
	  	 	43	  
	 4.6
	 	 SEC Filings and Financial Statements
	  	 	43	  
	 4.7
	 	 Solvency
	  	 	43	  
	 4.8
	 	 Issuance of Shares
	  	 	43	  
	 4.9
	 	 Financing
	  	 	43	  
		
	ARTICLE 5 CONDUCT PRIOR TO THE CLOSING	  	 	44	  
			
	 5.1
	 	 Conduct of Business of the Company
	  	 	44	  
	 5.2
	 	 Restrictions on Conduct of Business of the Company
	  	 	44	  
		
	ARTICLE 6 ADDITIONAL AGREEMENTS	  	 	47	  
			
	 6.1
	 	 No Solicitation
	  	 	47	  
	 6.2
	 	 Confidentiality; Public Disclosure
	  	 	49	  
	 6.3
	 	 Regulatory Approvals
	  	 	49	  
	 6.4
	 	 Reasonable Efforts
	  	 	50	  
	 6.5
	 	 Third Party Consents; Notices
	  	 	51	  
	 6.6
	 	 Litigation
	  	 	51	  
	 6.7
	 	 Access to Information
	  	 	51	  
	 6.8
	 	 Spreadsheet
	  	 	52	  
	 6.9
	 	 Expenses
	  	 	52	  
	 6.10
	 	 Certain Closing Certificates and Documents
	  	 	52	  
	 6.11
	 	 Corporate Matters
	  	 	52	  
	 6.12
	 	 Tax Matters
	  	 	53	  
	 6.13
	 	 Termination and Release
	  	 	53	  
	 6.14
	 	 Investment Representation Letter and Lock-up Agreement
	  	 	53	  
	 6.15
	 	 Additional Company Shareholders
	  	 	53	  
	 6.16
	 	 Repurchase
	  	 	53	  
	 6.17
	 	 CBI Loan Amendment
	  	 	53	  
	 6.18
	 	 Financial Reporting
	  	 	53	  
	 6.19
	 	 Additional CBI Loans
	  	 	54	  
	 6.20
	 	 Rule 144
	  	 	54	  
	 6.21
	 	 Employees
	  	 	54	  
	 6.22
	 	 CBI Cooperation
	  	 	54	  
	 6.23
	 	 Compliance with Obligations
	  	 	54	  
	 6.24
	 	 Pay-off Letter or Assignment of Guarantee
	  	 	54	  
		
	ARTICLE 7 CONDITIONS TO THE SHARE PURCHASE	  	 	55	  
			
	 7.1
	 	 Conditions to Obligations of Each Party to Effect the Share Purchase
	  	 	55	  
	 7.2
	 	 Additional Conditions to Obligations of the Company and the Company Shareholder
	  	 	55	  
	 7.3
	 	 Additional Conditions to the Obligations of Purchaser
	  	 	56	  
		
	ARTICLE 8 TERMINATION, AMENDMENT AND WAIVER	  	 	57	  

  
 ii 

							
	 8.1
	 	 Termination
	  	 	57	  
	 8.2
	 	 Effect of Termination
	  	 	58	  
	 8.3
	 	 Amendment
	  	 	58	  
	 8.4
	 	 Extension; Waiver
	  	 	58	  
		
	 ARTICLE 9 INDEMNIFICATION
	  	 	58	  
			
	 9.1
	 	 Unilateral Right of Set-Off
	  	 	58	  
	 9.2
	 	 Indemnification
	  	 	58	  
	 9.3
	 	 Indemnifiable Damage Threshold; Other Limitations
	  	 	59	  
	 9.4
	 	 Period for Claims
	  	 	60	  
	 9.5
	 	 Claims
	  	 	61	  
	 9.6
	 	 Resolution of Objections to Claims
	  	 	61	  
	 9.7
	 	 Third-Party Claims
	  	 	62	  
	 9.8
	 	 Indemnification by Purchaser
	  	 	62	  
	 9.9
	 	 Treatment of Indemnification Payments
	  	 	63	  
	 9.10
	 	 Tail D&O Insurance
	  	 	63	  
		
	ARTICLE 10 GENERAL PROVISIONS	  	 	63	  
			
	 10.1
	 	 Survival of Representations and Warranties and Covenants
	  	 	63	  
	 10.2
	 	 Release and Waiver
	  	 	64	  
	 10.3
	 	 Notices
	  	 	65	  
	 10.4
	 	 Interpretation
	  	 	66	  
	 10.5
	 	 Counterparts
	  	 	67	  
	 10.6
	 	 Entire Agreement; Nonassignability; Parties in Interest
	  	 	67	  
	 10.7
	 	 Assignment
	  	 	67	  
	 10.8
	 	 Severability
	  	 	67	  
	 10.9
	 	 Remedies Cumulative
	  	 	67	  
	 10.10
	 	 Governing Law; Submission to Jurisdiction
	  	 	68	  
	 10.11
	 	 Rules of Construction
	  	 	68	  
	 10.12
	 	 Parent’s and Purchaser’s Due Diligence Investigation
	  	 	68	  
	 10.13
	 	 WAIVER OF JURY TRIAL
	  	 	68	  
	 10.14
	 	 Waiver of Conflicts Regarding Representation
	  	 	68	  

 EXHIBITS 

Exhibit A     -     Definitions 

Exhibit B     -     Form of Waiver and Termination Agreement 

Exhibit C     -     Form of Instruction Letter 

Exhibit D     -     Form of Company Legal Opinion 

Exhibit E     -     Form of Investment Representation Letter and Lock-up Agreement 

Exhibit F     -     Form of Amendment to Loan Agreements 

  
 iii 

 SHARE PURCHASE AGREEMENT 

This SHARE PURCHASE AGREEMENT (this “Agreement”) is made and entered into
as of April 23, 2014 (the “Agreement Date”), by and among Hyperion Therapeutics, Inc., a Delaware corporation (“Parent”), Hyperion Therapeutics Israel Holding Corp. Ltd. an Israeli company and a
wholly-owned subsidiary of Parent (“Purchaser”), Clal Biotechnology Industries Ltd. (the “Company Shareholder”), and Andromeda Biotech Ltd., an Israeli company (the “Company”).

 RECITALS 

A. The Company Shareholder will represent the holders and the legal and beneficial owners of all of the Company Ordinary Shares as of the
Closing Date (as defined below). 
 B. Purchaser desires, subject to the terms and conditions set forth in this Agreement, to purchase from
the Company Shareholder and the Company Shareholder desires to sell to Purchaser all Company Ordinary Shares owned by the Company Shareholder free from any Encumbrances and subject to the terms and conditions set forth in this Agreement (the
“Share Purchase”). 
 C. The Company, Company Shareholder, Parent and Purchaser desire to make certain
representations, warranties, covenants and other agreements in connection with the Share Purchase as set forth herein. 
 D. The Board of
Directors of the Company (the “Board of Directors”) has unanimously approved this Agreement and the transfer of the Company Ordinary Shares contemplated hereby in accordance with all applicable Legal Requirements. 

E. Prior to the Closing (as defined below) and as a condition and material inducement to the willingness of Purchaser to consummate the
transactions contemplated by this Agreement, certain employees of the Company are executing an employee offer letter (each an “Offer Letter”) together with an employee invention assignment agreement, in each case to become
effective upon the Closing. 
 F. Prior to the Closing and as a condition and material inducement to the willingness of Purchaser to enter
into this Agreement all of the employees of the Company are entering into a waiver and termination agreement, in substantially the form attached hereto as Exhibit B (the “Termination and Release”). 

NOW, THEREFORE, in consideration of the representations, warranties, covenants and other agreements contained
herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 

ARTICLE 1 

THE SHARE PURCHASE 

1.1 Closing. Unless this Agreement is earlier terminated in accordance with Section 8.1, the closing (the
“Closing”) of the transactions contemplated hereby (the “Transactions”) shall take place (i) as promptly as practicable (and in any event within five (5) Business Days) after the satisfaction
or waiver of each of the conditions set forth in ARTICLE 7 (other than those conditions that by their nature are to be satisfied at the Closing, but subject to the fulfillment or waiver of those conditions) or (ii) as such other time and
date as Purchaser and the Company may agree in writing. The Closing shall take place remotely via the exchange of documents and signature pages or at such location as the parties hereto agree. The date on which the Closing occurs is herein referred
to as the “Closing Date.” 

  
 1 

 1.2 Closing Deliveries. 

(a) Parent and Purchaser Deliveries. Parent and/or Purchaser (jointly and severally) shall deliver to the Company and the Company
Shareholder, as applicable, at or prior to the Closing, each of the following: 
 (i) the CBI Cash Closing Amount; 

(ii) documentation satisfactory to the Company evidencing the appointment by Purchaser of at least one director of the Company, which
appointment is to become effective at the Closing; 
 (iii) a share transfer deed duly executed by Purchaser, for the receipt by Purchaser
of the Company Ordinary Shares; 
 (iv) a certificate, dated as of the Closing Date and executed on behalf of the Parent by its Secretary,
certifying true and correct copies of the resolutions adopted by the Board of Directors of the Parent authorizing the execution and delivery of this Agreement and the other agreements to which the Parent and/or Purchaser is a party pursuant to this
Agreement, the issuance of shares of Parent Common Stock contemplated hereby, and the consummation of the other transactions contemplated hereby; 

(v) a certificate, dated as of the Closing Date and executed on behalf of the Purchaser by a director of the Purchaser, certifying true and
correct copies of the resolutions adopted by the Board of Directors of the Purchaser authorizing the execution and delivery of this Agreement and the other agreements to which the Purchaser is a party pursuant to this Agreement, and the consummation
of the transactions contemplated hereby; 
 (vi) an executed copy of the Instruction Letter in the form attached hereto as Exhibit C
to be sent by Parent to its transfer agent immediately after the Closing, instructing the transfer agent to issue the certificate representing the Share Consideration; 

(vii) a certificate, dated as of the Closing Date, executed on behalf of Parent by a duly authorized officer of Parent to the effect that
each of the conditions set forth in clause (a) of Section 7.2 has been satisfied; 
 (viii) either (x) documentation
satisfactory to the Company evidencing the wiring by Purchaser to Bank Hapoalim of the total amount then required to cover the outstanding balance and to close such credit line, all in accordance with the Pay-off Letter (as defined below) to be
delivered at least 3 Business Days prior to the Closing or (y) the fully executed Guarantee Assignment Documentation (as defined below). 

(b) Company Deliveries. The Company shall deliver to Purchaser, at or prior to the Closing, each of the following: 

(i) a certificate, dated as of the Closing Date and executed on behalf of the Company by its Chief Executive Officer, to the effect that each
of the conditions set forth in Section 7.3(a) and Section 7.3(e) has been satisfied; 
 (ii) a certificate, dated
as of the Closing Date and executed on behalf of the Company by its Chief Executive Officer, certifying the Company’s (A) a true and complete copy of the Company’s articles of association, including all amendments thereto (the
“Articles of Association”), (B) a 

  
 2 

 
complete list of the officers and directors of the Company, and (C) copies of resolutions adopted by the Board of Directors and shareholders of the Company authorizing the execution and
delivery of this Agreement and the other agreements to which the Company is a party pursuant to this Agreement and the consummation of the Transactions; 

(iii) a printout from the Israeli Registrar of Companies with respect to the Company, dated as of the Closing Date, reflecting that
(x) the Company is not delinquent in payment of its annual dues or filing of an annual report, and (y) the Company has not been noted as being in breach of its legal filing requirements; and a printout from the Israeli Registrar of
Companies with respect to the Company, dated as of the Closing Date, reflecting that no Encumbrance is registered on any of the Company Ordinary Shares. 

(iv) a written opinion from the Company’s legal counsel, in the form set forth on Exhibit D, dated as of the Closing Date and
addressed to Purchaser; 
 (v) an Offer Letter, together with an employee invention assignment agreement, effective as of Closing, executed
by each of the Company’s four (4) key employees set forth on Schedule 1.2(b)(v) and by an additional four (4) employees that are not key employees (collectively, “Designated Employees”) (and such Offer
Letters shall be in full force and effect and shall not have been repudiated through the Closing); 
 (vi) documentation satisfactory to
Purchaser evidencing the resignation of each of the directors of the Company in office immediately prior to the Closing as directors of the Company, effective no later than immediately prior to the Closing; 

(vii) certificates representing the Company Ordinary Shares accompanied by a share transfer deed, duly executed by Company Shareholder, for
transfer of such Company Ordinary Shares to Purchaser, in form and substance satisfactory to Purchaser, together with a copy of the share registry of the Company indicating that Purchaser is the sole shareholder of the Company all effective as of
the Closing Date; 
 (viii) the Spreadsheet (as defined below) completed to include all of the information specified in
Section 6.8 in a form reasonably acceptable to Purchaser, and a certificate executed on behalf of the Company by the Chief Executive Officer of the Company, dated as of the Closing Date, certifying on behalf of the Company that such
Spreadsheet is true, correct and complete; 
 (ix) the Closing Expenses Certificate, which certificate shall be accompanied by such
supporting documentation, information and calculations as are reasonably necessary for Purchaser to verify and determine the amount of Transaction Expenses; 

(x) complete and correct copies of an investment representation letter and lock-up agreement addressed to Purchaser, in substantially the
form attached hereto as Exhibit E (the “Investment Representation Letter and Lock-up Agreement”), executed by the Company Shareholder; 

(xi) executed copies of the Termination and Release, executed by all of the employees of the Company; 

(xii) an executed amendment to each of the CBI Loan Agreements, in substantially the form of Amendment to Loan Agreements attached hereto as
Exhibit F (the “CBI Loan Amendment”); and 
 (xiii) either the Pay-off Letter or the Guarantee Assignment
Documentation. 

  
 3 

 (c) Receipt by any party hereto of any of the agreements, instruments, certificates or documents
delivered pursuant to this Section 1.2 shall not be deemed to be an agreement by such party that the information or statements contained therein are true, correct or complete, and shall not diminish such party’s remedies hereunder
if any of the foregoing agreements, instruments, certificates or documents are not true, correct or complete. 
 1.3 The Share
Purchase; Consideration. 
 (a) Payments to the Company Shareholder. Upon the terms and subject to the conditions set
forth herein, the Company Shareholder agrees to sell, transfer and deliver to Purchaser at the Closing, and Purchaser agrees to purchase from the Company Shareholder, all rights, title and interest in and to the Company Ordinary Shares owned by the
Company Shareholder as of immediately prior to the Closing (as set forth on the Spreadsheet) free and clear of all Encumbrances, in exchange for the payment and issuance by the Parent and/or Purchaser (jointly and severally) to the Company
Shareholder of the following consideration: 
 (i) at Closing – (a) an amount of cash (without interest) equal to the CBI Cash
Closing Amount, and (b) a number of shares of Parent Common Stock equal to the Share Consideration, 
 (ii) when and if Contingent
Payments are required to be made in accordance with the provisions of Section 1.11 and Section 1.12 and subject to the Set-Off Rights (as defined below), an amount of cash (without interest) equal to the product of
(x) the amount of such Contingent Payment, multiplied by (y) the then applicable CBI Ratio, 
 in the case of clauses (i) and
(ii) of this Section 1.3(a), until the Initial Threshold Payment (as defined below) has been made to Teva, 
 (iii) after
the Initial Threshold Payment has been made to Teva, when and if Contingent Payments are required to be made in accordance with the provisions of Section 1.11 and Section 1.12 and subject to the Set-Off Rights, an amount of
cash (without interest) equal to the product of (x) the amount of such Contingent Payment, multiplied by (y) fifty percent (50%), until the Final Threshold Payment (as defined below) has been made to Teva, 

(iv) after the Final Threshold Payment has been made to Teva, when and if Contingent Payments are required to be made in accordance with the
provisions of Section 1.11 and Section 1.12 and subject to the Set-Off Rights, the full amount of the Contingent Payments. 

(b) Payments to Teva. Upon the terms and subject to the conditions set forth herein, the Parent and/or Purchaser (jointly and
severally) shall pay to Teva, through the Company, the following payments in accordance with Section 5 of the Teva Share Purchase Agreement: 

(i) at Closing - an amount of cash (without interest) equal to the Teva Cash Closing Amount, 

(ii) when and if Contingent Payments are required to be made in accordance with the provisions of Section 1.11 and
Section 1.12 and subject to the Set-Off Rights, an amount of cash (without interest) equal to the product of (x) the amount of such Contingent Payment, multiplied by (y) the then applicable Teva Ratio, 

in the case of clauses (i) and (ii) of this Section 1.3(b), only until such time as the aggregate payments made to Teva
pursuant to clauses (i) and (ii) of this Section1.3(b), when combined with the aggregate amounts paid to Teva pursuant to Section 4 of the Teva Share Purchase Agreement, equal $36,210,545 (the “Initial Threshold
Payment”), 

  
 4 

 (iii) after the Initial Threshold Payment has been made, when and if Contingent Payments are
required to be made in accordance with the provisions of Section 1.11 and Section 1.12 and subject to the Set-Off Rights, an amount of cash (without interest) equal to the product of (x) the amount of such Contingent
Payment, multiplied by (y) fifty percent (50%), until such time as the aggregate payments made to Teva pursuant to clauses (i), (ii) and (iii) of this Section1.3(b), when combined with the aggregate amounts paid to Teva
pursuant to Section 4 of the Teva Share Purchase Agreement, equal $72,421,089 (the “Final Threshold Payment”). 

(c) Adjustments. In the event of any stock split, reverse stock split, stock dividend (including any dividend or distribution of
securities convertible into capital stock), bonus shares, reorganization, reclassification, combination, recapitalization or other like change with respect to the Company Ordinary Shares or Parent Common Stock occurring after the date hereof and
prior to the Closing, all references in this Agreement to specified numbers of shares of any class or series affected thereby, and all calculations provided for that are based upon numbers of shares of any class or series (or trading prices
therefor) affected thereby, shall be equitably adjusted to the extent necessary to provide the parties the same economic effect as contemplated by this Agreement prior to such stock split, reverse stock split, stock dividend, reorganization,
reclassification, combination, recapitalization or other like change. 
 (d) Rights Not Transferable. The rights of the Company
Shareholder under this Agreement as of immediately prior to the Closing are personal to such Company Shareholder and shall not be transferable for any reason otherwise than by operation of law, will or the laws of descent and distribution. Any
attempted transfer of such right by any holder thereof (otherwise than as permitted by the immediately preceding sentence) shall be null and void. 

(e) Fractional Shares. No fractional shares of Parent Common Stock will be issued in connection with the Share Purchase, but in lieu
thereof the Company Shareholder who would otherwise be entitled to a fraction of a share of Parent Common Stock (after aggregating for each particular stock certificate representing Company Ordinary Shares all fractional shares of Parent Common
Stock to be received by such holder) shall receive from Purchaser an amount of cash (rounded to the nearest whole cent) equal to the product of (i) such fraction and (ii) the Parent Stock Price, which shall be deemed to be the value of
each share of Parent Common Stock for all purposes. 
 1.4 Payment and Exchange Procedures. 

(a) Payment Procedures. 

(i) At the Closing Date, the Company Shareholder shall deliver to the Purchaser all share certificates formerly representing Company Ordinary
Shares, or in the event that any such share certificate has been lost, stolen, or destroyed, an affidavit of lost certificate executed by the Company Shareholder thereof in form and substance reasonably satisfactory to Purchaser. 

(ii) Against delivery to Purchaser of the applicable share certificate, or in the event that any such share certificate has been lost,
stolen, or destroyed, an affidavit of lost certificate executed by the Company Shareholder thereof in form and substance reasonably satisfactory to Purchaser, the Parent and/or Purchaser (jointly and severally) shall deliver to the Company
Shareholder (i) at the Closing, a check or amount via wire transfer, of immediately available funds, representing the cash amount that the Company Shareholder has the right to receive pursuant to Section 1.3(a), and
(ii) promptly after Closing, a certificate representing the number of shares of Parent Common Stock that the Company Shareholder has the right to receive pursuant to Section 1.3(a). 

  
 5 

 (iii) The Parent or Purchaser shall deliver to Teva at the Closing, a check or amount via wire
transfer, of immediately available funds, representing the cash amount that Teva has the right to receive pursuant to Section1.3(b). 

(iv) At or promptly following the Closing, and when and if Contingent Payments are required to be made in accordance with the provisions of
Section 1.11 and Section 1.12 and subject to the Set-Off Rights in connection with each of Milestones 1 through 5, the Parent and/or Purchaser (jointly and severally) shall pay (or cause the Company to pay) each of the
employees of the Company a check or amount via wire transfer, of immediately available funds, representing the portion of the Employee Closing Payment Amount or the portion of the Employee Contingent Payment Amount associated with such Contingent
Payment, as the case may be, that such employee has the right to receive pursuant to his or her respective Termination and Release on the Closing or upon the payment of such Contingent Payment, as the case may be, as set forth opposite such
employee’s name on the Spreadsheet. The Purchaser may (in which case it shall cause the Company to have sufficient funds to) make all payments required to made to the employees of the Company in respect of each Termination and Release through
the Company’s regular payroll system. All amounts payable pursuant to the Termination and Release shall be subject to any withholding of Taxes required by Legal Requirements to be withheld and shall be paid without interest. 

(b) No Interest. Notwithstanding anything to the contrary contained herein, no interest shall accumulate on any cash payable in
connection with the Share Purchase and the other Transactions. 
 (c) Transfers of Ownership. If any cash amount payable pursuant to
Section 1.3(a) is to be paid to a Person other than the Person to which the certificate surrendered in exchange therefor is registered, it shall be a condition of the payment thereof that the certificate so surrendered shall be properly
endorsed and otherwise in proper form for transfer and that the person requesting such exchange shall have paid to Purchaser or any agent designated by it any transfer or other Taxes required by reason of the payment of cash in any name other than
that of the registered holder of the certificate surrendered, or established to the satisfaction of Purchaser or any agent designated by it that such Tax has been paid or is not payable. 

(d) No Liability. Notwithstanding anything to the contrary in this Section 1.4, none of the Company, Purchaser or any party
hereto shall be liable to any Person for any amount properly paid to a public official pursuant to any applicable abandoned property, escheat or similar law. 

1.5 No Further Ownership Rights in the Company Ordinary Shares. All cash paid or payable following the surrender for exchange of
Company Ordinary Shares in accordance with the terms hereof shall be so paid or payable in full satisfaction of all rights pertaining to such Company Ordinary Shares and there shall be no further registration of transfers on the records of the
Company of Company Ordinary Shares, which were issued and outstanding immediately prior to the Closing. If, after the Closing, any certificate or agreement is presented to Purchaser for any reason, such certificate shall be canceled and exchanged as
provided in this ARTICLE 1. 
 1.6 Lost, Stolen or Destroyed Certificates. In the event any certificate shall have been lost, stolen
or destroyed, Purchaser shall issue in exchange for such certificate, following the making of an affidavit of that fact by the record holder thereof, such cash as may be required pursuant to Section 1.3(a) in respect of such certificate.

  
 6 

 1.7 Tax Consequences. Without derogating from the representations under Sections
2.13 and 3.6 below, no party to this Agreement makes any representations or warranties to the other parties hereto or to any of the Company Securityholders regarding the Tax treatment of the Share Purchase, or any of the Tax consequences
of such other parties to this Agreement, the Share Purchase or any of the other transactions or agreements contemplated hereby. Each party to this Agreement acknowledges that such party is relying solely on its own Tax advisors in connection with
this Agreement, the Share Purchase and the other transactions and agreements contemplated hereby. 
 1.8 Certain Taxes. All transfer,
documentary, sales, use, stamp, registration and other such similar Taxes and fees (including any penalties and interest) incurred by the Company Securityholders in connection with this Agreement (together, “Transfer Taxes”)
shall be paid by the Company Securityholders when due, and each Company Securityholder shall, at its own expense, file all necessary Tax Returns and other documentation with respect to all Transfer Taxes. 

1.9 Withholding Rights. 

(a) Each of the Company, Parent and Purchaser shall be entitled to deduct and withhold from any consideration otherwise deliverable under this
Agreement (including with respect to the making of Contingent Payments under Sections 1.11 and 1.12) and from any other payments otherwise required pursuant to this Agreement, to any continuing employee, holder of any Company Ordinary Shares or
Company Option or Teva, subject to its payment to the relevant Tax Authority, such amounts in cash or shares as the Company, Parent, or Purchaser is required to deduct and withhold with respect to any such deliveries and payments under the Code, the
ITO or any provision of state, local, provincial or foreign Tax law. To the extent that amounts are so withheld, such withheld amounts shall, subject to its timely payment to the relevant Tax Authority, be treated for all purposes of this
Agreement as having been delivered and paid to such holders in respect of which such deduction and withholding was made. Parent and/or Purchaser shall provide to payees a certificate confirming that such withholding has been made. 

(b) Notwithstanding the provisions of Section 1.9(a) above, with respect to Israeli Tax, neither Parent, Purchaser nor their agents
shall withhold or shall withhold a reduced amount of Israeli Tax if the payee has provided to Parent or Purchaser a Valid Certificate at least two (2) Business Days prior to any payment to each payee pursuant to this Agreement. A
“Valid Certificate” shall be a valid and applicable (in light of the timing, scope and the nature of the payment) certification or ruling issued by the ITA, (x) exempting Parent and Purchaser from the duty to withhold
Israeli Taxes with respect to such payee, (y) determining the applicable rate of Israeli Tax to be withheld from such payee or (z) providing any other instructions regarding the payment or withholding with respect to the applicable
consideration of such payee. Unless otherwise required by the ITA or applicable law, a valid certificate pursuant to the Israeli Income Tax Regulations (Withholding from Payments for Services or Assets), 5737 - 1977 (“Services and Assets
Certificate”) will be deemed a Valid Certificate with respect to any cash consideration paid for the Company Ordinary Shares if in force and applicable to payee on the date that payment is to be made, provided however that such payee has filed
an application to the ITA with respect to consideration payable to the payee in which it is expressly disclosed that the payee intends to rely on a Services and Assets Certificate with respect to the current and future payments of cash consideration
to such payee. In the event that a payee submits a Valid Certificate, no later than two (2) Business Days prior to the date that any payment is required to be made to the payee pursuant to the Agreement, then the deduction and withholding of
any Israeli Taxes shall be made only in accordance with the provisions of such Valid Certificate and the balance of the payment that is not withheld shall be promptly paid to such payee. If such payee (i) does not provide Parent or
Purchaser with a Valid Certificate by no later than two (2) Business Days before the date payment is due under this agreement, or (ii) submits a written request with Parent or Purchaser to release his, her or its payment and fails to
submit a Valid Certificate, then the amount to be withheld from such payment shall be calculated by the 

  
 7 

 
Parent or Purchaser in its reasonable discretion according to the applicable withholding rate, and shall be promptly delivered to the ITA by Parent or Purchaser or their agent. The balance
of the consideration due to such payee that is not so withheld shall be promptly delivered to such payee. Without derogating from the foregoing, the Company Shareholder shall provide Purchaser in advance with drafts of all applications and
submissions to the ITA in order to allow for good faith coordination. 
 1.10 Taking of Necessary Action; Further Action. If, at any
time after the Closing, any further action is necessary or desirable to carry out the purposes of this Agreement and to vest Purchaser with full right, title and interest in and to the Company Ordinary Shares, the officers and directors of the
Company are fully authorized, in the name and on behalf of the Company or otherwise, to take all lawful action necessary or desirable to accomplish such purpose or acts, so long as such action is not inconsistent with this Agreement. 

1.11 Contingent Payments. 

(a) Certain Definitions. For purposes of this Agreement, the following definitions shall apply: 

(i) “Buyer Group” means Parent, Purchaser (“Buyer”) and their respective direct and indirect
subsidiaries and Affiliates including, after the Closing, the Company, individually and collectively. 
 (ii)
“Canada” means Canada, its territories and possessions. 
 (iii) “Company Eligible Product”
means any of the following: (a) the Company Product, (b) any modifications, variations, derivative works, enhancements, developments, and customizations of or to the Company Product, (c) any product that contains the Company Product
or any of the other peptides sequences that are currently covered by the Patent Rights owned or licensed by the Company as of the Closing Date, or any composition or formulation comprising these peptides; and (d) if covered by (1) a
current, valid claim of an issued patent owned or licensed by the Company as of the Closing Date, or (2) any other valid claim of an issued patent within the Company Eligible IP, or (3) any other Patent Rights within the Company Eligible
IP - any product that is comprised of, contains or incorporates, is developed from, is based on, makes use of, or is otherwise covered by any of the Company Eligible IP. 

(iv) “Company Eligible IP” means (1) all Intellectual Property owned or licensed by the Company as of the
Closing Date, and (2) all Patent Rights arising after the Closing Date that claim priority to or are primarily based on any of the Intellectual Property described in clause (1). 

(v) “Patent Rights” means patents and all continuations, continuations-in-part, divisionals, reissues,
reexaminations and extensions or substitutions thereof and supplemental protection certificates relating thereto, any confirmation patents or registration patents or patents of addition based on any such patents, and all counterparts thereof or
substantial equivalents in any country, including utility models and industrial designs (collectively, “Patents”) and any applications or provisional applications for any of the foregoing (“Patent Applications”).

 (vi) “EMA” means the European Medicines Agency or any successor agency thereto. 

(vii) “European Union” or “EU” means all of the European Union member states as of the
applicable time, and its respective territories and possessions. 

  
 8 

 (viii) “FDA” means the United States Food and Drug Administration or any
successor entity thereto. 
 (ix) “Generic Competition” shall mean, with respect to Company Eligible Product in a
country, when (a) one or more Generic Product(s) are being marketed in such country and (b) all patents included in Company Eligible IP covering Company Eligible Product in such country have expired and there is no remaining applicable
regulatory or other exclusivity rights covering such Company Eligible Product, or the entity seeking marketing approval in such country has alleged that the patents in the Company Eligible IP are unenforceable and/or not infringed by the Generic
Product or challenges the scope or validity of any applicable regulatory or other exclusivity rights covering such Company Eligible Product. 

(x) “Generic Product” in a certain country, shall mean a product (a) whose active pharmaceutical ingredient is
the same as that of the Company Eligible Product being sold in a country, (b) that obtained regulatory approval as a generic product by the applicable regulatory authorities in such country by means of establishing equivalence to such Company
Eligible Product, and (c) that is legally marketed in such country by an entity other than the Buyer Group and its distributors and other sublicensees. A product shall not be considered as a Generic Product if the Buyer Group, any of their
Affiliates, or any one on their respective behalf was involved in its development, approval or commercialization. 
 (xi)
“Milestones” means, collectively, the milestones set forth in the Milestone Table. 
 (xii) “Net
Sales” means the all amounts invoiced by or on behalf of the Buyer Group or any of its sublicensees from the sale of the Company Eligible Products to un-Affiliated third parties (including distributors) in bona fide, arms length
transactions, as determined in accordance with the Buyer Group’s or sublicensee’s usual and customary accounting methods consistently applied by the Buyer Group or sublicensee, as applicable, less deductions for the following
items to the extent they are actually incurred and as directly related to such Company Eligible Products and are booked by the Buyer Group or its sublicensee in accordance with generally accepted accounting standards in the U.S. to calculate the
recorded net revenues from gross revenues, provided they are indicated as a separately invoiced line item (where applicable): 
 (1) normal
trade and cash discounts given in respect of such sales; 
 (2) allowances, amounts repaid or credited by reasons of defects, rejections,
recalls or returns; 
 (3) discounts, rebates and chargebacks to customers and third parties (including, without limitation, Medicare,
Medicaid, Managed Healthcare or any other governmental discounts, rebates or chargebacks); 
 (4) Taxes (including value added taxes, sales
taxes, or similar taxes, but excluding withholding Taxes and Taxes paid by the Buyer Group on the net income derived from sales of the Company Eligible Product), tariffs, customs duties, surcharges and other governmental charges incurred in
connection with the production, sale, transportation, delivery, use, exportation or importation of the Company Eligible Product that are incurred at time of sale and are directly related to the sale and not otherwise previously deducted; and; 

(5) insurance, customs charges and duties, freight, postage, shipping, handling, and other transportation costs; 

  
 9 

 (6) an allowance for uncollectible or bad debts determined in accordance with generally accepted
accounting principles; 
 (7) any other adjustments of specifically identifiable amounts related to products sold and reasonably allocated
to the Company Product as a portion of the total products sold, , deducted for reasons similar to those listed above in accordance with GAAP; 

With respect to the calculation of Net Sales: 

(1) Sales between or among members of the Buyer Group and authorized sublicensees shall be disregarded for purposes of calculating Net Sales,
but resales by any such Buyer Group members and authorized sublicensees will be included in Net Sales; provided that a distributor (that is not part of the Buyer Group) shall not be considered a sublicensee and sales to such distributor shall be
included in Net Sales, and provided further that sales to Group Members or sublicensees that are the end users of the sold product shall be included in Net Sales; 

(2) If the Company Eligible Product is delivered to the third party before being invoiced (or is not invoiced), Net Sales will be calculated
at the time all the revenue recognition criteria under the generally applicable accounting standards in the U.S. are met; 
 (3) any
consideration received not in cash or not on arms’ length terms shall be valued at the fair market value thereof assuming a transaction between un-Affiliated third parties on bona fide arm’s length terms. 

(4) If the Company Eligible Product is sold in combination with with an Other Component (as defined below), then for purposes of calculating
“Net Sales” of such Company Eligible Product, the Net Sales of such combination of Company Eligible Product and Other Components (after taking the above deductions) shall first be multiplied by the fraction equal to the quotient of
A/(A+B), where A is the weighted (by sales volume) average sale price in the relevant country of the Company Eligible Product that does not have an Other Component when sold as the sole active ingredient in finished form, and B is the weighted
average sale price (by sales volume) in that country of the product(s) containing the Other Component(s) as the sole active ingredient(s) in finished form. If the weighted average sale price cannot be determined for the Company Eligible Product or
for the Other Component included in the combination product, such unavailable weighted average sale price will be as reasonably determined by Parent and Purchaser, provided that in any event shall fraction shall not be less than 50%, and such
resulting amount shall be the “Net Sales” with respect to such Company Eligible Product. “Other Component” means an active pharmaceutical ingredient which has a clinical effect and is not derived from the Company
Product or otherwise covered by any Company Eligible IP. 
 (xiii) “ROW Distributor Revenues” means, with respect
to any ROW territory, the Net Sales received by the Buyer Group from third party distributor in such territory for or in connection with the sales of the Company Eligible Product. Amounts received to reimburse the Buyer Group for costs actually
incurred to perform research, development or similar services conducted for the Company Eligible Product or for reimbursement of patent or other out-of-pocket expenses relating to the Company Eligible Product, or in consideration for the purchase of
any debt or securities of the Buyer, in each case pursuant to arms-length, bona fide transactions, shall not be considered ROW Distributor Revenues. 

(xiv) “Sublicense Fees” means the aggregate consideration received by the Buyer and its Affiliates from
non-affiliated third party sublicensees in consideration for or in connection with the grant of a right or permission (or an option therefor) to develop, make, use or sell the Company Eligible Product or the Company Eligible IP, but excluding
(a) Net Sales or any portion of Net Sales that 

  
 10 

 
may be paid by the sublicensee, and (b) amounts received to reimburse the Buyer Group for costs actually incurred to perform research, development or similar services conducted for the
Company Eligible Product or for reimbursement of patent or other out-of-pocket expenses relating to the Company Eligible Product, or in consideration for the purchase of any debt or securities of the Buyer, in each case pursuant to arms-length, bona
fide transactions. 
 (xv) “U.S.” means the United States of America, its territories and possessions. 

(xvi) “ROW” means all counties outside of the EU and the U.S., and, in each case, their respective territories and
possessions. 
 (b) Contingent Payments. As additional consideration for the Share Purchase, and subject to the set-off rights of
Purchaser pursuant to Section 1.12(h) (the “Set-Off Rights”), Parent and/or Purchaser (jointly and severally) shall pay contingent payments (collectively, the “Contingent Payments”) when
and if required to be made in accordance with the provisions of the Section 1.11 and Section 1.12, which shall be allocated in accordance with Section 1.3 above. The Contingent Payments shall include the Milestone
Payments (as defined below) and the Contingent Sales Payments (as defined below); provided, however, that notwithstanding anything to the contrary contained herein, each Contingent Payments shall be reduced by the amount paid or
payable in connection with such Contingent Payment as set forth on Schedule 1.11(b). 
 (c) Contingent Milestone Payments.
Subject to the Set-Off Rights, Parent and/or Purchaser (jointly and severally) shall make the one-time payments (the “Milestone Payments”) set forth in the following table (the “Milestone Table”) to
the Company Shareholder and Teva in accordance with Section 1.3(a) and Section 1.3(b), respectively, after and subject to, and conditioned on the achievement of each Milestone (for the avoidance of doubt, each Milestone Payment is only
due one time on the first occurrence of the applicable Milestone): 
  

							
	 	  	 Milestone
	  	Milestone
Payment Amount	 
			
	Milestone 1	  	The filing by Buyer Group and acceptance of a New Drug Application by the FDA for authorization to market a Company Eligible Product in the U.S.	  	$	[	*] 
			
	Milestone 2	  	The filing by Buyer Group and acceptance of a Marketing Authorization Application by the EMA for authorization to market a Company Eligible Product in the European Union.	  	$	[	*] 
			
	Milestone 3	  	The filing by Buyer Group and acceptance of an application for [*] in [*].	  	$	[	*] 
			
	Milestone 4	  	The earlier to occur of the (i) the [*] approval of [*] filed by Buyer Group for authorization to [*] in the [*] and (ii) the [*] approval of [*] filed by Buyer Group for [*] in [*].	  	$	[	*] 
			
	Milestone 5	  	The later to occur of the (i) the [*] approval of [*] filed by Buyer Group for [*] in the [*] and (ii) the [*] approval of [*] filed by Buyer Group for [*] in [*].	  	$	[	*] 

  
 11 

  
 [*] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

							
			
	Milestone 6	  	The [*] in [*] received by Buyer Group.	  	$	[	*] 
			
	Milestone 7	  	The [*] approval of [*] filed by Buyer Group for a Company Eligible Product in the [*] with [*] indication.	  	$	[	*] 
			
	Milestone 8	  	The [*] approval of [*] filed by Buyer Group for a Company Eligible Product in the [*] with [*] indication.	  	$	[	*] 
			
	Milestone 9	  	The first consecutive twelve calendar month period during which the aggregate of worldwide Net Sales (inclusive of ROW Distributor Revenues) and Sublicense Fees exceed $450,000,000.	  	$	[	*] 
			
	Milestone 10	  	The first consecutive twelve calendar month period during which the aggregate of worldwide Net Sales (inclusive of ROW Distributor Revenues) and Sublicense Fees exceed $[*].	  	$	[	*] 
			
	Milestone 11	  	The first consecutive twelve calendar month period during which the aggregate of worldwide Net Sales (inclusive of ROW Distributor Revenues) and Sublicense Fees exceed $[*].	  	$	[	*] 
			
	Milestone 12	  	The first consecutive twelve calendar month period during which the aggregate of worldwide Net Sales (inclusive of ROW Distributor Revenues) and Sublicense Fees exceed $[*].	  	$	[	*] 
			
	Milestone 13	  	The first consecutive twelve calendar month period during which the aggregate of worldwide Net Sales (inclusive of ROW Distributor Revenues) and Sublicense Fees exceed $[*].	  	$	[	*] 

 The Milestone Payments for Milestones 9-13 are separate payments in respect of each Milestone, and two
or more Milestone Payments shall be paid simultaneously, on an accumulated basis, if the respective Milestones to which such Milestone Payments apply are achieved simultaneously (e.g. if the first consecutive twelve calendar month period during
which the aggregate of worldwide Net Sales (inclusive of ROW Distributor Revenues) and any Sublicense Fees received from sublicensees for the licensing of Company Eligible IP exceed $[*], is also the first consecutive twelve calendar month
period during which such aggregate exceeds $[*], thereby achieving Milestones 9 and 10 at the same time). 

  
 12 

  
 [*] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (d) Contingent Sales Consideration. Subject to the Set-Off Rights, Parent and/or Purchaser
(jointly and severally) shall make the following payments to the Company Shareholder and Teva in accordance with Section 1.3, (i) on all ROW Distributor Revenues - at the rate of 25% of such ROW Distributor Revenues, and
(ii) on all Net Sales (excluding such Net Sales that are ROW Distributor Revenues to distributors in ROW that are subject to clause (i) above), at the respective rates set forth in the below tables (clauses (i) and (ii), collectively,
the “Contingent Sales Payments”): 
  

			
	 Aggregate Annual worldwide Net Sales, ROW Distributor Revenues and Sublicense Fees:
	  	 Contingent Payment Rate

		
	Annual worldwide Net Sales, ROW Distributor Revenues and Sublicense Fees are of $300,000,000 or less.	  	10% of Net Sales (but not of ROW Distributor Revenues)
		
	Annual worldwide Net Sales, ROW Distributor Revenues and Sublicense Fees of more than $[*] but equal to or less than $[*].	  	[*]% of Net Sales (but not of ROW Distributor Revenues)
		
	Annual worldwide Net Sales, ROW Distributor Revenues and Sublicense Fees of more than $[*] but equal to or less than $1,200,000,000.	  	[*]% of Net Sales (but not of ROW Distributor Revenues)
		
	Annual worldwide Net Sales, ROW Distributor Revenues and Sublicense Fees of more than $1,200,000,000.	  	17% of Net Sales (but not of ROW Distributor Revenues)

 (e) Contingent Sales Consideration Reductions. 

(i) Anti-Stacking. If the Buyer Group or its sublicensees are required to pay royalties to any third party in order to make, have
made, use, sell, offer to sale or import Company Eligible Product, including under any existing licenses by the Company, then none of such third party royalty payments shall be credited against the Contingent Sales Payments due under this Agreement.

 (ii) Generic Competition. Upon commencement of Generic Competition with respect to Company Eligible Product in a country, and
thereafter for so long as such Generic Competition persists, the Contingent Sales Payments due under clause (ii) of Section 1.11(d) above with respect to such Company Eligible Product sold in such country shall be: 

(1) reduced by [*] percent ([*]%) if such Generic Product(s) represent a total prescription volume of at least [*] percent ([*]%) but less
than [*] percent ([*]%) of such Company Eligible Product and such Generic Product(s), in the aggregate, in such country in such calendar year, determined by the number of unit equivalents for such Company Eligible Product and such Generic
Product(s), in the aggregate, during such calendar year (as measured by an IMS audit or other mechanism agreed upon by the parties), and 

(2) reduced by [*] percent ([*]%) if such Generic Product(s) represent a total prescription volume of at least [*] percent ([*]%) of such
Company Eligible Product and such Generic Product(s), in the aggregate, in such country in such calendar year, determined by the number of unit equivalents for such Company Eligible Product and such Generic Product(s), in the aggregate, during such
calendar year (measured as described above). 
 (f) Contingent Payments Not Certain. The Company Shareholder hereby acknowledges that
receipt of the Contingent Payments is uncertain and that the Buyer Group may not achieve any of the Milestones or generate any Net Sales and it is therefore not assured that Purchaser will be required to pay the Contingent Payments at all. 

(g) Purchaser Discretion. The Buyer Group shall have sole and absolute discretion over all matters relating to the Company Eligible
Product from and after the Closing, including, but not limited to, any matter relating to the development, testing, regulatory submission, regulatory approval, manufacturing, marketing, sales, pricing, service or maintenance thereof. Furthermore,
the Company 

  
 13 

  
 [*] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Shareholder acknowledges that circumstances may exist that (i) delay or prevent the achievement of the Milestones or (ii) limit, reduce or otherwise negatively impact the amount of Net
Sales, if any, thereby correspondingly eliminating or reducing the amount of any Contingent Payments based thereon. Accordingly, nothing herein shall be deemed to be an agreement on the part of the Buyer Group to achieve the Milestones or to
generate any amount of Net Sales. From time to time and at the reasonable request of the Company Shareholder, Parent and Purchaser shall provide the Company Shareholder with updates concerning the progress and planning of the Buyer Group’s
research and development activities, testing, clinical results, regulatory filings, commercialization efforts and strategy for achieving the Milestones and Net Sales. 

(h) Subject to the provisions of Section 1.11(g), Buyer shall make, and shall cause the Company and the other Buyer Group members to make
such commercially reasonable and continuous efforts, all as are consistent with the commercial efforts generally applied to innovative products of similar potential at similar states in their life cycles, in order to pursue the development and
commercialization of the Company Product, and if the Buyer Group in its sole discretion develops a different Company Eligible Product, to pursue the commercialization of such Company Eligible Product, (A) to achieve, and to implement and
conduct all development, regulatory and manufacturing activities that are components of or related to or required for the achievement of each of the Milestones, and (B) to achieve, and to implement and conduct all manufacturing and
commercialization activities that are components of or directly related to or required for the achievement of the Contingent Sales Payments, which may involve conducting clinical trials, preparing, submitting, seeking approval for, maintaining and
updating Marketing Approval applications, Marketing Approvals and other regulatory approvals and applications for regulatory approvals in respect of the Company Product in the applicable countries, obtainment of pricing and reimbursement for Company
Product (or such Company Eligible Product, as applicable), marketing, promotion and other commercialization activities. If the Buyer (or the applicable member of the Buyer Group) terminates or abandons applicable development and, if commenced as of
such time, commercialization activities with respect to any Company Product (or such Company Eligible Product, as applicable), then, promptly following such termination, the Buyer shall send written notice thereof to the Company Shareholder together
with an explanation of the reasons for such cessation of activities. 
 (i) Following the Closing, neither Purchaser nor the Company or any
other Buyer Group member may sell or transfer the Company or any Company Eligible IP or any right to a Company Eligible Product (either directly or through a stock sale, merger or other change in control of the Company), or assign or exclusively
license any Company Eligible IP or any right to a Company Eligible Product to any third party who is not a Buyer Group member, unless such third party expressly assumes in writing to the Company Shareholder the obligations of Parent and Purchaser
under this Agreement. 
 1.12 Payment of Contingent Payments. 

(a) Milestone Payments. On or prior to the thirtieth (30th) day following the achievement of any Milestone, Parent and/or
Purchaser (jointly and severally) shall notify the Company Shareholder in writing of the occurrence of such an event shall deliver to each of the Company Shareholder and Teva that portion of the respective Milestone Payment amount allocated to the
Company Shareholder and Teva pursuant to Section 1.3(a) and Section 1.3(b), as applicable. 
 (b) Contingent Sales
Payments. Beginning with the Buyer Group’s first receipt of a Marketing Authorization for marketing any Company Eligible Product, on or prior to the forty-fifth
(45th)

  
 14 

  
 [*] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
day following the last day of each successive three month period (such period, a “Payment Quarter”), Parent and Purchaser shall deliver to the Company Shareholder a
certificate (each, a “Contingent Payment Certificate”), setting forth for such Payment Quarter (i) the amount of Net Sales and ROW Distributor Revenues for the Payment Quarter and (ii) Parent’s and
Purchaser’s determination of the amount of the Milestone Payment and/or Contingent Sales Payment due for such Payment Quarter (including the calculation thereof, in reasonable detail); together with a reasonably detailed report, detailing the
Company Eligible Products sold, the prices invoiced therefor, the deduction made, and the Sublicense Fees or ROW Distributor Revenues received, during such quarter. The Contingent Sales Payment will be due and payable by Parent and Purchaser within
ten (10) days following delivery of the Contingent Payment Certificate. 
 (c) Company Shareholder Audit Rights. The Buyer Group
hereby grants the Company Shareholder and its representatives and advisers, at the Company Shareholder’s expense, the right, exercisable no more than once during each six (6) month period following the end of a calendar year, subject to
the execution of, and compliance with, a standard confidentiality agreement, to examine and have full access to the Buyer Group’s books of account and records of the applicable Company Eligible Products, Net Sales, Sublicense Fees and ROW
Distributor Revenues with respect to which the Contingent Payment Certificates that have been delivered during such preceding calendar year, at the location of such records on prior written notice of at least ten (10) days, for the purpose of
verifying and assessing the amount of the applicable Net Sales, Sublicense Fees and ROW Distributor Revenues, as well as the determination (or lack thereof) of the Company Eligible Products (each such review shall be referred to herein as an
“Audit”); provided, however that the Audit to assess and verify the determination (or lack thereof) of whether or not a certain product that is being sold is a Company Eligible Product may only occur once and
only in respect of the first two (2) calendar years in which such product is sold. For the purpose of conducting an Audit, the Company Shareholder may hire, at its expense, one or more auditors or attorneys, or other applicable experts, of the
Company Shareholder’s choosing to assist in such examination; provided, that such auditors or attorneys have entered into standard confidentiality agreements. The Company Shareholder and such representatives shall have access to all of the
books and records required in the good faith judgment of the Company Shareholder to perform any Audit for a thirty (30) day period, beginning on the date on which access to substantially all of such books and records is first given to the
Company Shareholder. Nothing in this Section shall be deemed to require any member of the Buyer Group to keep any books of account or records other than those which it maintains in the ordinary course of business in its usual and customary practice,
to retain any such books of account or records for any period in excess of the period for which it retains such records in the ordinary course of business in its usual and customary practice, or to provide access to any books and records other than
that specified above. 
 (d) Dispute Notice. In the event that the Company Shareholder does not agree with the amount of Net Sales,
Sublicense Fees or ROW Distributor Revenues, or the determination (or lack thereof) of Company Eligible Products set forth on any Contingent Payment Certificate that was delivered during such preceding calendar year, the Company Shareholder shall be
entitled, during the period following the end of such preceding calendar year and ending on the earlier of (i) one hundred eighty days (180) days after the end of such calendar year and (ii) thirty (30) days following the
completion of an Audit (the “Dispute Period”), to give Parent written notice (a “Dispute Notice”) of such disagreement. In the event that the Company Shareholder does not deliver a Dispute Notice
during the Dispute Period, the amount of Net Sales, Sublicense Fees or ROW Distributor Revenues, or the determination (or lack thereof) of Company Eligible Products set forth on the Contingent Payment Certificates that were delivered during such
calendar year shall irrevocably be deemed to be the final Net Sales, Sublicense Fees or ROW Distributor Revenues amount, and Company Eligible Products, for the period covered by such Contingent Payment Certificate for all purposes of this Agreement.

  
 15 

 (e) Agreed Contingent Payment. In the event that the Company Shareholder delivers a
Dispute Notice within the Dispute Period, the Company Shareholder and Parent shall for a period of not less than thirty (30) days after delivery of the Dispute Notice attempt in good faith to resolve the amount of Net Sales, Sublicense Fees or
ROW Distributor Revenues, or the determination (or lack thereof) of Company Eligible Products that is in dispute (the “Disputed Contingent Payment Matters”), and mutually determine any adjustments to such amount of Net Sales,
Sublicense Fees or ROW Distributor Revenues, or the determination (or lack thereof) of Company Eligible Products and the resulting Contingent Sales Payment (the “Agreed Contingent Payment Amount”). The Buyer Group and the
Company Shareholder shall provide each other with such information, records and material kept in the ordinary course of business in such party’s possession and which such party may disclose without violating confidentiality obligations to third
parties, as is reasonably necessary and appropriate in attempting to resolve such Disputed Contingent Payment Matters, including the delivery of a copy to the Company Shareholder of any such information, records and material, to the extent then
available, that was used to calculate the amount of Net Sales. 
 (f) Arbitration of Disputes. In the event that no agreement can be
reached by the Company Shareholder and Parent as to the calculation of the Disputed Contingent Payment Matters within ninety (90) days after delivery of a Dispute Notice, then either party shall have the right to submit the Disputed Contingent
Payment Amount to arbitration by one (1) of the following entities, or such other accountants (or other applicable experts who have the appropriate expertise to be able to assess whether or not the product in question is a Company Eligible
Product), as the Company Shareholder and Parent may mutually agree, so long as such entity is not the principal regularly-engaged outside accountant or other applicable expert to Parent or the Company or any auditor or applicable expert that may
have assisted the Company Shareholder in any Audit: Ernst & Young LLP or BDO USA LLP or any successor entity to the foregoing (individually, an “Accountant,” and collectively, the
“Accountants”). The Company Shareholder and Parent shall jointly select which of the Accountants will perform the calculation within thirty (30) days after the Company Shareholder and Parent determine that they are
unable to settle the Disputed Contingent Payment Matters independently; provided, that in the event that the Company Shareholder and Parent are unable to agree upon the Accountant to perform such calculation within such thirty (30) day period,
then each of the Company Shareholder and Parent shall select one of the Accountants and such Accountants shall jointly select a third Accountant to perform such calculation. The Accountant selected in accordance with the foregoing sentence (the
“Appraiser”) shall be responsible for the determination of the Disputed Contingent Payment Matters. The engagement and charge of the Appraiser shall be limited to determining the Net Sales, Sublicense Fees or ROW Distributor
Revenues, or the determination of Company Eligible Products, as the case may be, for the applicable Payment Quarter(s). The Appraiser shall determine the Disputed Contingent Payment Matters within the limitations set forth above within ninety
(90) days after the date of such Appraiser’s engagement and the Appraiser shall be provided with such information and records, which may include on-site access and access to personnel, relating to such dispute as it may reasonably request.
Any Disputed Contingent Payment Matters determined by an Appraiser in accordance with this Section shall be deemed to be the final Net Sales, Sublicense Fees or ROW Distributor Revenues, or the determination of Company Eligible Products, as the case
may be, for the applicable Payment Quarter(s) for all purposes of this Agreement. The fees and expenses of the Appraiser shall be paid by the Company Shareholder, provided, that if the final determination by the Appraiser in any examination
conducted pursuant to this Section is greater than the Net Sales, Sublicense Fees or ROW Distributor Revenues, as the case may be, set forth on the relevant Contingent Payment Certificate by an amount equal to 5% or more, then Parent shall pay all
of the fees and expenses of the Appraiser and all reasonable out-of-pocket costs and expenses actually incurred by the Company Shareholder in connection with any Audit. 

  
 16 

 (g) Final Calculation and Payment of Contingent Sales Payment. With respect to any
Contingent Sales Payment for any Payment Quarter: 
 (i) In the event the Company Shareholder does not deliver a Dispute Notice with
respect to the Contingent Sales Payment set forth on the Contingent Payment Certificate delivered for such Payment Quarter within the Dispute Period, or the Company Shareholder delivers to Parent a written notice informing Parent of its agreement
with the Contingent Sales Payment set forth on such Contingent Payment Certificate, the Contingent Sales Payment set forth in the relevant Contingent Payment Certificate shall irrevocably be deemed to be the final such Contingent Sales Payment for
such Payment Quarter for all purposes of this Agreement. 
 (ii) In the event that the Company Shareholder delivers a Dispute Notice with
respect to a Contingent Sales Payment, and Parent and the Company Shareholder shall mutually determine the Agreed Contingent Payment Amount, then the Agreed Contingent Payment Amount shall irrevocably be deemed to be the final such Contingent Sales
Payment for such Payment Quarter for all purposes of this Agreement and Parent shall, within ten (10) days after such Agreed Contingent Payment Amount is determined, pay the amounts required to be paid based on such Agreed Contingent Payment
Amount. 
 (iii) In the event that the final Contingent Sales Payment for such Payment Quarter is determined by an Appraiser, and
additional amounts are owed by Parent or Purchaser, then Parent and Purchaser shall, within ten (10) days after such determination, pay such additional amounts, and if Parent and Purchaser paid in excess of what was due, then Parent and
Purchaser will have the right to offset future the excess against future Contingent Sales Payment. 
 (iv) The determination of any
Contingent Sales Payment shall, in the absence of fraud and willful misconduct, be conclusive, and in the absence of fraud and willful misconduct, the Buyer Group, the Company Shareholder and Appraiser shall each be free from any and all liability
resultant from such determination except as expressly set forth herein. 
 (h) Unilateral Right of Set-Off. Subject to the express
limitations and procedures set forth in ARTICLE 9 hereof, the obligation of Purchaser to make any Contingent Payment shall be qualified by the right of Purchaser to reduce the amount of any one or more of the Milestone Payments or the Contingent
Sales Payments, by the amount of any Indemnifiable Damages for which an Indemnified Person may be entitled to indemnification pursuant to ARTICLE 9; provided, that the right of Purchaser to reduce any Contingent Payment pursuant to this Section is
subject to the limitations, notice requirements and procedures set forth in ARTICLE 9. In the event that (A) Purchaser sets off the amount of any Contingent Payment by the amount of any Indemnifiable Damages that have not been, at the time such
Contingent Payment is made, incurred by Purchaser or (B) the Company Shareholder objects to a Claim Certificate as set forth in Section 9.6, and it is later finally determined that the full amount of such Indemnifiable Damages will
not be incurred by Indemnified Person, or the applicable Indemnified Person is not entitled to indemnification pursuant to ARTICLE 9 with respect to any portion of such Indemnifiable Damages, as the case may be, then, following such determination,
Purchaser shall pay to the Company Shareholder and Teva, promptly after such determination and without interest, the amount of the prior reduction attributable to such Indemnifiable Damages that will not be incurred by Purchaser (or for which the
applicable Indemnified Person is not entitled to indemnification) in the form of an additional Contingent Payment that is otherwise paid in accordance with the terms of this Agreement. 

(i) No Security. The Company Shareholder understands and agrees that (a) the contingent rights to receive any Contingent Payment
will not be represented by any form of certificate, are not transferable, except by operation of law relating to descent and distribution, divorce and community property, and do not constitute an equity or ownership interest in any member of the
Buyer Group, (b) neither the Company Shareholder nor Teva shall have any rights as a security holder of any member of the Buyer Group as a result of the Company Shareholder’s or Teva’s contingent right to receive any Contingent
Payment hereunder and (c) no interest is payable with respect to any Contingent Payment. 

  
 17 

 (j) Contingent Payments Not Royalties. The Contingent Payments provided for pursuant to
this Agreement are provided as a result of bona fide difficulties in determining the present value of the Company. The Contingent Payments represent (and shall be reported by Parent and Purchaser as) additional consideration for the Company Ordinary
Shares and are not intended to be royalty payments. 
 ARTICLE 2 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 Subject to the disclosures set forth in the disclosure letter of the Company delivered to Purchaser concurrently with the
parties’ execution of this Agreement (the “Company Disclosure Letter”) (each of which disclosures, in order to be effective, shall clearly indicate the Section and, if applicable, the Subsection of this ARTICLE 2 to
which it relates (unless and only to the extent the relevance to other representations and warranties is readily apparent from the actual text of the disclosures without any reference to extrinsic documentation or any independent knowledge on the
part of the reader regarding the matter disclosed), and each of which disclosures shall also be deemed to be representations and warranties made by the Company to Purchaser under this ARTICLE 2), the Company represents and warrants to Purchaser, as
of the date hereof and as of the Closing Date, as follows: 
 2.1 Organization, Standing, Power and Subsidiaries. 

(a) The Company is a corporation duly organized and validly existing under the laws of the State of Israel. The Company has the corporate
power to own its properties and to conduct its business as now being conducted and as currently proposed by it to be conducted and is duly qualified to do business and is in good standing in each jurisdiction where the failure to be so qualified and
in good standing, individually or in the aggregate with any such other failures, would reasonably be expected to result in liability that is material to the Company. The Company is not in violation of any of the provisions of its Articles of
Association. 
 (b) Except as set forth on Schedule 2.1(b) of the Company Disclosure Letter, the Company has and, since its inception
has had, no subsidiaries or any Equity Interest, whether direct or indirect, in, or any loans to, any corporation, partnership, limited liability company, joint venture or other business entity. 

(c) Schedule 2.1(c) of the Company Disclosure Letter sets forth a true, correct and complete list of: (i) the names of the members
of the Board of Directors (or similar body) of the Company; (ii) the names of the members of each committee of the Board of Directors (or similar body) of the Company; and (iii) the names and titles of the officers of the Company. 

(d) Schedule 2.1(d) of the Company Disclosure Letter sets forth (i) a list of all jurisdictions throughout the world in which the
Company is authorized or qualified to do business as a foreign corporation, (ii) a true, correct and complete listing of the locations of all sales office, manufacturing facilities, and any other office or facilities of the Company and
(iii) a true and complete list of all jurisdictions in which the Company maintains any employees or contractors. 
 2.2 Capital
Structure. 
 (a) The authorized share capital of the Company consists of NIS 20,000, divided into 2,000,000 Company Ordinary Shares. As
of the Agreement Date, (i) a total of 1,317,398 Company 

  
 18 

 
Ordinary Shares are issued and outstanding and (ii) there are no other issued and outstanding share capital or other securities of the Company and no outstanding commitments or Contracts to
issue any share capital or other securities of the Company other than pursuant to the exercise of outstanding Company Options under the Company Option Plans. As of the Closing Date, (i) a total of 1,102,021 Company Ordinary Shares are issued
and outstanding and (ii) there are no outstanding Company Options or other issued and outstanding share capital or other securities of the Company and no outstanding commitments or Contracts to issue any share capital or other securities of the
Company. The Company holds no treasury shares. Schedule 2.2(a) of the Company Disclosure Letter accurately sets forth, as of the Agreement Date, the name of each Person that is the registered owner of any Company Ordinary Shares and the
number of such shares so owned by such Person. The number of such shares set forth as being so owned by such Person constitutes the entire interest of such Person in the issued and outstanding capital stock or voting securities of the Company. All
issued and outstanding Company Ordinary Shares are duly authorized, validly issued, fully paid and non-assessable and are free of any Encumbrances, preemptive rights, rights of first refusal or “put” or “call” rights created by
statute, the Articles of Association of the Company or any Contract to which the Company is a party or by which the Company is bound. All corporate actions and proceedings on the part of the Company in connection with all transactions involving the
sale of the Company’s securities among and between the Company’s present and past shareholders have complied with all applicable securities laws. The Company has never declared or paid any dividends on any Company Ordinary Shares. There is
no liability for dividends accrued and unpaid by the Company. The Company is not under any obligation to register under any securities laws any Company Ordinary Shares or any other securities of the Company, whether currently outstanding or that may
subsequently be issued. All issued and outstanding Company Ordinary Shares were issued in compliance with any applicable Legal Requirements and all requirements set forth in the Articles of Association and any applicable Contracts to which the
Company is a party or by which the Company or any of its assets is bound. The Company Shareholder is the sole legal and beneficial owner of the Company Ordinary Shares set forth on Schedule 2.2(a) of the Company Disclosure Letter as being so
owned by the Company Shareholder and constitute the entire interest of the Company Shareholder in the issued and outstanding share capital or voting securities of the Company, and, to the Company’s knowledge, no other Person has any right,
title or interest in or to such Company Ordinary Shares. As of the Agreement Date, Teva is the sole legal and, to the Company’s knowledge, beneficial owner of the Company Ordinary Shares set forth on Schedule 2.2(a) of the Company
Disclosure Letter as being so owned by Teva and constitute the entire interest of Teva in the issued and outstanding share capital or voting securities of the Company, and, to the Company’s knowledge, no other Person has any right, title or
interest in or to such Company Ordinary Shares. 
 (b) As of the Agreement Date, the Company has reserved 52,632 Company Ordinary Shares for
issuance to employees, non-employee directors and consultants pursuant to the Company Option Plans, of which 51,450 shares are subject to outstanding and unexercised Company Options, and 1,182 shares remain available for issuance thereunder.
Schedule 2.2(b)-1 of the Company Disclosure Letter sets forth, as of the Agreement Date, a true, correct and complete list of all holders of outstanding Company Options, whether or not granted under the Company Option Plan, including the
number of Company Ordinary Shares subject to each Company Option, the date of grant, the exercise or vesting schedule (and the terms of any acceleration thereof), the exercise price per share, the tax track under which such Options were granted
under the ITO, the term of each Company Option, and the plan from which such Company Option was granted. In addition, Schedule 2.2(b)-2 of the Company Disclosure Letter sets forth a true, correct and complete list (which schedule shall be a
subset Schedule 2.2(b)-1 of the Company Disclosure Letter) of all holders of outstanding Company Options that are held by Persons that are not employees of the Company (including non-employee directors, consultants, advisory board members,
vendors, service providers or other similar persons), including a description of the relationship between each such Person and the Company. Correct and complete copies of each Company Option Plan, all agreements and instruments relating to or issued
under each Company Option Plan (including executed copies of all Contracts relating to each Company Option and the Company Ordinary Shares 

  
 19 

 
purchased under such option) have been provided to Purchaser’s counsel, and such plans and Contracts have not been amended, modified or supplemented since being provided to Purchaser’s
counsel, and there are no agreements, understandings or commitments to amend, modify or supplement such plans or Contracts in any case from those provided to Purchaser’s counsel. No benefits under any of such Company Option Plans will
accelerate in connection with the Share Purchase. No other outstanding Company Options, whether under the Company Option Plans or otherwise, will be accelerated in connection with the Share Purchase. All Company Options were issued in compliance
with all applicable Legal Requirements and all requirements set forth in applicable Contracts, including, but not limited to the Company Option Plans. Each Option granted under the “capital gain track” described in Section 102(b)(2)
of the ITO was notified to and deposited with the Section 102 Trustee in a timely manner in accordance with the requirements of current ITA guidelines so as to qualify as capital gain track grants. 

(c) Other than as set forth on Schedules 2.2(a), 2.2(b)-1, and 2.2(b)-2 of the Company Disclosure Letter, as of the
Agreement Date, no Person has any right to acquire any Company Ordinary Shares or any Company Options or other rights to purchase Company Ordinary Shares or other securities of the Company, from the Company or the Company Shareholder or, to the
Company’s knowledge, Teva. 
 (d) No bonds, debentures, notes or other indebtedness of the Company (i) granting its holder the
right to vote on any matters on which shareholders may vote (or which is convertible into, or exchangeable for, securities having such right) or (ii) the value of which is any way based upon or derived from capital or voting stock of the
Company, is issued or outstanding as of the Agreement Date (collectively, “Company Voting Debt”). 
 (e) Except for
the Company Options described in Schedule 2.2(b)-1 and 2.2(b)-2 of the Company Disclosure Letter, there are no options, warrants, calls, rights or Contracts of any character to which the Company is a party or by which it is bound
obligating the Company to issue, deliver, sell, repurchase or redeem, or cause to be issued, delivered, sold, repurchased or redeemed, any Company Ordinary Shares, Company Options or other rights to purchase Company Ordinary Shares or other
securities of the Company, or any Company Voting Debt, or obligating the Company to grant, extend, accelerate the vesting and/or repurchase rights of, change the price of, or otherwise amend or enter into any such Company Option, call, right or
Contract. There are no Contracts relating to voting, purchase, sale or transfer of any Company Ordinary Shares (i) between or among the Company and any Company Securityholder, other than written contracts granting the Company the right to
purchase unvested shares upon termination of employment or service, and (ii) to the knowledge of the Company, between or among any of the Company Securityholders. Neither the Company Option Plan nor any Contract of any character to which the
Company is a party to or by which the Company is bound relating to any Company Options requires or otherwise provides for any accelerated vesting of any Company Options in connection with the Share Purchase or any other transaction contemplated by
this Agreement or upon termination of employment or service with the Company or with Purchaser, or any other event, whether before, upon or following the Share Purchase or otherwise. 

(f) The Spreadsheet will accurately set forth, as of the Closing, the name of each Person that is the registered owner of any Company Ordinary
Shares and the number and kind of such shares so owned. The number of such shares set forth as being so owned by such Person will constitute the entire interest of such person in the issued and outstanding capital stock, voting securities or other
securities of the Company. As of the Closing, no other Person not disclosed in the Spreadsheet will have a right to acquire any Company Ordinary Shares and/or Company Options from the Company. In addition, the Company Ordinary Shares disclosed in
the Spreadsheet will be, as of the Closing, free and clear of any Encumbrances created by the Articles of Association of the Company or any Contract to which the Company is a party or by which it is bound. 

  
 20 

 2.3 Authority; Noncontravention. 

(a) The Company has all requisite corporate power and authority to enter into this Agreement and to consummate the transactions contemplated
hereby. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary corporate action on the part of the Company. This Agreement has been duly executed and
delivered by the Company and constitutes the valid and binding obligation of the Company enforceable against the Company in accordance with its terms subject only to the effect, if any, of (i) applicable bankruptcy and other similar laws
affecting the rights of creditors generally and (ii) rules of law governing specific performance, injunctive relief and other equitable remedies. The Board of Directors, by resolutions duly adopted (and not thereafter modified or rescinded) by
the unanimous vote of the Board of Directors, has approved and adopted this Agreement and approved the Share Purchase. The vote of the Company Shareholders is required in connection with the execution, delivery or performance of this Agreement by
the Company or the Company Shareholder and the consummation of the Share Purchase and the other transactions contemplated by this Agreement. 

(b) The execution and delivery of this Agreement by the Company does not, and the consummation of the transactions contemplated hereby will
not, (i) result in the creation of any Encumbrance on any of the material properties or assets of the Company or to the knowledge of the Company, any of the Company Ordinary Shares or (ii) conflict with, or result in any violation of or
default under (with or without notice or lapse of time, or both), or give rise to a right of termination, cancellation or acceleration of any obligation or loss of any benefit under, or require any consent, approval or waiver from any Person
pursuant to, (A) any provision of the Articles of Association, in each case as amended to date, (B) any Contract of the Company or any Contract applicable to any of their respective material properties or assets, or (C) any Legal
Requirements applicable to the Company or any of their respective material properties or assets. 
 (c) No consent, approval, order or
authorization of, or registration, declaration or filing with, any Governmental Entity is required by or with respect to the Company in connection with the execution and delivery of this Agreement or the consummation of the transactions contemplated
hereby, except for (i) the filing of the OCS Notice and the execution by Purchaser of an undertaking in customary form in favor of the OCS to comply with the applicable Israeli Encouragement of Industrial Research and Development Law, 1984, and
(ii) such other consents, authorizations, filings, approvals, notices and registrations which, if not obtained or made, would not be material to the Company’s ability to consummate the Share Purchase or to perform its obligations under
this Agreement and would not prevent, materially alter or delay any of the transactions contemplated by this Agreement. 
 (d) The Company,
its Board of Directors and the Company Shareholders have taken all actions such that the restrictive provisions of any “fair price,” “moratorium,” “control share acquisition,” “business combination,”
“interested shareholder” or other similar anti-takeover statute or regulation, and any anti-takeover provision in the governing documents of the Company will not be applicable to any of the Company or Purchaser or to the execution,
delivery of, or performance of the transactions contemplated by this Agreement or to the Transactions. 
 2.4 Financial Statements.

 (a) The Company has delivered to Purchaser its audited consolidated financial statements for each of its fiscal years ending
December 31, 2013, December 31, 2012 and December 31, 2011 (including, in each case, balance sheets, statements of operations and statements of cash flows (collectively, the “Financial Statements”), which
are included as Schedule 2.4(a) of the Company Disclosure Letter. The Financial Statements (i) are derived from and in accordance with the books and records of the Company, (ii) complied as to form in all material respects with
applicable accounting 

  
 21 

 
requirements with respect thereto as of their respective dates, (iii) have been prepared in accordance with International Financial Reporting Standards (“IFRS”)
applied on a consistent basis throughout the periods indicated and consistent with each other, (iv) fairly and accurately present the consolidated financial condition of the Company at the dates therein indicated and the consolidated results of
operations and cash flows of the Company for the periods therein specified, and (v) are true, complete and correct in all material respects.  

(b) The Company has no Liabilities of the type that would be required to be disclosed as a liability on a balance sheet prepared in accordance
with IFRS, or in footnotes that would be included with financial statements prepared in accordance with IFRS, other than (i) those set forth or adequately provided for in the balance sheet included in the Financial Statements as of
December 31, 2013 (the “Company Balance Sheet”), (ii) those incurred in the conduct of the Company’s business since December 31, 2013 (the “Company Balance Sheet Date”) in
accordance with the Company’s budget as approved by its Board of Directors, a copy of which has been made available to Purchaser (the “Company Budget”), and (iii) those incurred by the Company in connection with the
execution of this Agreement. Except for Liabilities reflected in the Financial Statements, the Company has no off balance sheet Liability of any nature to, or any financial interest in, any third party or entities, the purpose or effect of which is
to defer, postpone, reduce or otherwise avoid or adjust the recording of expenses incurred by the Company. Without limiting the generality of the foregoing, the Company has never guaranteed any debt or other obligation of any other Person. All
reserves that are set forth in or reflected in the Company Balance Sheet have been established in accordance with IFRS consistently applied and are adequate. 

(c) The Company has established and maintains a system of internal accounting controls sufficient to provide reasonable assurances
(i) that transactions of the Company are being executed and made only in accordance with appropriate authorizations of management and the Board of Directors of Company, (ii) that transactions are recorded as necessary (A) to permit
preparation of financial statements in conformity with IFRS and (B) to maintain accountability for assets, (iii) that access to assets is permitted only in accordance with management authorization, and (iv) that the amount recorded
for assets on the books and records of the Company is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Neither the Company nor the Company’s independent auditors, nor to
the Company’s knowledge, any current or former employee, consultant or director of Company, has identified or been made aware of any fraud, whether or not material, that involves Company’s management or other current or former employees,
consultants directors of Company, or any claim or allegation regarding any of the foregoing. Neither the Company nor, to the Company’s knowledge, any director, officer, employee, auditor, accountant or representative of the Company has received
or otherwise had or obtained knowledge of any material complaint, allegation, assertion or claim, whether written or oral, in each case, regarding deficient accounting or auditing practices, procedures, methodologies or methods of the Company or
their respective internal accounting controls or any material inaccuracy in the Company’s financial statements. No attorney representing the Company, whether or not employed by the Company, has reported to the Board of Directors or any
committee thereof or to any director or officer of the Company evidence of a material violation of securities laws, breach of fiduciary duty or similar violation by the Company or its officers, directors, employees or agents. There are no
significant deficiencies or material weaknesses in the design or operation of the Company’s internal controls which could adversely affect the Company’s ability to record, process, summarize and report financial data. At the Company
Balance Sheet Date, there were no material loss contingencies (as such term is used in International Accounting Standards No. 37 (“IAS 37”), Provisions, Contingent Liabilities and Contingent Assets, issued by the
International Accounting Standards Board in September 1998) that are not adequately provided for in the Company Balance Sheet as required by said IAS 37. There has been no change in the Company accounting policies since the Company’s inception,
except as described in the Financial Statements. 

  
 22 

 (d) Schedule 2.4(d) of the Company Disclosure Letter sets forth the names and locations of
all banks, trust companies, savings and loan associations and other financial institutions at which the Company maintains accounts of any nature and the names of all Persons authorized to draw thereon or make withdrawals therefrom. 

(e) Schedule 2.4(e) of the Company Disclosure Letter accurately lists all indebtedness of Company for money borrowed
(“Company Debt”), including, for each item of Company Debt, the agreement governing the Company Debt and the interest rate, maturity date and any assets or properties securing such Company Debt. All Company Debt may be
prepaid at the Closing without penalty under the terms of the Contracts governing such Company Debt. 
 2.5 Absence of Certain
Changes. Since the Company Balance Sheet Date, the Company has conducted its business only in the ordinary course consistent with past practice and: 

(a) there has not occurred a Material Adverse Effect on the Company, 

(b) the Company has not made or entered into any Contract or letter of intent with respect to, or otherwise effected, any acquisition, sale,
license, disposition or transfer of any asset of the Company, 
 (c) except as required by IFRS, there has not occurred any change in
accounting methods or practices (including any change in depreciation or amortization policies or rates or revenue recognition policies or establishment of reserves) by the Company or any revaluation by the Company of any of its assets, 

(d) the Company has not made any Tax election, prepared any Tax Returns in a manner which is inconsistent with the past practices of the
Company with respect to the treatment of items on such Tax Returns, incurred any material liability for Taxes other than in the ordinary course of business consistent with past practice, filed an amended Tax Return or a claim for refund of Taxes
with respect to the income, operations or property of the Company, or settled any claim relating to Taxes, 
 (e) there has not occurred any
declaration, setting aside, or payment of a dividend or other distribution with respect to any securities of the Company, or any direct or indirect redemption, purchase or other acquisition by the Company of any of its securities, or any change in
any rights, preferences, privileges or restrictions of any of its outstanding securities, 
 (f) the Company has not entered into, amended,
renewed or terminated any Material Contract, and there has not occurred any default or breach under any Material Contract to which the Company is a party or by which it is, or any of its assets and properties are, bound, 

(g) there has not occurred any amendment or change to the Articles of Association, 

(h) there has not occurred any increase in or modification of the compensation or benefits payable or to become payable by the Company to any
of its directors, officers, employees or consultants (other than increases in the base salaries of employees who are not officers in an amount that does not exceed 10% of such base salaries), any adoption or modification of any employee benefit plan
or any new loans or advances or extension of existing loans or advances to any such Persons (other than routine expense advances to employees of the Company consistent with past practice), and neither the Company has entered into any Contract to
grant or provide (nor has granted any) severance, acceleration of vesting or other similar benefits to any such Persons, 

  
 23 

 (i) there has not occurred the execution of any Contracts or the extension of the term of any
existing Contract with any Person in the employ or service of the Company, 
 (j) there has not occurred any change in title, office or
position, or material reduction in the responsibilities of, or change in identity with respect to the management, supervisory or other key personnel of the Company, any termination of employment of any such employees, or any labor dispute or claim
of unfair labor practices involving the Company, 
 (k) the Company has not incurred, created or assumed any Encumbrance (other than a
Permitted Encumbrance) on any of its assets or properties, any Liability for borrowed money or any Liability as guarantor or surety with respect to the obligations of any other Person, 

(l) the Company has not paid or discharged any Encumbrance or Liability which was not shown on the Company Balance Sheet or incurred in the
ordinary course of business consistent with past practice since the Company Balance Sheet Date, 
 (m) the Company has not incurred any
Liability to its directors, officers or shareholders (other than Liabilities to pay compensation or benefits in connection with services rendered in the ordinary course of business, consistent with past practice), 

(n) the Company has not cancelled or waived any Liabilities owed to it, 

(o) the Company has not made any deferral of the payment of any accounts payable other than in the ordinary course of business, consistent
with past practice, or in an amount in excess of $100,000, or given any discount, accommodation or other concession other than in the ordinary course of business, consistent with past practice, in order to accelerate or induce the collection of any
receivable, 
 (p) there has been no material damage, destruction or loss, whether or not covered by insurance, affecting the assets,
properties or business of the Company, 
 (q) the Company has not sold, disposed of, transferred or licensed to any Person any rights to any
Company-Owned IP Rights, 
 (r) there has been no application for or receipt of a Government Grant, and 

(s) there has not occurred any announcement of, any negotiation by or any entry into any Contract by the Company to do any of the things
described in the preceding clauses (a) through (q) (other than negotiations and agreements with Purchaser and its representatives regarding the transactions contemplated by this Agreement). 

2.6 Litigation. There is no private or governmental action, suit, proceeding, claim (including any claim for injury by participants in
clinical studies), mediation, arbitration or investigation pending before any Governmental Entity (a “Legal Proceeding”), or, to the knowledge of the Company, threatened against the Company or any of its assets or properties
or any of its directors, officers or employees (in their capacities as such or relating to their employment, services or relationship with the Company), nor, to the knowledge of the Company, is there any reasonable basis for any such action, suit,
proceeding, claim, mediation, arbitration or investigation. There is no judgment, decree, injunction or order against the Company, any of its assets or properties, or, to the knowledge of the Company, any of their respective directors, officers or
employees (in their capacities as such or relating to their employment, services or relationship with the Company). To the knowledge of the Company, there is no reasonable basis for any Person to assert a claim against the Company based upon the
Company entering into this Agreement or any of the other transactions or agreements contemplated hereby. The Company 

  
 24 

 
does not have any Legal Proceeding pending against any other Person. Schedule 2.6 of the Company Disclosure Letter contains a complete and accurate description of all Legal Proceedings,
during the past seven (7) years, to which the Company has been a party or which relate to any its assets or properties or any of its officers or directors (in their capacities as such or relating to their employment, services or relationship
with the Company), or any such Legal Proceedings which were settled prior to the institution of formal proceedings, other than Legal Proceedings brought by the Company for collection of monies owed in the ordinary course of business. 

2.7 Restrictions on Business Activities. There is no Contract, judgment, injunction, order or decree binding upon the Company that has
or would reasonably be expected to have, whether before or after consummation of the Share Purchase, the effect of prohibiting, restricting or impairing any current or presently proposed business practice of the Company, any acquisition of property
by the Company or the conduct or operation of the Business or limiting the freedom of the Company to engage in any line of business, to sell, license or otherwise distribute services or the Company Product in any market or geographic area, or to
compete with any Person. 
 2.8 Compliance with Laws; Governmental Permits. 

(a) The Company has complied in all material respects with, is not in violation of, and has not received any notices of violation with respect
to, any applicable Legal Requirement with respect to the conduct of its business, or the ownership or operation of its business. To the Company’s knowledge, no event has occurred, and no condition or circumstance exists, that will (with or
without notice or lapse of time) constitute or result in a material violation by the Company of, or a failure on the part of the Company to comply with, any Legal Requirement. Neither the Company nor any director, officer, or employee thereof (in
their capacities as such or relating to their employment, services or relationship with the Company), has given, offered, paid, promised to pay or authorized payment of any money, any gift or anything of value, with the purpose of influencing any
act or decision of the recipient in his or her official capacity or inducing the recipient to use his or her influence to affect an act or decision of a government official or employee, to any (i) governmental official or employee,
(ii) political party or candidate thereof, or (iii) Person while knowing that all or a portion of such money or thing of value would be given or offered to a governmental official or employee or political party or candidate thereof. 

(b) The Company has obtained each federal, state, county, local or foreign governmental consent, license, permit, grant, or other
authorization of a Governmental Entity (i) pursuant to which the Company currently operates or holds any interest in any of its assets or properties or (ii) that is required for the operation of the Business or the holding of any such
interest (all of the foregoing consents, licenses, permits, grants, and other authorizations, collectively, the “Company Authorizations”), and all of the Company Authorizations are in full force and effect. The Company has
not received any notice or other communication from any Governmental Entity regarding (i) any actual or possible violation of law or any Company Authorization or any failure to comply with any term or requirement of any Company Authorization or
(ii) any actual or possible revocation, withdrawal, suspension, cancellation, termination or modification of any Company Authorization. The Company has materially complied with all of the terms of the Company Authorizations. None of the Company
Authorizations will be terminated or impaired, or will become terminable, in whole or in part, as a result of the consummation of the transactions contemplated by this Agreement. 

2.9 Title to, Condition and Sufficiency of Assets. 

(a) The Company has good and valid title to, or valid leasehold interests in, all of its respective properties, and interests in properties
and assets, real and personal, reflected on the Company Balance Sheet or acquired after the Company Balance Sheet Date (except properties and assets, or 

  
 25 

 
interests in properties and assets, sold or otherwise disposed of since the Company Balance Sheet Date in the ordinary course of business consistent with past practice), or, with respect to
leased properties and assets, valid leasehold interests in such properties and assets that afford the Company valid leasehold possession of the properties and assets that are the subject of such leases, in each case, free and clear of all
Encumbrances, except (i) Permitted Encumbrances incurred in the ordinary course of business consistent with past practice for obligations not past due, (ii) such imperfections of title and non-monetary Encumbrances as do not and will not
detract from or interfere with the use of the properties subject thereto or affected thereby, or otherwise impair business operations involving such properties, and (iii) liens securing indebtedness that is reflected on the Company Balance
Sheet. The plant, property and equipment of each of the Company that are used in the operations of their its businesses are (i) in good operating condition and repair, subject to normal wear and tear and (ii) not obsolete, dangerous or in
need of renewal or replacement, except for renewal or replacement in the ordinary course of business, consistent with past practice. All properties used in the operations of the Company are reflected on the Company Balance Sheet to the extent
required under IFRS to be so reflected. Schedule 2.9(a) of the Company Disclosure Letter identifies each parcel of real property leased by the Company. The Company has adequate rights of ingress and egress into any real property used in the
operation of the Business. The Company has heretofore provided to Purchaser’s counsel true, correct and complete copies of all leases, subleases and other agreements under which the Company uses or occupies or has the right to use or occupy,
now or in the future, any real property or facility, including all modifications, amendments and supplements thereto. The Company does not currently own any real property. 

(b) The assets owned by the Company constitute all of the assets that are necessary for the Company to conduct, operate and continue the
business of the Company as such business is currently conducted , and (ii) constitute all of the assets that are used in the business of the Company as such business is currently conducted, without the breach or violation of any Contract. 

2.10 Intellectual Property Rights. 

(a) The Company (i) owns and has independently developed or acquired, or (ii) has the valid right or license to, all Company IP
Rights. The Company IP Rights are sufficient for the conduct of the business of the Company as currently conducted and as currently proposed by the Company to be conducted by the Company. 

(b) The Company has not transferred ownership of any Intellectual Property that is or was Company-Owned IP Rights to any third party, or
knowingly permitted the Company’s rights in any Intellectual Property that is or was Company-Owned IP Rights to enter the public domain or, with respect to any Intellectual Property for which the Company have submitted an application or
obtained a registration, lapse (other than through the expiration of registered Intellectual Property at the end of its maximum statutory term). 

(c) The Company owns and has good and exclusive title to each item of Company-Owned IP Rights and each item of Company Registered Intellectual
Property, free and clear of any Encumbrances (other than Permitted Encumbrances). To the knowledge of the Company, the right, license and interest of the Company in and to all Third Party Intellectual Property Rights licensed by the Company from a
third party are free and clear of all Encumbrances (excluding restrictions contained in the applicable written license agreements with such third parties and Permitted Encumbrances) (for clarity, Company does not make any representation or warranty
that the Third Party Intellectual Property Rights are free of Encumbrances). 
 (d) Neither the execution and delivery or effectiveness of
this Agreement nor the performance of the Company’s obligations under this Agreement will cause the forfeiture or termination of, or give rise to a right of forfeiture or termination of, any Company-Owned IP Right, or impair the right of the
Company or Purchaser to use, possess, sell or license any Company-Owned IP Right or portion thereof. 

  
 26 

 (e) Schedule 2.10(e) of the Company Disclosure Letter sets forth a true, correct and
complete list as of the Agreement Date of all Company Registered Intellectual Property, including the owner(s) of each such item of Company Registered Intellectual Property and the jurisdictions in which each such item of Company Registered
Intellectual Property has been issued or registered or in which any application for such issuance and registration has been filed, or in which any other filing or recordation has been made. Schedule 2.10(e) of the Company Disclosure Letter
sets forth a list of all actions that are required to be taken by the Company within 120 days of the Agreement Date with respect to any of the Company Registered Intellectual Property in order to avoid prejudice to, impairment or abandonment of such
Company Registered Intellectual Property. 
 (f) To the knowledge of the Company, each item of Company Registered Intellectual Property is
valid and enforceable (or in the case of applications, subsisting), and no such item has been abandoned or allowed to lapse. The Company Registered Intellectual Property listed in Schedule 2.10(f) of the Company Disclosure Letter has
been filed, prosecuted and maintained in good faith and in a commercially reasonable manner and in compliance with applicable Legal Requirements, and is in good administrative standing. All registration, maintenance and renewal fees currently due in
connection with the Company Registered Intellectual Property listed in Schedule 2.10(f) of the Company Disclosure Letter have been paid and all documents, recordations and certificates in connection with such Company Registered
Intellectual Property currently required to be filed have been filed with the relevant patent, copyright, trademark or other authorities in the United States, Israel or foreign jurisdictions, as the case may be, for the purposes of prosecuting,
maintaining and perfecting such Company Registered Intellectual Property and recording the Company’s or the relevant licensor’s ownership interests therein. To the knowledge of the Company, none of the Company Registered Intellectual
Property is currently involved in any interference, inventorship dispute, reissue, reexamination, opposition, or cancellation claim or proceeding or any claim or proceeding, and the Company has not received any written notice from any Person
regarding any such claim or proceeding and to the Company’s knowledge no grounds exist for any such action or proceeding. To the knowledge of the Company, there is no threatened claim or proceeding of the nature described in the immediately
preceding sentence, nor any facts or circumstances that could reasonably be expected to give rise to the same. The Company has not entered into any Contract granting any person the right to control the prosecution of any of the Company Registered
Intellectual Property listed in Schedule 2.10(f) of the Company Disclosure Letter. 
 (g) The Company is not or shall not be as
a result of the execution and delivery or effectiveness of this Agreement or the performance of the Company’s obligations under this Agreement, in breach of Company IP Rights Agreements and the consummation of the transactions contemplated by
this Agreement will not result in the modification, cancellation, termination, suspension of, or acceleration of any payments with respect to the Company IP Rights Agreements, or give any non-Company party to any Company IP Rights Agreement the
right to do any of the foregoing. Following the Closing, the Company (as wholly-owned by Purchaser) will be permitted to exercise all of the Company’s rights under the Company IP Rights Agreements to the same extent the Company would have been
able to had the transactions contemplated by this Agreement not occurred and without the payment of any additional amounts or consideration other than ongoing fees, royalties or payments which the Company would otherwise be required to pay. 

(h) None of the Company IP Rights Agreements grants any third party exclusive rights to or under any Company IP Rights or grants any third
party the right to sublicense any Company IP Rights. 

  
 27 

 (i) There are no royalties, honoraria, fees or other payments payable by the Company to any
Person (other than (i) one time, lump-sum fees payable for end-user or other licenses to generally commercially available software or products and (ii) salaries payable to employees, consultants and independent contractors not contingent
on or related to use of their work product) as a result of the ownership, use, possession, license-in, license-out, sale, marketing, advertising or disposition of any Company IP Rights by the Company. 

(j) To the knowledge of the Company, there is no unauthorized use, unauthorized disclosure, infringement or misappropriation of any
Company-Owned IP Rights, by any third party, including any employee or former employee of the Company. The Company has not brought any action, suit or proceeding for infringement or misappropriation of any Intellectual Property or breach of any
Company IP Rights Agreement. The Company has not entered into any Contract granting any Person the right to bring infringement, or misappropriation actions with respect to, or otherwise to enforce rights with respect to, any of the Company-Owned IP
Rights. 
 (k) The Company has not been sued in any suit, action or proceeding (or received any written notice or, to the knowledge of the
Company, threat) which involves a claim of infringement or misappropriation of any Third Party Intellectual Property Rights or which contests the validity, ownership or right of the Company to own or exercise any Intellectual Property right and to
the Company’s knowledge no grounds exist for any such suit, action or proceeding. The Company has not received any written communication that involves an offer to license or grant any other rights or immunities under any Third Party
Intellectual Property Rights. 
 (l) To the knowledge of the Company, the Company has no Liability for infringement or misappropriation of
Third Party Intellectual Property Rights or for unfair competition or unfair trade practices under the laws of any jurisdiction. To the knowledge of the Company, the operation of the business of the Company as such business is currently conducted
and as currently proposed by the Company to be conducted by the Company has not and does not infringe(d) or misappropriate(d) any Third Party Intellectual Property Rights and does not constitute unfair competition or unfair trade practices under the
laws of any jurisdiction and there is no substantial basis for a claim that the operation of the business of the Company will infringe, is infringing or has infringed on or misappropriated any Third Party Intellectual Property Rights, or constitutes
or has constituted unfair competition or unfair trade practices under the laws of any jurisdiction. The Company has not received any opinion of counsel that any Company Product or the operation of the business of the Company as previously or
currently conducted by the Company infringes or misappropriates any Third Party Intellectual Property Rights. 
 (m) None of the
Company-Owned IP Rights, the Company Products, or the Company is subject to any proceeding or outstanding order, or stipulation (A) restricting in any manner the use, transfer, or licensing by the Company of any Company-Owned IP Right or any
Company Product, or which may affect the validity, use or enforceability of any such Company-Owned IP Right or Company Product, or (B) restricting the conduct of the business of the Company in order to accommodate Third Party Intellectual
Property Rights. 
 (n) The Company has secured from all Persons who independently or jointly contributed to the conception, reduction to
practice, creation or development of any Company-Owned IP Rights and Company Registered Intellectual Property unencumbered and unrestricted exclusive ownership of, all such third party’s Intellectual Property in such contribution that the
Company does not already own by operation of law and such third party has not retained any rights or licenses with respect thereto. Without limiting the foregoing, the Company has obtained proprietary information and invention disclosure and
assignment agreements from all current and former employees and consultants of the Company, waiving all moral rights (to the extent applicable), and waiving any right or interest in and to any royalty or other remuneration provided by local custom,
administrative regulation, governmental statute or otherwise (including under Section 134 of the Israeli Patent Law 1967 and any other applicable Legal Requirement). 

  
 28 

 (o) To the knowledge of the Company, no current or former employee, consultant or independent
contractor of the Company: (i) is in violation of any term or covenant of any Contract relating to employment, invention disclosure (including patent disclosure), invention assignment, non-disclosure or any other Contract with any other party
by virtue of such employee’s, consultant’s or independent contractor’s being employed by, or performing services for, the Company or using trade secrets or proprietary information of others without permission; or (ii) has
developed, created or discovered any Company-Owned IP Rights for the Company that is subject to any agreement under which such employee, consultant or independent contractor has assigned or otherwise granted to any third party any rights to any
Intellectual Property in the Company-Owned IP Rights. 
 (p) The employment of any employee of the Company or the use by the Company of the
services of any consultant or independent contractor does not subject the Company to any Liability to any third party for improperly soliciting such employee, consultant or independent contractor to work for the Company, whether such Liability is
based on contractual or other legal obligations to such third party. 
 (q) No current or former employee, consultant or independent
contractor of the Company has any right, license, claim or interest whatsoever in or with respect to any Company-Owned IP Rights, nor any option to obtain any such right, license, claim or interest. 

(r) The Company has taken all commercially reasonable steps to protect and preserve the confidentiality of all confidential or non-public
information included in the Company IP Rights, including, but not limited to, trade secrets (“Confidential Information”). All use, disclosure or appropriation of Confidential Information owned by the Company by or to a third
party has been pursuant to the terms of a written Contract between the Company and such third party. All use, disclosure or appropriation of Confidential Information by the Company not owned by the Company has been pursuant to the terms of a written
agreement between the Company or such Affiliate and the owner of such Confidential Information, or is otherwise lawful. All current and former employees and consultants of the Company having access to Confidential Information or proprietary
information of any of their respective customers or business partners have executed and delivered to the Company an agreement regarding the protection of such Confidential Information or proprietary information (in the case of proprietary
information of the Company’s customers and business partners, to the extent required by such customers and business partners). 
 (s)
To the knowledge of the Company, all Company Products sold or delivered by the Company and all services provided by or through the Company on or prior to the Closing Date conform to applicable contractual commitments, express and implied warranties
(to the extent not subject to legally effective express exclusions thereof) and applicable Legal Requirements. 
 (t) Neither the Company
nor, to the knowledge of the Company, any other Person then acting on the Company’s behalf has disclosed, delivered or licensed to any third party Person, agreed to disclose, deliver or license to any third party Person, or permitted the
disclosure or delivery to any escrow agent or other third party Person of, any Company Proprietary Specifications. To the knowledge of the Company, no event has occurred, and no circumstance or condition exists, that (with or without notice or lapse
of time, or both) will, or would reasonably be expected to, result in the disclosure, delivery or license by the Company or any Person then acting on the Company’s behalf to any third party Person of any Company Proprietary Specifications. 

  
 29 

 (u) The Company has complied with all applicable Legal Requirements and its internal privacy
policies relating to the use, collection, storage, disclosure and transfer of any personally identifiable information collected by the Company. The execution, delivery and performance of this Agreement, will comply with all applicable Legal
Requirements relating to privacy and with the Company’s privacy policies. The Company has not received a complaint regarding the Company’s collection, use or disclosure of personally identifiable information. 

(v) The Company has implemented and maintains a comprehensive security plan which (i) identifies internal and external risks to the
security of the Confidential Information, including personally identifiable information; (ii) implements, monitors and improves adequate and effective administrative, electronic and physical safeguards to control those risks; and
(ii) maintains notification procedures in compliance with applicable Legal Requirements in the case of any breach of security compromising unencrypted data containing personally identifiable information. To the knowledge of the Company, the
Company has not experienced any breach of security or otherwise unauthorized access by third parties to the Confidential Information, including personally identifiable information in the Company’s possession, custody or control. 

(w) Except as set forth in Schedule 2.10(w), no funding from any granting agency and no government funding (including OCS funding),
facilities of a university, college, other educational institution or research center, or funding from any Person was used in the creation or development of any Company-Owned IP Rights. To the knowledge of the Company, no current or former employee,
consultant or independent contractor, who was involved in, or who contributed to, the creation or development of any Company-Owned IP Rights, has performed services for any Governmental Entity, a university, college, or other educational
institution, or a research center, during a period of time during which such employee, consultant or independent contractor was also performing services used in the creation or development of the Company-Owned IP Rights, or performed such services
prior to the period of time during which such employee, consultant or independent contractor performed services for the Company such that a government, university, college or other educational institution or research center is entitled to notice or
any other right or benefit in connection with any Company-Owned IP Rights. The Company is not a party to any contract, license or agreement with any Governmental Entity that grants to such Governmental Entity any right or license with respect to any
Company-Owned IP Rights. 
 2.11 Confidentiality Agreements. Commercially reasonable measures have been taken to maintain the
confidentiality of the inventions, trade secrets, formulae, know-how, technical information, research data, research raw data, laboratory notebooks, procedures, designs, proprietary technology and information of the Company, and all other
information the value of which to the Company is contingent upon maintenance of the confidentiality thereof. Without limiting the generality of the foregoing, except as listed in Schedule 2.11-A, each current or former employee, officer,
director of the Company or consultant or agent or independent contractor of the Company who had, has or is proposed to have access to confidential and/or proprietary information of the Company is a signatory to and bound by a confidentiality
agreement in the form attached as Schedule 2.11-B. 
 2.12 Environmental Matters. 

(a) As used in this Agreement, the following terms shall have the meanings indicated below: 

(i) “Environmental and Safety Laws” shall mean any federal, state or local laws, ordinances, codes, regulations,
rules, policies and orders that are intended to assure the protection of the environment, or that classify, regulate, call for the remediation of, require reporting with respect to, or list or define air, water, groundwater, solid waste, hazardous
or toxic substances, materials, wastes, pollutants or contaminants, or which are intended to assure the safety of employees, workers or other persons, including the public, including without limitation the Israeli Hazardous Substances Law, 1993 and
related regulations. 

  
 30 

 (ii) “Hazardous Materials” shall mean any toxic or hazardous substance,
material or waste or any pollutant or contaminant, or infectious or radioactive substance, material or waste defined in or regulated under any Environmental and Safety Laws, but excludes office and janitorial supplies properly and safely maintained.

 (iii) “Property” shall mean all real property leased or owned by the Company either currently or in the past.

 (iv) “Facilities” shall mean all buildings and improvements on the Property. 

(b) (i) All Hazardous Materials and wastes of the Company have been disposed of in accordance in all material respects with all
Environmental and Safety Laws; (ii) the Company has not received any notice of any noncompliance of the Facilities or its past or present operations with Environmental and Safety Laws; (iii) no notices or Legal Proceedings are pending or
threatened relating to an actual or alleged violation of any applicable Environmental and Safety Laws by the Company; (iv) the Company is not a potentially responsible party under the federal Comprehensive Environmental Response, Compensation,
and Liability Act of 1980, as amended to date, or any analogous state, local or foreign laws arising out of events occurring prior to the Closing Date; (v) to the Company’s knowledge, there have not been in the past, and are not now, any
Hazardous Materials on, under or migrating to or from any of the Facilities or any Property; (vi) to the Company’s knowledge, there have not been in the past, and are not now, any underground tanks or underground improvements at, on or
under any Property, including treatment or storage tanks, sumps, or water, gas or oil wells; and (vii) the Facilities and the Company’s uses and activities therein have at all times materially complied with all Environmental and Safety
Laws. 
 (c) Complete and accurate copies of all written environmental reports, audits or assessments, which have been conducted, either by
the Company, or any Person engaged by the Company for such purpose, at any Facility or Property owned of formerly owned by the Company have been made available to Purchaser and a list of all such reports, audits and assessments is set forth on
Schedule 2.12(c) of the Company Disclosure Letter. The listing of such reports on Schedule 2.12(c) of the Company Disclosure Letter does not in any way create any exceptions to the representations and warranties of this Schedule
2.12, and any such exceptions shall be specifically set forth in the appropriate paragraph of Schedule 2.12 of the Company Disclosure Letter. 

2.13 Taxes. 
 (a) The
Company, and any consolidated, combined, unitary or aggregate group for Tax purposes of which the Company is or has been a member, have properly completed and timely filed all Tax Returns required to be filed by them and have timely paid all Taxes
required to be paid. All Tax Returns were complete and accurate in all material respects and have been prepared in compliance with all applicable Legal Requirements. The Company has delivered to Purchaser correct and complete copies of all Tax
Returns, examination reports, and statements of deficiencies assessed against or agreed to by the Company. The Company has not requested or received any legal or accounting opinions relating to any position taken on any Tax Return that has not been
made available to Purchaser. 
 (b) (i) the Company Balance Sheet reflects all Liabilities for unpaid Taxes of the Company for periods (or
portions of periods) through the Company Balance Sheet Date, (ii) the Company does not have any Liability for unpaid Taxes accruing after the Company Balance Sheet Date except for Taxes arising in the ordinary course of business subsequent to
the Company Balance Sheet Date, and (iii) the Company has no Liability for unpaid Taxes for any period (or portions of any period) prior to or through the Closing Date. 

  
 31 

 (c) All Tax deficiencies that have been claimed, proposed, or asserted in writing by any
Governmental Entity against the Company have been fully paid or finally settled. 
 (d) To the knowledge of the Company, there is
(i) no claim for Taxes being asserted against the Company that has resulted in a lien against the property of the Company other than liens for Taxes not yet due and payable, (ii) no formal or informal audit or pending audit of,
administrative or judicial Tax proceedings, or Tax controversy associated with, any Tax Return of the Company being conducted by a Tax Authority, (iii) no extension of any statute of limitations on the assessment of any Taxes granted by the
Company currently in effect, (iv) no agreement to any extension of time for filing any Tax Return which has not been filed and (v) no power of attorney granted by or with respect to the Company relating to Taxes that is currently in force.
The Company has not received from any Governmental Entity any (i) notice, whether or not in written form, indicating an intent to open an audit or other review with respect to Taxes, (ii) written request for information related to Tax
matters, or (iii) notice, whether or not in written form, of deficiency or proposed adjustment for any amount of Tax. 
 (e) To the
Company’s knowledge, no written claim has ever been made by any Governmental Entity in a jurisdiction where the Company does not file Tax Returns that the Company is or may be subject to taxation by that jurisdiction. 

(f) The Company has timely reported, withheld and paid all Taxes required to have been withheld and paid in connection with any amounts paid
or owing to any employee, independent contractor, equity interest holder, or other third party. 
 (g) The Company is not a party to or
bound by any Tax sharing, Tax indemnity, or Tax allocation agreement nor does the Company have any Liability or potential Liability to another party under any such agreement. 

(h) Neither the Company nor any predecessor of the Company has ever been a member of a consolidated, combined, unitary or aggregate group of
which the Company or any predecessor of the Company was not the ultimate parent corporation. 
 (i) To the Company’s knowledge, the
Company will not be required to include in income, or exclude any item of deduction from, Taxable income for any Taxable period (or portion thereof) ending on or prior to the Closing Date as a result of any (i) change in method of accounting
for a Taxable period ending on or prior to the Closing Date; (i) agreement in writing with any Tax Authority relating to the liability of the Company in respect of any Tax for any taxable period ending on or prior to; (iv) installment sale
or open transaction disposition made on or prior to the Closing Date; or (ii) prepaid amount received on or prior to the Closing Date. 

(j) The Company has provided to Purchaser all material information and documentation relating to any Tax attributes (including net operating
loss carry forwards and general business Tax credits) of the Company and all such documentation and information are true and correct in all material aspects. 

(k) The Company has in its possession official foreign government receipts for any Taxes paid by it to any foreign Tax Authority. 

(l) The Company has provided to Purchaser all documentation relating to any applicable Tax holidays or incentives. To the knowledge of the
Company, the Company is in compliance with the requirements for any applicable Tax holidays or incentives and none of the Tax holidays or incentives will be jeopardized by the transaction contemplated in this Agreement. 

  
 32 

 (m) The Company has timely and properly collected and maintained all resale certificates,
exemption certificates and other documentation required to qualify for any exemption from the collection of sales Taxes imposed on or due from the Company. 

(n) The Company is not and has not been a “United States real property holding corporation” within the meaning of Section 897
of the Code during the applicable period specified in Section 897(c)(1)(A)(ii) of the Code. 
 (o) The Company has complied (and
until the Closing will comply) with all applicable Legal Requirements relating to the payment, reporting and withholding of withholding of Taxes pursuant to Sections 1441, 1442, 1445 and 1446 of the Code or similar provisions under any applicable
foreign law, has, within the time and in the manner prescribed by law, withheld from Taxes (including employee wages or consulting compensation and paid over to the proper governmental authorities (or is properly holding for such timely payment) all
amounts required to be so withheld and paid over under all applicable Legal Requirements, including federal and state income Taxes, Federal Insurance Contribution Act, Medicare, Federal Unemployment Tax Act, relevant state income and employment Tax
withholding laws, and has timely filed all withholding Tax Returns, for all periods through and including the Closing Date. 
 (p) None of
the Company or the Company Shareholder (with respect to the Shares held by it) is subject to restrictions or limitations pursuant to Part E2 of the ITO or pursuant to any Tax ruling made in connection with the provisions of Part E2 of the ITO. 

(q) The Company has not undertaken any transaction which will require special reporting in accordance with Section 131(g) of the ITO and
the Israeli Income Tax Regulations (Tax Planning Requiring Reporting), 2006, regarding aggressive tax planning. 
 (r) The Company has
collected all amounts on account of any Israeli Value Added Tax (“VAT”) required by the Israeli Laws and Regulations to be collected by it, and has remitted to the appropriate Governmental Entity any such amounts required by
applicable Israeli Legal Requirements within the time prescribed by such requirements. The Company has not deducted any input VAT, received any refund of VAT or claimed zero rate VAT that such the Company was not so entitled to deduct, receive or
claim, as applicable. 
 (s) Any related party transactions subject to Section 85A of the ITO conducted by the Company have been on an
arms-length basis in accordance with Section 85A of the ITO and the regulations promulgated thereunder. 
 (t) Except as otherwise
provided in Schedule 2.13(t) of the Company Disclosure Letter, the Company has not received any “taxation decision” (hachlatat misui)from the ITA. 

(u) Except as otherwise provided in Schedule 2.13(u) of the Company Disclosure Letter, neither the Company nor any Company Shareholder
(on behalf of or in connection with the Company) has applied for or received any Government Grants from any supranational, national, local or foreign Governmental Entity, including the OCS. The Company has made available to Purchaser copies of all
material documents requesting or evidencing Government Grants, Government Grants received and of all letters of approval, certificates of completion, and supplements and amendments thereto and all material correspondence related thereto.
Section 2.13(u) of the Company Disclosure Letter sets forth: (a) all material undertakings of the Company given in connection with the Government Grants; (b) the 

  
 33 

 
aggregate amount of each Government Grant; (c) the aggregate outstanding obligations of the Company under each Government Grant with respect to royalties or other payments; (d) the
outstanding amounts to be paid by any Governmental Entity to the Company under the Government Grants, if any and (e) the composition of such obligations or amount by the patent, other Intellectual Property, product or product family to which it
relates. The Company is in compliance, in all material respects, with the terms and conditions of all Government Grants and have duly fulfilled, in all material respects, all the undertakings required to be fulfilled thereby prior to the date
hereof. To the knowledge of the Company, there is no event or other set of circumstances which would reasonably be expected to lead to the revocation or material modification of any of the Government Grants. To the knowledge of the Company, neither
the execution, delivery or performance of this Agreement, nor the consummation of the transactions contemplated under this Agreement, would reasonably be expected to (with or without notice or lapse of time) give rise to any right to revoke,
withdraw, suspend, cancel, terminate or modify any Government Grant identified or required to be identified in Schedule 2.13(u) of the Company Disclosure Letter. 

(v) The Company has provided to Purchaser all material information, documentation and records relating to the costs and expenses of all
research and development, activities, testing, clinical results, regulatory filings, commercialization efforts, and manufacturing relating to the Company Eligible Product and the Company Eligible IP, and all such information, documentation and
records are true and correct in all material aspects. 
 2.14 Employee Benefit Plans and Employee Matters. The Company does not have
any employees who reside or work outside of the State of Israel. With respect to employees of the Company who reside or work in Israel (each, an “Israeli Employee”), except as set forth in Schedule 2.14: (i) the
employment of each Israeli Employee is subject to termination upon not more than thirty (30) days prior written notice under the termination notice provisions included in the employment Contract with such Israeli Employee or applicable Legal
Requirements, (ii) all obligations of the Company to provide statutory severance pay to all Israeli Employees pursuant to the Severance Pay Law, 1963, are fully funded or accrued on the Financial Statements, whether in accordance with
Section 14 or otherwise, (iii) no Israeli Employee’s employment by the Company requires any special license, permit or other authorization of a Governmental Entity, (iv) there are no foreign employees employed by the Company in
Israel; (v) there are no material unwritten policies, practices or customs of the Company that, by extension, could reasonably be expected to entitle any Israeli Employee to benefits in addition to what such Israeli Employee is entitled to by
applicable Legal Requirements or under the terms of such Israeli Employee’s employment Contract (including, by way of example, material unwritten customs or practices concerning bonuses, the payment of statutory severance pay when it is not
required under applicable Legal Requirements), (vi) all amounts that the Company is legally or contractually required either (A) to deduct from Israeli Employees’ salaries or to transfer to such Israeli Employees’ pension or
provident, life insurance, incapacity insurance, continuing education fund (‘keren hishtalmut’) or other similar funds or (B) to withhold from their Israeli Employees’ salaries and benefits and to pay to any Governmental
Entity as required by the ITA and National Insurance Law or otherwise, have, in each case, been duly deducted, transferred, withheld and paid, and the Company does not have any outstanding obligation to make any such deduction, transfer, withholding
or payment (other than routine payments to be made in the ordinary course of business, consistent with past practice), and (vii) the Company is in compliance in all material respects with all applicable Legal Requirements and Contracts relating
to employment, employment practices, wages, bonuses, pension benefits and other compensation matters and terms and conditions of employment related to Israeli Employees, including The Prior Notice to the Employee Law, 2002, The Notice to Employee
(Terms of Employment) Law, 2002, the Prevention of Sexual Harassment Law, 1998, the Hours of Work and Rest Law, 1951, the Annual Leave Law, 1951, the Salary Protection Law, 1958, The Employment by Human Resource Contractors Law, 1996, and Law for
Increased Enforcement of Labor Laws, 2011, and (viii) the Company has not engaged any consultants, sub-contractors or freelancers, in a full-time position engaged on the Company’s premises. The Company is not subject to, and no employee of
the Company benefits from, any extension order (‘tzavei harchava’) 

  
 34 

 
except for such extension orders which generally apply to all private sector employees in Israel. The Company has furnished to Purchaser (x) copies of all Contracts with Israeli human
resource contractors, or with Israeli consultants, sub-contractors or freelancers and (y) copies of material manuals and material written policies relating to the employment of Israeli Employees or termination thereof. There is no liability
with respect to pension or provident funds and/or severance pay and/or in any other respect in connection with the employment of former employees of the Company and/or the termination of their employment. 

2.15 Interested Party Transactions. None of the officers and directors of the Company and, to the knowledge of the Company, none of the
employees or shareholders of the Company, nor any immediate family member of an officer, director, employee or shareholder of the Company, has any direct or indirect ownership, participation, royalty or other interest in, or is an officer, director,
employee of or consultant or contractor for any firm, partnership, entity or corporation that competes with, or does business with, or has any contractual arrangement with, the Company (except with respect to any interest in less than 5% of the
stock of any corporation whose stock is publicly traded). None of said officers, directors, employees or shareholders or any member of their immediate families, is a party to, or to the knowledge of the Company, otherwise directly or indirectly
interested in, any Contract to which the Company is a party or by which the Company or any of its assets or properties may be bound or affected, except for normal compensation for services as an officer, director or employee thereof. To the
knowledge of the Company, none of said officers, directors, employees, shareholders or immediate family members has any interest in any property, real or personal, tangible or intangible (including any Intellectual Property) that is used in, or that
relates to, the business of the Company, except for the rights of shareholders under applicable Legal Requirements. 
 2.16
Insurance. The Company maintains the policies of insurance and bonds set forth in Schedule 2.16 of the Company Disclosure Letter. Schedule 2.16 of the Company Disclosure Letter sets forth the name of the insurer under each such policy
and bond, the type of policy or bond, the coverage amount and any applicable deductible and any other material provisions as of the Agreement Date as well all material claims made under such policies and bonds since inception. The Company has
provided to Purchaser correct and complete copies of all such policies of insurance and bonds issued at the request or for the benefit of the Company. There is no claim pending under any of such policies or bonds as to which coverage has been
questioned, denied or disputed by the underwriters of such policies or bonds. All premiums due and payable under all such policies and bonds have been timely paid and the Company is otherwise in compliance with the terms of such policies and bonds.
All such policies and bonds remain in full force and effect, and the Company has no knowledge of any threatened termination of, or material premium increase with respect to, any of such policies. 

2.17 Books and Records. The Company has provided to Purchaser or its counsel correct and complete copies of each document that has been
requested by Purchaser or its counsel in connection with their legal and accounting review of the Company (other than any such document that does not exist or is not in the Company’s possession or subject to its control). Without limiting the
foregoing, the Company has provided to Purchaser or its counsel complete and correct copies of (a) all documents identified on the Company Disclosure Letter, (b) the Articles of Association as currently in effect, (c) the minute books
containing records of all proceedings, consents, actions and meetings of the Board of Directors, committees of the Board of Directors and shareholders of the Company, (d) the shareholder registry, journal and other records reflecting all share
issuances and transfers and all stock option and warrant grants and agreements of the Company, and (e) all permits, orders and consents issued by any regulatory agency with respect to the Company, or any securities of the Company, and all
applications for such permits, orders and consents. The minute books of the Company provided to Purchaser contain a complete and accurate summary of all meetings of directors and shareholders or actions by written consent since the time of
incorporation of the Company through the date of this Agreement. The books, records and accounts of the Company (i) are true, correct and complete in all material respects, (ii) have 

  
 35 

 
been maintained in accordance with reasonable business practices on a basis consistent with prior years, (iii) are stated in reasonable detail and accurately and fairly reflect all of the
transactions and dispositions of the assets and properties of the Company, and (iv) accurately and fairly reflect the basis for the Financial Statements. 

2.18 Material Contracts. 

(a) Schedule 2.18, which identifies each contract by applicable subsection(s), sets forth all of the Contracts, to which the Company is
a party or by which the Company or its assets may be bound (each, a “Material Contract” and collectively, “Material Contracts”): 

(i) all licenses, sublicenses and other Contracts pursuant to which the Company has (A) granted any Person any right or interest in any
Company IP Rights (except with respect to manufacturers and other service providers who were granted a non-exclusive license to use Company IP Rights solely in connection with the provision of their services to the Company), or (B) agreed to
any restriction on the right of the Company to use or enforce any Company-Owned IP Rights or pursuant to which the Company agrees to encumber, transfer or sell rights in or with respect to any Company-Owned IP Rights; 

(ii) other than end-user licenses to generally commercially available software that have an individual acquisition cost of $1,000 or less,
all licenses, sublicenses and other Contracts pursuant to which the Company acquired or is authorized to exercise any rights in Intellectual Property; 

(iii) any Contract limiting the freedom of the Company to engage or participate, or compete with any other Person, in any line of business,
market, therapeutic or geographic area, or to make use of any Intellectual Property, or any Contract granting most favored nation pricing, exclusive sales, distribution, marketing or other exclusive rights, rights of refusal, rights of first
negotiation or similar rights and/or terms to any Person, or any Contract otherwise limiting the right of the Company to sell, distribute or manufacture any products or services or to purchase or otherwise obtain any products or services; 

(iv) any Contract providing for the development of any compound, product or product candidate, technology or Intellectual Property,
independently or jointly, by or for the Company, including, but not limited to, any proof-of-concept, collaboration, development or co-development agreement; any Contract to license or authorize any third party to manufacture any Company Products;

 (v) any Contract involving a supply or tolling agreement or arrangement (including without limitation, any Contract for the supply of
raw materials, intermediates, bulk or finished drug product, research, clinical trial, development, distribution, or sale) that commits the Company to purchase goods or services or to sell any supplies for clinical studies or commercial use; 

(vi) Contracts of the Company with any current or former employees, officers, directors of the Company or consultants or agent or independent
contractors are parties; 
 (vii) partnership or joint venture Contracts with any Person; 

(viii) leases from or to any Person of any real or personal property; 

(ix) Contracts under which the Company has created, incurred, assumed or guaranteed (or may create, incur, assume or guarantee) Company Debt
or which provides for the imposition of any Encumbrance on any of its assets, tangible or intangible; 

  
 36 

 (x) Contracts which restrict the ability of the Company to solicit for hire or to hire any
Person; 
 (xi) Contracts obligating any Person to maintain confidentiality of information relating to the Company or obligating the
Company to maintain confidentiality of information relating to any Person; 
 (xii) stock Contracts, asset Contracts or other acquisition
or divestiture Contracts entered into by the Company at any time since its inception; 
 (xiii) Contracts with respect to the lending or
investing of funds by the Company to or in any Person; 
 (xiv) collective bargaining Contracts with any labor union; 

(xv) settlement Contracts of any nature; 

(xvi) Contracts relating to Government Grants 

(xvii) Contracts not otherwise required to be disclosed by this Section 2.18, requiring payments after the date hereof to or by
the Company of more than $100,000 over the life of the Contract unless terminable by the Company on less than 10 days’ notice without payment or penalty; or 

(xviii) Contracts which, individually or with all other Contracts with the same or Affiliated parties (whether or not required to be
disclosed under any of the other clauses of this Section 2.18), are material to the Company irrespective of amount. 
 (b) The
Company has delivered to Purchaser a true and complete copy of each Material Contract (including all amendments thereto) required to be listed in Schedule 2.18. Neither the Company nor, to the Company’s knowledge, any other party to any
Material Contract, is in breach or violation of, or default under, any of the Material Contracts and no event has occurred which, with notice or lapse of time or both would constitute a breach, violation or default thereof or permit termination or
modification thereof or acceleration thereunder. The Company has not waived any material rights under any Material Contract. Each Material Contract is a valid agreement, binding, in full force and effect and enforceable by the Company in accordance
with its terms, except in each case where enforceability may be limited by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium or similar Legal Requirements affecting the enforcement of creditors’ rights and
(ii) general rules governing specific performance, injunctive relief and other equitable remedies. 
 2.19 Certain Regulatory
Matters. 
 (a) The Company has conducted, and is conducting, its business in full compliance with all applicable rules and regulations
including, without limitation, applicable portions of the FD&C Act, the PHSA, and applicable similar laws outside of the United States. 

(b) The Company has complied with all Regulatory Authority regulations and requirements including, without limitation, those relating to drug
development, the Investigational New Drug Application (“IND”) (or its equivalent if filed outside of the United States), clinical and preclinical testing, manufacture, storing, recordkeeping, distribution, as well as Good
Laboratory Practices, Good Clinical Practices, Good Manufacturing Practices (as such terms are defined by applicable Regulatory Authorities and applicable ICH guidelines and guidances issued by a Regulatory Authority in effect at the relevant time).

  
 37 

 (c) The Company has not (nor, to Company’s knowledge, has any supplier, contract
manufacturer or clinical or laboratory site) received any Warning Letter, Form 483, untitled letter, or similar letters or notices issued by a Regulatory Authority or any other Governmental Entity, domestic or foreign, alleging any violation of any
applicable Legal Requirement. The Company has not received any notice from any Regulatory Authority or Governmental Entity of any intent to bring any enforcement action against the Company, including, but not limited to, any consent decree,
injunction, seizure, or criminal or civil prosecution. Schedule 2.19(c) lists all serious as well as non-serious adverse experiences with the Company Product or compounds and all such serious and frequent non-serious adverse experiences from
all clinical sites. The Company has provided Purchaser with any finding from tests in laboratory animals that suggests a significant risk for human subjects, including reports of mutagenicity, teratogenicity, or carcinogenicity. The Company has
reported all serious and/or unexpected adverse events to the appropriate Regulatory Authority in accordance with applicable reporting obligations, and has provided Purchaser with copies of all such reports. There have been no product recalls
conducted by or issued to the Company and no requests from any Regulatory Authority requesting the Company to cease to investigate, test, manufacture or distribute the Company Product or study drugs. 

(d) To the knowledge of the Company, all animal studies or other preclinical tests performed in connection with or intended to be submitted to
any Regulatory Authority in support of approval or clearance of the Company Product either (i) have been conducted in accordance, in all material respects, with applicable Good Laboratory Practice requirements contained in 21 CFR Part 58
(“GLPs”), and, where applicable, the Israeli Prevention of Cruelty to Animals Law (Research Using Animals), 1994, and regulations promulgated thereunder, or (ii) involved experimental research techniques that could not
be performed by a registered GLP testing laboratory (with appropriate notice being given to the FDA) and have employed in all material respects the procedures and controls generally used by qualified experts in animal or preclinical study of
products comparable to those being developed by the Company. The Company has not received any written notice or other written communication from any Governmental Entity requiring the termination or suspension of any preclinical study with respect to
the Company Product. 
 (e) All studies and clinical trials conducted by or on behalf of the Company are listed on Schedule
2.19(e)-1. True, complete and accurate copies of all data and reports with respect to the studies and trials listed in Schedule 2.19(e)-1 have been provided for review to Purchaser and the Company has otherwise provided for review all
preclinical and clinical studies and trials and all other information regarding the efficacy and safety of the Company Product or study drugs. The Company has heretofore provided for review to Purchaser all correspondence and contact information
between the Company and any Regulatory Authority or other Governmental Entities regarding the Company Product and study drugs, and, to the extent provided to the Company, between any Regulatory Authority and other Governmental Entities relating to
the Company, its clinical studies or trials, or the Company Product and study drugs. All clinical trials conducted by or on behalf of the Company have been, or are being, conducted in full compliance with Good Clinical Practice
(“GCP”) requirements, as that term is defined by applicable Regulatory Authorities. The Company has not received any written notice or other written communication from any Governmental Entity requiring the termination or
suspension of any clinical trial with respect to the Company Product. 
 (f) (i) the Company has obtained all consents, clearances,
approvals, certifications, authorizations, licenses and permits of, and has made all filings with, or notifications to, all Regulatory Authorities pursuant to applicable requirements of all Regulatory Authority regulations, and all applicable Legal
Requirements, including all consents, clearances, approvals, certifications, authorizations, licenses, and permits to permit the design, development, testing, and manufacture of the Company Product in jurisdictions where it currently conducts such
activities, including any authorizations required to be obtained with respect to the conduct of clinical studies pursuant to the Guidelines for Clinical Trials in Human Subjects implemented pursuant to the Israeli Public Health Regulations (Clinical
Trials in Human 

  
 38 

 
Subjects), as was in effect at the relevant time; and (ii) all representations made by the Company in connection with any such consents, clearances, approvals, certifications,
authorizations, licenses, permits, filings and notifications were true and correct in all material respects at the time such representations and warranties were made. 

(g) Neither the Company nor, to the Company’s knowledge, any officer, employee or agent of the Company, has made an untrue statement of a
material fact or fraudulent statement to any Regulatory Authority or other Governmental Entity, failed to disclose a material fact required to be disclosed to any Regulatory Authority or other Governmental Entity, or committed an act, made a
statement, or failed to make a statement that, at the time such disclosure was made, would reasonably be expected to provide a basis for any Regulatory Authority or other Governmental Entity to invoke its policy respecting “Fraud, Untrue
Statements of Material Facts, Bribery, and Illegal Gratuities”, set forth in 56 Fed. Reg. 46191 (September 10, 1991) or any similar law outside of the United States. 

(h) To the Company’s knowledge, the Company has not used in any capacity the services of any Persons debarred under any country’s
debarment provisions, including, but not limited to, subsections 306(a) or 306(b) of the Generic Drug Enforcement Act of 1992, disqualified as a testing facility under CFR Part 58, subpart K, or disqualified as a clinical investigator under 21 CFR
312.70, in connection with any of the services performed by Company or its contractors. To the Company’s knowledge, there are no pending or threatened actions, suits, claims, investigations or legal or administrative proceedings relating to the
debarment or disqualification of any Person performing any services for Company. Neither the Company nor, to the Company’s knowledge, any officer, employee or agent of the Company or any of its Subsidiaries, has been convicted of any crime or
engaged in any conduct for which such person or entity could be excluded from participating in the federal health care programs under Section 1128 of the Social Security Act or any similar applicable Legal Requirement. 

(i) The Company either directly or indirectly through its clinical sites has obtained all necessary patient consents, including privacy
authorizations, informed consent, and applicable institutional review board approvals (initial and ongoing) of patient consents and protocols to conduct all clinical studies. 

2.20 Accounts Receivable and Payable. 

(a) As determined in accordance with IFRS, the Company does not have any accounts receivable. 

(b) All accounts payable and notes payable of the Company arose in the ordinary course of business, consistent with past practices in bona
fide arms’ length transactions and no such account payable or note payable is delinquent by more than sixty (60) days in its payment. 

2.21 Inventory. Schedule 2.21 sets forth a complete and accurate list of all inventory of raw materials, components, active
pharmaceutical ingredients, packaging materials and final finished products as well as the location of such inventory and expiration dates for all such inventory, if applicable. All such inventory is in good and usable condition, has been
manufactured and stored in accordance with Good Manufacturing Practices and can reasonably be anticipated to be used and consumed in the ordinary course of business. 

2.22 Transaction Fees. The Company is not obligated for the payment of any fees or expenses of any investment banker, broker, advisor,
finder or similar party in connection with the origin, negotiation or execution of this Agreement or in connection with the Share Purchase or any other transaction contemplated by this Agreement. 

  
 39 

 2.23 Data Protection and Privacy. The Company has (i) complied in all material
respects with all applicable Legal Requirements with respect to data protection and privacy (including Israel’s Protection of Privacy Law, 1981, and related regulations and directives) and other applicable Legal Requirement regarding the
disclosure of data, and (ii) without derogation from subsection (i), otherwise taken commercially reasonable steps to protect and maintain the confidential nature of the personal information provided to the Company by any party in
accordance with its applicable law or privacy policies. 
 2.24 Anti-Corruption. Neither the Company nor any of its officers,
directors, employees, shareholders, agents or representatives, nor to the Company’s knowledge, any Person associated with or acting for or on behalf of the Company, have directly or indirectly, unlawfully: (a) made or attempted to make or
promised any contribution, gift, bribe, rebate, payoff, influence payment, kickback, or other payment to any Person, private or public, regardless of what form, whether in money, property, or services in order (i) to obtain favorable treatment
for business or Contracts secured, (ii) to pay for favorable treatment for business or Contracts secured, (iii) to obtain special concessions or for special concessions already obtained, or (iv) in violation of any requirement of
applicable Legal Requirements, or (b) established or maintained any fund or asset that has not been recorded on the Company’s books and records. 

2.25 Representations Complete. None of the representations or warranties made by the Company herein or in any exhibit or schedule
hereto, including the Company Disclosure Letter, or in any certificate furnished by the Company pursuant to this Agreement, when all such documents are read together in their entirety, contains any untrue statement of a material fact, or omits to
state any material fact necessary in order to make the statements contained herein or therein, in the light of the circumstances under which made, not misleading. 

ARTICLE 3 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY
SHAREHOLDER 
 The Company Shareholder represents and warrants to Purchaser as follows: 

3.1 Power and Capacity. The Company Shareholder possesses all requisite capacity necessary to carry out the transactions
contemplated by this Agreement. 
 3.2 Enforceability; Non-contravention. 

(a) This Agreement has been duly executed and delivered by the Company Shareholder, and constitutes a valid and legally binding obligation,
enforceable against the Company Shareholder in accordance with its terms, except as may be limited by (i) applicable bankruptcy, insolvency, reorganization or other laws of general application relating to or affecting the enforcement of
creditors’ rights generally and (ii) the effect of rules of law governing the availability of specific performance, injunctive relief and other equitable remedies. 

(b) The execution, delivery and performance by the Company Shareholder of this Agreement does not, and the consummation of the transactions
contemplated hereby will not, conflict with, or result in any violation of or default under (with or without notice or lapse of time, or both), or give rise to a right of termination, cancellation or acceleration of any obligation or loss of any
benefit under, or require any consent, approval or waiver from any Person pursuant to, or result in the creation of any Encumbrance upon the Company Ordinary Shares pursuant to (i) any Contract or Order to which the Company Shareholder is
subject or (ii) any applicable Legal Requirements, except where such conflict, violation, default, termination, cancellation or acceleration, individually or in the aggregate, would not be material to the Company Shareholder’s ability to
consummate the Share Purchase or to perform its obligations under this Agreement. 

  
 40 

 (c) No consent, approval, order or authorization of, or registration, declaration or filing with,
any Governmental Entity or any other Person is required by or with respect to the Company Shareholder in connection with the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby that would reasonably
be expected to adversely affect the ability of the Company Shareholder to consummate the Share Purchase or any of the other transactions contemplated hereby, except for (i) such filings and notifications as may be required to be made by the
Company Shareholder in connection with the Share Purchase and other Transactions under the HSR Act, the RTPA and other applicable foreign antitrust laws and the expiration or early termination of applicable waiting periods under the HSR Act, the
RTPA and other applicable foreign antitrust laws. 
 3.3 Title to Shares. The Company Shareholder owns of record and beneficially the
Company Ordinary Shares as set forth opposite the Company Shareholder’s name on Schedule 2.2(a) of the Company Disclosure Letter, and has good and valid title to such Company Ordinary Shares, free and clear of all Encumbrances and, at
Closing and contingent thereon, shall deliver to Purchaser good and valid title to such Company Ordinary Shares, free and clear of all Encumbrances and Taxes. The Company Shareholder does not own, and does not have the right to acquire, directly or
indirectly, any other Company Ordinary Shares, except as set forth in Schedule 2.2(a) of the Company Disclosure Letter. The Company Shareholder is not a party to any option, warrant, purchase right, or other Contract or commitment that could
require the Company Shareholder to sell, transfer, or otherwise dispose of any Company Ordinary Shares (other than this Agreement). The Company Shareholder is not a party to any voting trust, proxy, or other agreement or understanding with respect
to the voting of any share capital of the Company, except as set forth on the Company Disclosure Letter. 
 3.4 Litigation. There are
no actions, suits, arbitrations, mediations, proceedings or claims pending or, to the knowledge of the Company Shareholder, threatened against the Company Shareholder that seek to restrain or enjoin the consummation of the transactions contemplated
hereby. 
 3.5 Solvency. The Company Shareholder is not bankrupt or insolvent and has not proposed a voluntary arrangement or made or
proposed any arrangement or composition with the Company Shareholder’s creditors or any class of such creditors, and no petition in respect of any such arrangement or composition has been presented to the Company Shareholder. The consummation
of the Share Purchase and the other transactions contemplated hereby shall not constitute a fraudulent transfer by the Company Shareholder under applicable bankruptcy and other similar laws relating to bankruptcy and insolvency of the Company
Shareholder. 
 3.6 Tax Withholding Information. All information, if any, provided or to be provided to the Purchaser, by or on
behalf of the applicable Company Shareholder for purposes of enabling Purchaser to determine the amount to be deducted and withheld, if any, from the consideration payable to such Shareholder pursuant to this Agreement under applicable Legal
Requirements is and will be accurate and complete when provided. 
 ARTICLE 4 

REPRESENTATIONS AND WARRANTIES OF PARENT AND
PURCHASER 
 Parent and Purchaser represent and warrant to the Company as follows: 

4.1 Organization and Standing. Each of Parent and Purchaser is a corporation duly organized, validly existing and in good standing
under the laws of its jurisdiction of organization. Niether Parent nor Purchaser is in violation of any of the provisions of its Certificate of Incorporation or Bylaws 

  
 41 

 
(or similar organizational documents). Each of Parent and Purchaser and have the requisite corporate power and authority to conduct its business as it is presently being conducted and as
currently proposed to be conducted by Parent and Purchaser and to own, lease or operate its respective properties and assets. 
 4.2
Authority; Noncontravention. 
 (a) Each of Parent and Purchaser have all requisite corporate power and authority to enter into this
Agreement and to consummate the transactions contemplated hereby. The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary corporate action on the part of
Parent and Purchaser. This Agreement has been duly executed and delivered by Parent and Purchaser and constitutes the valid and legally binding obligation of Parent and Purchaser enforceable against Parent and Purchaser, in accordance with its
terms, subject only to the effect, if any, of (i) applicable bankruptcy and other similar laws affecting the rights of creditors generally and (ii) rules of law governing specific performance, injunctive relief and other equitable
remedies. 
 (b) The execution, delivery and performance of this Agreement by Parent and Purchaser does not, and the consummation of the
transactions contemplated hereby will not, conflict with, or result in any violation of, or default under (with or without notice or lapse of time, or both), or give rise to a right of termination, cancellation or acceleration of any obligation or
loss of any benefit under, or require any consent, approval or waiver from any Person pursuant to, or result in the creation of any Encumbrance upon any of the properties or assets of Parent or Purchaser to (i) any Contract or Order to which
Parent or Purchaser is subject, (ii) any provision of the Certificate of Incorporation or Bylaws (or similar organizational documents) of Parent or Purchaser, in each case as amended to date, or (iii) any applicable Legal Requirement,
except where such conflict, violation, default, termination, cancellation or acceleration, individually or in the aggregate, would not be material to Parent or Purchaser’s ability to consummate the Share Purchase or to perform its obligations
under this Agreement. 
 (c) No consent, approval, order or authorization of, or registration, declaration or filing with, any Governmental
Entity or any other Person, is required by or with respect to Parent or Purchaser in connection with the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby, except for (i) the execution by
Purchaser of an undertaking in customary form in favor of the OCS to comply with the applicable Israeli Encouragement of Industrial Research and Development Law, 1984, (ii) such filings and notifications as may be required to be made by Parent
or Purchaser in connection with the Share Purchase and other Transactions under the HSR Act, the RTPA or other applicable foreign antitrust laws and the expiration or early termination of applicable waiting periods under the HSR Act, the RTPA or
other applicable foreign antitrust laws, and (iii) such other consents, authorizations, filings, approvals, notices and registrations which, if not obtained or made, would not be material to Parent or Purchaser’s ability to consummate the
Share Purchase or other Transactions or to perform its obligations under this Agreement and would not prevent, alter or delay any of the transactions contemplated by this Agreement. 

4.3 Capitalization. As of the Agreement Date, the authorized capital stock of Parent consists of (i) 100,000,000 shares of Parent
Common Stock and (ii) 10,000,000 shares of preferred stock, par value $0.0001 per share (“Parent Preferred Stock”). As of December 31, 2013, 20,137,145 shares of Parent Common Stock were issued and outstanding and
no shares of Parent Preferred Stock were outstanding. As of the date of this Agreement, no bonds, debentures, notes or other indebtedness of Parent having the right to vote (or convertible into, or exchangeable for, securities having the right to
vote) on any matters on which shareholders of Parent may vote are issued or outstanding. All outstanding shares of capital stock of Parent are, and all shares which may be issued in connection with the transactions contemplated hereby will be, when
issued, duly authorized, validly issued, fully paid and nonassessable and not subject to preemptive rights. 

  
 42 

 4.4 Litigation. There are no actions, suits, arbitrations, mediations, proceedings or
claims pending or, to the knowledge of the Parent or Purchaser, threatened against or affecting Parent or Purchaser or any of their Affiliates or any of their respective properties, that, individually or in the aggregate, seek to restrain or enjoin
the consummation of the transactions contemplated hereby or would otherwise prevent or materially delay the consummation by Parent and Purchaser of the transactions contemplated hereby or the performance by Parent and Purchaser of its covenants and
obligations hereunder. 
 4.5 No Israeli Presence. Parent maintains no operations in Israel, other than its ownership of Purchaser.
Except for Purchaser, which is a newly incorporated wholly-owned subsidiary of Parent that has no operations in Israel, neither Parent nor Purchaser has any subsidiaries incorporated in or operating in Israel, and neither Parent nor Purchaser
conducts business on a regular basis in Israel. 
 4.6 SEC Filings and Financial Statements. Parent has filed all forms, reports and
documents required to be filed with the Securities and Exchange Commission (the “SEC”) since December 31, 2013 (the “SEC Reports”). As of its respective date (or, if amended or superseded by a
filing prior to the Agreement Date, then on the date of such subsequent filing), each SEC Report (i) complied in all material respects with the requirements of the Exchange Act or the Securities Act applicable to the SEC Reports, as the case
may be, and (ii) did not at the time they were filed (or, if subsequently amended or superseded by a filing prior to the Agreement Date, then on the date of such subsequent filing) contain any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The consolidated financial statements (including, in each case,
any related notes thereto) contained in the SEC Reports were prepared in accordance with GAAP (except, in the case of unaudited statements, as permitted by Form 10-Q of the SEC) and fairly present the
consolidated financial position of Parent and its consolidated subsidiaries as of the respective dates thereof and the consolidated results of their operations and cash flows for the periods indicated (subject, in the case of unaudited statements,
to normal year-end audit adjustments). 
 4.7 Solvency. Neither Parent nor Purchaser is bankrupt or insolvent nor proposed a
voluntary arrangement or made or proposed any arrangement or composition with the Parent’s or Purchaser’s creditors or any class of such creditors, and no petition in respect of any such arrangement or composition has been presented to
Parent or Purchaser. The consummation of the Share Purchase and the other transactions contemplated hereby shall not constitute a fraudulent transfer by Parent or Purchaser under applicable bankruptcy and other similar laws relating to bankruptcy
and insolvency of Parent or Purchaser. 
 4.8 Issuance of Shares. The shares of Parent Common Stock comprising a portion of the Total
Consideration when issued by Parent in accordance with the terms of this Agreement, assuming the accuracy of the representations and warranties of the Company Shareholder contained in this Agreement and the Investment Representation Letter and
Lock-up Agreement will be duly issued, fully paid and nonassessable, and issued in compliance with Israeli Legal Requirements and United States federal and state securities laws. 

4.9 Financing. Parent and Purchaser have, or have available to it, sufficient funds to consummate the transactions contemplated by this
Agreement. 

  
 43 

 ARTICLE 5 

CONDUCT PRIOR TO THE CLOSING 

5.1 Conduct of Business of the Company. During the period from the Agreement Date and continuing until the earlier of the termination
of this Agreement and the Closing: 
 (a) the Company shall conduct its business solely in the usual, regular and ordinary course in
substantially the same manner as heretofore conducted (except to the extent expressly provided otherwise in this Agreement or as consented to in writing by Purchaser) and in compliance with all applicable Legal Requirements; 

(b) the Company shall (A) pay all of its debts and Taxes when due, subject to good faith disputes with the relevant Tax Authority over
such debts or Taxes, (B) pay or perform its other obligations when due, (C) use commercially reasonable efforts consistent with past practice and policies to collect accounts receivable when due and not extend credit outside of the
ordinary course of business consistent with past practices, and (D) use its commercially reasonable efforts consistent with past practice and policies to preserve intact its present business organizations, keep available the services of its
present officers and key employees and preserve its relationships with suppliers, licensors, licensees, and others having business dealings with it to the end that its goodwill and going business shall be unimpaired; 

(c) the Company shall promptly notify Purchaser of any change, occurrence or event not in the ordinary course of its business, or of any
change, occurrence or event which, individually or in the aggregate with any other changes, occurrences and events, would reasonably be expected to be materially adverse to the Company taken together or cause any of the conditions to closing set
forth in ARTICLE 7 not to be satisfied; 
 (d) the Company shall assure that each of its Contracts other than with Parent and Purchaser)
entered into after the Agreement Date will not require the procurement of any consent, waiver or novation or provide for any change in the obligations of any party in connection with, or terminate as a result of the consummation of, the Share
Purchase or other Transactions, and shall give reasonable advance notice to Purchaser prior to allowing any Material Contract or right thereunder to lapse or terminate by its terms; and 

(e) the Company shall maintain each of its leased premises in accordance with the terms of the applicable lease. 

5.2 Restrictions on Conduct of Business of the Company. Without limiting the generality or effect of the provisions of
Section 5.1, except as set forth on Schedule 5.2 of the Company Disclosure Letter, during the period from the Agreement Date and continuing until the earlier of the termination of this Agreement and the Closing, the Company
shall not do, cause or permit any of the following (except to the extent expressly provided otherwise in this Agreement or as consented to in writing by Purchaser): 

(a) Charter Documents. Cause or permit any amendments to its Articles of Association; 

(b) Dividends; Changes in Share Capital. Declare or pay any dividends on or make any other distributions (whether in cash, stock or
property) in respect of any of its share capital, or split, combine or reclassify any of its share capital or issue or authorize the issuance of any other securities in respect of, in lieu of or in substitution for share capital, or repurchase or
otherwise acquire, directly or indirectly, any shares capital except from former employees, non-employee directors and consultants in accordance with agreements providing for the repurchase of shares in connection with any termination of service,
except in accordance with the Teva Share Purchase Agreement; 
 (c) Material Contracts. Enter into any Contract that would constitute
a Material Contract, other material Contract or a Contract requiring a novation or consent in connection with the Share Purchase, or violate, terminate, amend, or otherwise modify (including by entering into a new Contract with such party or
otherwise) or waive any of the terms of any of its Material Contracts; 

  
 44 

 (d) Issuance of Securities. Issue, deliver or sell or authorize or propose the issuance,
delivery or sale of, or purchase or propose the purchase of, any Company Voting Debt or any Company Ordinary Shares or securities convertible into, or subscriptions, rights, warrants or options to acquire, or other Contracts of any character
obligating it to issue any such shares or other convertible securities, other than the issuance of Company Ordinary Shares pursuant to the exercise of Company Options that are outstanding as of the Agreement Date or pursuant to the conversion of the
CBI Total Loan Amounts; 
 (e) Employees; Consultants; Independent Contractors. (i) Hire any additional officers or other
employees, or any consultants or independent contractors, (ii) terminate the employment, change the title, office or position, or materially reduce the responsibilities of any management, supervisory or other key personnel of the Company,
(iii) enter into, amend or extend the term of any employment or consulting agreement with any officer, employee, consultant or independent contractor, or (iv) enter into any Contract with a labor union or collective bargaining agreement
(unless required by applicable Legal Requirements); 
 (f) Loans and Investments. Make any loans or advances (other than routine
expense advances to employees of the Company consistent with past practice) to, or any investments in or capital contributions to, any Person, or forgive or discharge in whole or in part any outstanding loans or advances, or prepay any indebtedness
for borrowed money; 
 (g) Intellectual Property. Transfer or license from any Person any rights to any Intellectual Property, or
transfer or license to any Person any rights to any Company Intellectual Property; 
 (h) Patents. Take any action regarding a
patent, patent application or other Intellectual Property right, other than filing continuations for existing patent applications or completing or renewing registrations of existing patents, domain names, trademarks or service marks in the ordinary
course of business; 
 (i) Exclusive Rights and Most Favored Party Provisions. Enter into or amend any agreement pursuant to which
any other party is granted exclusive rights or “most favored party” rights of any type or scope with respect to the Company Product, technology, Intellectual Property or business, or containing any non-competition covenants or other
restrictions relating to its or Parent’s business activities; 
 (j) Dispositions. Sell, lease, license or otherwise dispose of
any of its properties or assets; 
 (k) Indebtedness. Incur any indebtedness for borrowed money or guarantee any such indebtedness;

 (l) Leases. Enter into any operating lease requiring an annual payment in excess of $50,000 or any leasing transaction of the type
required to be capitalized in accordance with IFRS; 
 (m) Payment of Obligations. Pay, discharge or satisfy (i) any Liability
to any Person who is an officer, director or shareholder of the Company (other than compensation due for services as an officer or director), or (ii) any claim or Liability arising otherwise than in the ordinary course of business, other than
the payment, discharge or satisfaction of Liabilities reflected or reserved against in the Financial Statements and Transaction Expenses, or defer payment of any accounts payable other than in the ordinary course of business consistent with past
practice, or give any discount, accommodation or other concession other than in the ordinary course of business consistent with past practice, in order to accelerate or induce the collection of any receivable; 

  
 45 

 (n) Non-Budgeted Expenditures. Make any expenditures not included in the Company Budget;

 (o) Insurance. Materially change the amount of any insurance coverage; 

(p) Termination or Waiver. Cancel, release or waive any claims or rights held by it; 

(q) Employee Benefit Plans; Pay Increases. Adopt or materially amend any employee or compensation benefit plan, including any stock
issuance or stock option plan, or materially amend any compensation, benefit, entitlement, grant or award provided or made under any such plan, except in each case as required under applicable Legal Requirements, materially amend any deferred
compensation plan, pay any special bonus or special remuneration to any employee or non-employee director or consultant or increase the salaries, wage rates or fees of its employees or consultants (other than pursuant to preexisting plans, policies
or Contracts which have been disclosed to Purchaser and are set forth on Schedule 5.2(q) of the Company Disclosure Letter); 

(r) Severance Arrangements. Grant or pay, or enter into any Contract providing for the granting of any severance (other than statutory
severance), retention or termination pay, or the acceleration of vesting or other benefits, to any Person (other than payments or acceleration made pursuant to preexisting plans, policies or Contracts which have been disclosed to Purchaser and are
set forth on Schedule 5.2(r) of the Company Disclosure Letter); 
 (s) Lawsuits; Settlements. (i) Commence a lawsuit
other than (A) for the routine collection of bills, (B) in such cases where it in good faith determines that failure to commence suit would result in the material impairment of a valuable aspect of its business (provided that it
consults with Purchaser prior to the filing of such a suit), or (C) for a breach of this Agreement or (ii) settle or agree to settle any pending or threatened lawsuit or other dispute; 

(t) Acquisitions. Acquire or agree to acquire by merging or consolidating with, or by purchasing a substantial portion of the assets
of, or by any other manner, any business or any corporation, partnership, association or other business organization or division thereof, or otherwise acquire or agree to acquire any assets which are material, individually or in the aggregate, to
its business, or enter into any Contract with respect to a joint venture, strategic alliance or partnership; 
 (u) Taxes. Make or
change any election in respect of Taxes, adopt or change any accounting method in respect of Taxes, file any federal, state, or foreign income Tax Return or any other Tax Return, file any amendment to a federal, state, or foreign income Tax Return
or any other Tax Return, enter into any Tax sharing or similar agreement or closing agreement, settle any claim or assessment in respect of Taxes, or consent to any extension or waiver of the limitation period applicable to any claim or assessment
in respect of Taxes, or enter into intercompany transactions giving rise to deferred gain or loss of any kind, or take any other similar action relating to the filing of any Tax Return or the payment of any Tax, if such election, adoption or other
action would have the effect of increasing the Tax liability of the Company for any period ending after the Closing Date or decreasing any Tax attribute of the Company existing on the Closing Date, or apply for or receive a Tax ruling from the ITA
on behalf of the Company, or any shareholder of the Company, other than an application to or receipt of a Tax ruling from the ITA with respect to the tax generated from any transaction under this Agreement, including without limitations, an
application for a tax arrangement under Section 104H of the ITO; 
 (v) Accounting. Change accounting methods or practices
(including any change in depreciation or amortization policies) or revalue any of its assets (including writing down the value of inventory or writing off notes or accounts receivable otherwise than in the ordinary course of business), except in
each case as required by changes in IFRS as concurred with its independent accountants and after notice to Purchaser; 

  
 46 

 (w) Real Property. Enter into any agreement for the purchase, sale or lease of any real
property; 
 (x) Encumbrances. Place or allow the creation of any Encumbrance (other than a Permitted Encumbrance) on any of its
properties; 
 (y) Interested Party Transactions. Enter into any Contract in which any officer, director, employee, agent or
shareholder of the Company (or any member of their immediate families) has an interest under circumstances that, if entered immediately prior to the Agreement Date, would require that such Contract be listed on Schedule 2.18 of the
Company Disclosure Letter; 
 (z) Government Grants. Apply for, negotiate or receive a Government Grant; 

(aa) Other. Take or agree in writing or otherwise to take, any of the actions described in clauses (a) through (y) in this
Section 5.2, or any action which would reasonably be expected to make any of the Company’s representations or warranties contained in this Agreement untrue or incorrect (such that the condition set forth in the first sentence of
Section 7.3(a) would not be satisfied) or prevent the Company from performing or cause the Company not to perform one or more covenants required hereunder to be performed by the Company (such that the condition set forth in the second
sentence of Section 7.3(a) would not be satisfied). 
 ARTICLE 6 

ADDITIONAL AGREEMENTS 

6.1 No Solicitation. 

(a) From and after the date of this Agreement until the Closing or termination of this Agreement pursuant to ARTICLE 8, neither the Company
nor the Company Shareholder will, nor will any of them authorize or permit any of their respective officers, directors, Affiliates, shareholders or employees or any investment banker, attorney or other advisor or representative retained by any of
them (all of the foregoing collectively being the “Company Representatives”) to, directly or indirectly, (i) solicit, initiate, seek, entertain, encourage, facilitate, support or induce the making, submission or
announcement of any inquiry, expression of interest, proposal or offer that constitutes, or could reasonably be expected to lead to, an Acquisition Proposal (as defined below), (ii) enter into, participate in, maintain or continue any
communications (except solely to provide written notice as to the existence of these provisions) or negotiations regarding, or deliver or make available to any Person any non-public information with respect to, or take any other action regarding,
any inquiry, expression of interest, proposal or offer that constitutes, or could reasonably be expected to lead to, an Acquisition Proposal, (iii) agree to, accept, approve, endorse or recommend (or publicly propose or announce any intention
or desire to agree to, accept, approve, endorse or recommend) any Acquisition Proposal, (iv) enter into any letter of intent or any other Contract contemplating or otherwise relating to any Acquisition Proposal, (v) submit any Acquisition
Proposal to the vote of any securityholders of Company or (vi) enter into any other transaction or series of transactions not in the ordinary course of the Company’s business consistent with past practice, the consummation of which could
reasonably be expected to impede, interfere with, prevent or materially delay the Share Purchase. The Company will (A) immediately cease and cause to be terminated any and all existing activities, discussions or negotiations with any Persons
conducted prior to or on the date of this Agreement with respect to any Acquisition Proposal and (B) immediately revoke or withdraw access of any Person (other than Purchaser and its representatives) to any data room (virtual or actual)
containing any non-public information with respect to the Company in connection with an 

  
 47 

 
Acquisition Proposal and request from each Person (other than Purchaser and its representatives) the prompt return or destruction of all non-public information with respect to the Company
previously provided to such Person in connection with an Acquisition Proposal. If any Company Representative, whether in his or her capacity as such or in any other capacity, takes any action that the Company or a Company Shareholder is obligated
pursuant to this Section 6.1 not to authorize or permit such Company Representative to take, then the Company and the Company Shareholder, respectively, shall be deemed for all purposes of this Agreement to have breached this
Section 6.1. 
 “Acquisition Proposal” shall mean, with respect to the Company, any agreement, offer,
proposal or bona fide indication of interest (other than this Agreement or any other offer, proposal or indication of interest by Parent or Purchaser), or any public announcement of intention to enter into any such agreement (other than in respect
of this Agreement) or of (or intention to make) any offer, proposal or bona fide indication of interest, relating to, or involving: (A) any acquisition or purchase from the Company, or from the shareholders of the Company, by any Person or
Group (as defined below) of more than a 10% interest in the total outstanding voting securities of Company or any tender offer or exchange offer that if consummated would result in any Person or Group beneficially owning 10% or more of the total
outstanding voting securities of the Company or any merger, consolidation, business combination or similar transaction involving the Company; (B) any sale, lease, mortgage, pledge, exchange, transfer, license (other than in the ordinary course
of business consistent with past practice), acquisition, or disposition of more than 10% of the assets of the Company in any single transaction or series of related transactions; (C) any liquidation, dissolution, recapitalization or other
significant corporate reorganization of the Company, or any extraordinary dividend, whether of cash or other property; or (D) any other transaction outside of the ordinary course of the Company’s business consistent with past practice the
consummation of which would reasonably be expected to materially impede, interfere with, prevent or delay the Share Purchase or other Transactions. 

“Group” shall have the definition ascribed to such term under Section 13(d) of the Exchange Act, the rules and
regulations thereunder. 
 (b) The Company shall immediately (but in any event, within 48 hours) notify Purchaser in writing after receipt
by the Company (or, to the knowledge of the Company, by any of the Company Representatives), of (i) any Acquisition Proposal, (ii) any inquiry, expression of interest, proposal or offer that constitutes, or would reasonably be expected to
lead to, an Acquisition Proposal, (iii) any other notice that any Person is considering making an Acquisition Proposal, or (iv) any request for nonpublic information relating to the Company or for access to any of the properties, books or
records of the Company by any Person or Persons other than Parent, Purchaser and their Representatives. Such notice shall describe the material terms and conditions of such Acquisition Proposal, inquiry, expression of interest, proposal, offer,
notice or request. The Company shall keep Purchaser fully informed of the status and details of, and any modification to, any such inquiry, expression of interest, proposal or offer and any correspondence or communications related thereto and shall
provide to Purchaser a true, correct and complete copy of such inquiry, expression of interest, proposal or offer and any amendments, correspondence and communications related thereto, if it is in writing, or a reasonable summary thereof, if it is
not in writing, without, however, disclosing the identity of the Person or Group making any such Acquisition Proposal, inquiry, expression of interest, proposal, offer, notice or request, or any amendments, correspondence and communications related
thereto. The Company shall provide Purchaser with 48 hours prior notice (or such lesser prior notice as is provided to the members of the Board of Directors) of any meeting of the Board of Directors at which the Board of Directors is reasonably
expected to discuss any Acquisition Proposal. 

  
 48 

 6.2 Confidentiality; Public Disclosure. 

(a) The parties hereto acknowledge that Parent and the Company have previously executed a Mutual Nondisclosure Agreement, dated as of
December 5, 2013 (the “Confidentiality Agreement”) which shall continue in full force and effect in accordance with its terms, and Purchaser hereby agrees to be bound by such Confidentiality Agreement as if a party
thereto to the same extent to which it applies to and is binding upon Parent. The Company Shareholder hereby agrees to be bound by the terms and conditions of the Confidentiality Agreement to the same extent as though the Company Shareholder was a
party thereto. With respect to the Company Shareholder, as used in the Confidentiality Agreement the term “Information” shall include information relating to the Share Purchase or this Agreement received by the Company Shareholder after
the Closing or relating to the period after the Closing. 
 (b) Neither Parent, Purchaser nor the Company shall, and each of the Parent,
Purchaser and the Company shall cause each of their respective representatives not to, directly or indirectly, issue any press release or other public statement relating to the terms of this Agreement or the transactions contemplated hereby or use
each of Parent’s, Purchaser’s or Company’s name or refer to Parent, Purchaser or the Company directly or indirectly in connection with the transaction contemplated hereby in any media interview, advertisement, news release, press
release or professional or trade publication, or in any print media, whether or not in response to an inquiry, without the prior written approval of Parent or the Company, as the case maybe, unless required by law or stock exchange regulations (in
which event the disclosing or announcing party shall, to the extent feasible, give Parent or the Company, as the case may be, the opportunity to comment on such disclosure prior to the making of such disclosure) and except as reasonably necessary
for the Company to obtain the consents and approvals of third parties contemplated by this Agreement. Notwithstanding anything herein or in the Confidentiality Agreement, after the Closing, Parent and Purchaser may issue such press releases or make
such other public statements regarding this Agreement or the transactions contemplated hereby as Parent or Purchaser may, in their sole discretion, determine; provided, however, that in the event of any such press releases or
other public statement, in Parent’s good faith judgment, is reasonably likely to include material nonpublic information regarding the Company Product or the Contingent Payments, then Parent shall use commercially reasonable efforts to advise
the Company Shareholder in writing of its intention to make such press releases or other public statement (subject, if requested by Parent, the Company Shareholder’s agreement to maintain the confidentiality of such information until
such press releases or other public statement is made). 
 (c) For purposes of securities Law compliance, Parent, Purchaser and the
Company Shareholder reserve the right, without the Company’s or Parent’s or Purchaser’s, as the case may be, prior consent, to make any public disclosure it believes in good faith is required by applicable securities laws or
securities listing standards, in which case the Parent, Purchaser and the Company Shareholder, as the case may be, agrees to (i) advise Parent or the Company Shareholder, as the case may be, of its intention to make such disclosure and
(ii) give Parent or the Company Shareholder, as the case may be, and their respective advisors the opportunity to comment on such disclosure prior to the making of such disclosure. 

6.3 Regulatory Approvals. 

(a) The Company shall, promptly execute and file, or join in the execution and filing of, any application, notification (including any
notification or provision of information, if any, that may be required under the HSR Act, the RTPA or other applicable foreign antitrust laws) or other document that may be necessary in order to obtain the authorization, approval or consent of any
Governmental Entity, whether federal, state, local or foreign, which may be reasonably required, or which Purchaser may reasonably request, in connection with the consummation of the Share Purchase and the other transactions contemplated by this
Agreement, including an OCS Notice. The Company shall use commercially reasonable efforts to obtain, and to cooperate with Purchaser to promptly obtain, all such authorizations, approvals and consents and shall pay any associated filing fees payable
by the Company 

  
 49 

 
with respect to such authorizations, approvals and consents. The Company shall promptly inform Purchaser of any material communication between the Company and any Governmental Entity regarding
any of the transactions contemplated hereby. If the Company receives any formal or informal request for supplemental information or documentary material from any Governmental Entity with respect to the transactions contemplated hereby, then the
Company shall make, or cause to be made, as soon as reasonably practicable, a response in compliance with such request. The Company shall direct, in its sole discretion, the making of such response, but shall consider in good faith the views of
Purchaser. 
 (b) Parent and Purchaser shall promptly execute and file, or join in the execution and filing of, any application,
notification (including any notification or provision of information, if any, that may be required under the HSR Act, the RTPA or other applicable foreign antitrust laws) or other document that may be necessary in order to obtain the authorization,
approval or consent of any Governmental Entity, whether foreign, federal, state, local or municipal, which may be reasonably required in connection with the consummation of the Share Purchase and the other transactions contemplated by this
Agreement. Parent and Purchaser shall use commercially reasonable efforts to obtain all such authorizations, approvals and consents and shall pay any associated filing fees payable by Parent or Purchaser with respect to such authorizations,
approvals and consents. Parent and Purchaser shall promptly inform the Company of any material communication between Parent or Purchaser and any Governmental Entity regarding any of the transactions contemplated hereby. If Parent or Purchaser or any
affiliate of Parent or Purchaser receives any formal or informal request for supplemental information or documentary material from any Governmental Entity with respect to the transactions contemplated hereby, then Parent and Purchaser shall make, or
cause to be made, as soon as reasonably practicable, a response in compliance with such request. Parent and Purchaser shall direct, in its sole discretion, the making of such response, but shall consider in good faith the views of the Company. 

(c) Notwithstanding anything in this Agreement to the contrary, if any administrative or judicial action or proceeding is instituted (or
threatened to be instituted) challenging any transaction contemplated by this Agreement as violative of any federal, state or foreign statutes, rules, regulations, orders or decrees that are designed to prohibit, restrict or regulate actions having
the purpose or effect of monopolization or restraint of trade (collectively, “Antitrust Laws”), it is expressly understood and agreed that: (i) neither Purchaser nor the Company or the Company Shareholder shall have any
obligation to litigate or contest any administrative or judicial action or proceeding or any decree, judgment, injunction or other order, whether temporary, preliminary or permanent; and (ii) neither Purchaser nor the Company or the Company
Shareholder shall be under any obligation to make proposals, execute or carry out agreements or submit to orders providing for (1) the sale, license, transfer or other disposition or holding separate (through the establishment of a trust or
otherwise) of any assets or categories of assets of such party or any of its Affiliates or the Company, (2) the discontinuation of any product or service of such part or any of its Affiliates or the, (3) the licensing or provision of any
technology, software or other Intellectual Property of such party or any of its Affiliates or the Company to any Person, (4) the imposition of any limitation or regulation on the ability of such party or any of its Affiliates to freely conduct
their business or own their respective assets, or (3) the holding separate of the Company Ordinary Shares or any limitation or regulation on the ability of Purchaser or any of its Affiliates to exercise full rights of ownership of the Company
Ordinary Shares (any of the foregoing, an “Antitrust Restraint”). Nothing in this Section 6.3 shall limit a party’s right to terminate this Agreement pursuant to Section 8.1(b) if such party has,
until such date, complied in all material respects with its obligations under this Section 6.3. 
 6.4 Reasonable
Efforts. Subject to the limitations set forth in Section 6.3, each of the parties hereto agrees to use its commercially reasonable efforts, and to cooperate with each other party hereto, to take, or cause to be taken, all actions,
and to do, or cause to be done, all things necessary, appropriate or desirable to consummate and make effective, in the most expeditious manner practicable, the Share Purchase and the other transactions contemplated hereby, including the
satisfaction of the respective 

  
 50 

 
conditions set forth in ARTICLE 7, and including to execute and deliver such other instruments and do and perform such other acts and things as may be necessary or reasonably desirable for
effecting completely the consummation of the Share Purchase and the other transactions contemplated hereby. 
 6.5 Third Party Consents;
Notices. The Company shall use commercially reasonable efforts to obtain prior to the Closing, and deliver to Purchaser at or prior to the Closing, all consents, waivers and approvals under each Contract (if any) entered into after the Agreement
Date that would have been required to be listed or described on Schedule 2.3(b)(ii)(B) of the Company Disclosure Letter if entered into prior to the Agreement Date. 

6.6 Litigation. During the period commencing on the date hereof and continuing until the earlier of the termination of this Agreement
and the Closing: 
 (a) The Company will (i) notify Purchaser in writing promptly after learning of any Legal Proceeding initiated by
or against it, or known by the Company to be threatened against the Company or any of its directors, officers, employees or shareholders in their capacity as such (a “Company New Litigation Claim”), (ii) notify Purchaser
of ongoing material developments in any Company New Litigation Claim and (iii) consult in good faith with Purchaser regarding the conduct of the defense of any Company New Litigation Claim. 

(b) The Parent and Purchaser will (i) notify the Company in writing promptly after learning of any Legal Proceeding initiated by or
against any of it, or known by the Parent or Purchaser to be threatened against the Parent or Purchaser or any of their respective directors, officers, employees or shareholders in their capacity as such that, seek to restrain or enjoin the
consummation of the transactions contemplated hereby or which could reasonably be expected to impede, interfere with, prevent or materially delay the Share Purchase (a “Purchaser New Litigation Claim”), (ii) notify
Company of ongoing material developments in any such Purchaser New Litigation Claim and (iii) consult in good faith with Company regarding the conduct of the defense of any Purchaser New Litigation Claim. 

6.7 Access to Information. 

(a) During the period commencing on the date hereof and continuing until the earlier of the termination of this Agreement and the Closing,
(i) the Company shall afford Purchaser and its accountants, counsel and other representatives, reasonable access during business hours to (A) all of the Company’s properties, books, Contracts and records and (B) all other
information concerning the business, properties and personnel of the Company as Purchaser may reasonably request, and (ii) the Company shall provide to Purchaser and its accountants, counsel and other representatives correct and complete copies
of the Company’s (A) internal financial statements, (B) Tax Returns, and all other records and workpapers relating to Taxes, and (C) a schedule of any deferred intercompany gain or loss with respect to transactions to which the
Company has been a party. 
 (b) Subject to compliance with applicable Legal Requirements, from the date hereof until the earlier of the
termination of this Agreement and the Closing, the Company shall confer from time to time as reasonably requested by Purchaser with one or more representatives of Purchaser to discuss any material changes or developments in the operational matters
of the Company and the general status of the ongoing operations of the Company. 
 (c) No information or knowledge obtained by Purchaser
during the pendency of the transactions contemplated by this Agreement in any investigation pursuant to this Section 6.7 shall affect or be deemed to modify any representation, warranty, covenant, condition or obligation under this
Agreement. 

  
 51 

 6.8 Spreadsheet. The Company shall prepare and deliver to Purchaser, at or prior to the
Closing, a spreadsheet (in Microsoft Excel form) (the “Spreadsheet”) reasonably acceptable to Purchaser, which: 

(a) shall set forth all of the following information (in addition to the other required data and information specified therein) as of the
Closing Date and immediately prior to the Closing: (i) the name of the Company Shareholder and its addresses and taxpayer identification number; (ii) the number of Company Ordinary Shares held by such Person and the respective certificate
numbers; (iii) the calculation of the CBI Cash Closing Amount, CBI Initial Loan Amount, CBI Total Loan Amount, CBI Recent Loan Amount, Closing Cash Consideration, Closing Value, Employee Closing Payment Amount, Employee Contingent Payment
Amount, the percentage and maximum dollar amount payable to each employee in connection with each of Milestones 1 through 5 in connection with such employee’s Termination and Release, the percentage and, with respect to Milestone Payments, the
maximum dollar amount, payable to MTS Securities LLC (“MTS”) in connection with each Contingent Payment pursuant to that certain Letter Agreement, dated as of October 3, 2013, between MTS and the Company, as amended by
that certain letter agreement between the Company and MTS, dated as of February 5, 2014 (together, the “MTS Agreement”), the Share Consideration, Teva Cash Closing Amount (including a footnote that all such amounts are
subject to withholding of Taxes in accordance with Section 1.9 hereof); and (iv) the CBI Net New Funding Amount, CBI Ratio, Teva Net New Funding Amount and Teva Ratio (in each case calculated as of the Closing Date); and 

(b) shall include a set of formulas (within the spreadsheet cells) which assumes that all Milestone Payments occur in a consecutive
chronological order and that no Set-Off is applied with respect to such payments that accurately, and in a manner consistent with the terms and requirements of the Teva Share Purchase Agreement, calculate for each Contingent Payment that may be made
under this Agreement: (i) the CBI Net New Funding Amount, CBI Ratio, Teva Net New Funding Amount and Teva Ratio that apply to such Contingent Payment and (ii) the amount of such Contingent Payment to be paid to Teva in accordance with the
requirements of the Teva Share Purchase Agreement. 
 6.9 Expenses. Whether or not the Share Purchase is consummated, all costs and
expenses incurred in connection with this Agreement and the transactions contemplated hereby (including Transaction Expenses) shall be paid by the party incurring such expense; provided, however, that if the Share Purchase is consummated, Purchaser
shall pay all Transaction Expenses; provided, further, that all Transaction Expenses shall be taken into account in the calculation of the Total Consideration according to the definition of such term. 

6.10 Certain Closing Certificates and Documents. The Company shall prepare and deliver to Purchaser, a draft of each of the Closing
Expenses Certificate and the Spreadsheet not later than three Business Days prior to the Closing Date. The Company shall prepare and deliver to Purchaser at or prior to the Closing the Closing Expenses Certificate. Without limiting the generality or
effect of the foregoing or the provisions of Section 6.7(c), Company shall provide to Purchaser, promptly after Purchaser’s request, copies of the documents or instruments evidencing the amounts set forth on any such draft or final
certificate. 
 6.11 Corporate Matters. The Company shall at the Closing, deliver to Purchaser the minute books containing the
records of all proceedings, consents, actions and meetings of the Board of Directors, committees of the Board of Directors and shareholders of the Company and the share registries, journals and other records reflecting all share issuances and
transfers. 

  
 52 

 6.12 Tax Matters. 

(a) Allocation of Tax Liability. For all purposes under this Agreement, in the case of any Taxable period that includes (but does not
end on) the Closing Date, the portion of such Tax which relates to the portion of such Taxable period ending on the end of the Closing Date shall (x) in the case of any Tax other than Tax based upon or related to income or receipts, be deemed
to be the amount of such Tax for the entire Taxable period multiplied by a fraction the numerator of which is the number of days in the Taxable period ending on the end of the Closing Date and the denominator of which is the number of days in the
entire Taxable period, and (y) in the case of any Tax based upon or related to income or receipts be deemed equal to the amount which would be payable if the relevant Taxable period ended on the end of the Closing Date. 

(b) Each of Parent, Purchaser, the Company Shareholder and the Company shall cooperate fully, as and to the extent reasonably requested by the
other party, in connection with the filing of Tax Returns and any audit, litigation or other proceeding with respect to Taxes, including any proceeding with the OCS. Such cooperation shall include the retention and (upon the other party’s
request) the provision of records and information reasonably relevant to any such audit, litigation, or other proceeding and making employees available on a mutually convenient basis to provide additional information and explanation of any material
provided hereunder. Parent, Purchaser, the Company Shareholder and the Company agree to retain all books and records with respect to Tax and OCS matters pertinent to the Company relating to any Taxable period beginning before the Closing Date until
expiration of the statute of limitations of the respective Taxable periods, and to abide by all record retention agreements entered into with any Taxing Authority. 

(c) The Company shall cause the Company Shareholder to further agree, upon request, to use their reasonable best efforts to obtain any
certificate or other document from any Governmental Entity or any other Person as may be necessary to mitigate, reduce or eliminate any Tax that could be imposed (including with respect to the transactions contemplated hereby). 

6.13 Termination and Release. Prior to the Closing, the Company shall use commercially reasonable efforts to obtain an executed
Termination and Release from all of the employees of the Company. 
 6.14 Investment Representation Letter and Lock-up Agreement. The
Company shall use commercially reasonable efforts to obtain an executed Investment Representation Letter and Lock-up Agreement from CBI. 

6.15 Additional Company Shareholders. The Company shall not issue additional Company Ordinary Shares, Company Options or any other
securities of the Company, other than the issuance of Company Ordinary Shares pursuant to the exercise of Company Options that are outstanding as of the Agreement Date or pursuant to the conversion of the CBI Total Loan Amounts. 

6.16 Repurchase. The Company shall use commercially reasonable effort to repurchase all of the Company Ordinary Shares held by Teva in
accordance with the terms of the Teva Share Purchase Agreement. 
 6.17 CBI Loan Amendment. Prior to the Closing, the Company shall
obtain an executed CBI Loan Amendment from CBI with respect to each of the CBI Loan Agreements. 
 6.18 Financial Reporting. The
Company shall provide Purchaser with the financial statements (including, balance sheets, statements of operations, statements of cash flows and related footnotes) and the other financial information listed on Schedule 6.18 attached hereto
that is reasonably necessary or appropriate for Purchaser to comply with its financial reporting obligations (the “Required Financial Reports”). 

  
 53 

 6.19 Additional CBI Loans. Between the date hereof and the Closing Date, the Company may
borrow additional money from CBI; provided, however, that such loans shall covert into Company Ordinary Shares in accordance with the terms of the CBI Loan Amendment and shall include no right or obligation that survives such conversion (other than
the right to receive the Company Ordinary Shares pursuant to such conversion). 
 6.20 Rule 144. With a view to making available to
the Company Shareholder the benefits of Rule 144 and any other rule or regulation of the SEC that may at any time permit the Company Shareholder to sell shares of Parent Common Stock to the public without registration, so long as the Company
Shareholder owns any shares of Parent Common Stock acquired pursuant to this Agreement, the Parent shall use commercially reasonable efforts to: 

(a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after
the date of this Agreement; 
 (b) file with the SEC in a timely manner all reports and other documents required of Parent under the
Securities Act and the Exchange Act; and 
 (c) furnish to the Company Shareholder, so long as it owns any shares of Parent Common Stock,
forthwith upon request, to the extent accurate, a written statement by Parent that it has complied with the reporting requirements of SEC Rule 144, the Securities Act, and the Exchange Act. 

6.21 Employees. The Purchaser shall offer continued employment with the Company to all employees of the Company. Nothing in this
Section 6.21 will be or be deemed to be an amendment of any employment agreement or benefit plan of the Company or will require Purchaser to continue the service relationship (whether as an employee, director, consultant, or otherwise)
of any particular individual for any particular period of time. 
 6.22 CBI Cooperation. CBI agrees to use its commercially
reasonable efforts, and to cooperate with Purchaser, to take, or cause to be taken, all actions, and to do, or cause to be done, all things reasonably necessary, appropriate or desirable to facilitate the orderly transition of the Company to
Purchaser, but only to the extent that such activities and things required to be taken by CBI are consistent with CBI’s past practice with the Company during the year preceding the Closing. 

6.23 Compliance with Obligations. Parent hereby agrees to cause Purchaser to honor Purchaser’s obligations under this Agreement
and the other agreements to which Purchaser is a party pursuant to this Agreement. 
 6.24 Pay-off Letter or Assignment of Guarantee.
Prior to the Closing, the Purchaser and the Company shall each use its commercially reasonable efforts to either (x) obtain an executed pay-off letter (the “Pay-off Letter”) in a form reasonably satisfactory to Purchaser
and Company Shareholder from Bank Hapoalim, which Pay-off Letter shall include: (i) the balance required to pay-off all amounts owed to Bank Hapoalim in full at Closing (including any prepayment penalties); (ii) the per-diem interest
amount; and (iii) wiring instructions or (y) assign Company Shareholder’s guarantee of the Company’s indebtedness owed to Bank Hapoalim to the Purchaser or Parent on terms reasonably satisfactory to CBI (such documentation
reflecting the assignment described in clause (y), the “Guarantee Assignment Documentation”). 

  
 54 

 ARTICLE 7 

CONDITIONS TO THE SHARE PURCHASE 

7.1 Conditions to Obligations of Each Party to Effect the Share Purchase. The respective obligations of each party hereto to consummate
the transactions contemplated hereby shall be subject to the satisfaction at or prior to the Closing of each of the following conditions: 

(a) Illegality. No temporary restraining order, preliminary or permanent injunction or other order issued by any court of competent
jurisdiction or other legal or regulatory restraint or prohibition preventing the consummation of the Share Purchase shall be in effect, nor shall any action have been taken by any Governmental Entity seeking any of the foregoing, and no statute,
rule, regulation or order shall have been enacted, entered, enforced or deemed applicable to the Share Purchase, which makes the consummation of the Share Purchase illegal. 

(b) Governmental Approvals. Parent, Purchaser and the Company shall have timely obtained from each Governmental Entity all approvals,
waivers and consents, if any, necessary for consummation of, or in connection with, the Share Purchase and the other transactions contemplated hereby. All applicable waiting periods under the HSR Act, the RTPA or other applicable foreign antitrust
laws shall have expired or early termination of such waiting periods shall have been granted by both the Federal Trade Commission and the United States Department of Justice (or, with respect to foreign antitrust laws, the applicable foreign
Governmental Entity). 
 7.2 Additional Conditions to Obligations of the Company and the Company Shareholder. The obligations of the
Company and the Company Shareholder to consummate the transactions contemplated hereby shall be subject to the satisfaction at or prior to the Closing of each of the following conditions (it being understood that each such condition is solely for
the benefit of the Company and the Company Shareholder and may be waived by the Company and the Company Shareholder in writing in its sole discretion without notice or Liability to any Person): 

(a) Representations, Warranties and Covenants. The representations and warranties of Parent and Purchaser in this Agreement shall be
true and correct in all material respects (except for such representations and warranties that are qualified by their terms by a reference to materiality or Material Adverse Effect, which representations and warranties as so qualified shall be true
and correct in all respects) on and as of the date hereof and on and as of the Closing Date as though such representations and warranties were made on and as of such date (except for representations and warranties which address matters only as to a
specified date, which representations and warranties shall be true and correct with respect to such specified date). Parent and Purchaser shall have performed and complied in all material respects with all covenants, obligations and conditions of
this Agreement required to be performed and complied with by it at or prior to the Closing. 
 (b) Receipt of Closing Deliveries. The
Company and the Company Shareholder, as applicable, shall have received each of the agreements, instruments and other documents and deliveries set forth in Section 1.2(a) ; provided, however, that such receipt shall not be deemed
to be an agreement by the Company and Company Shareholder that any of the agreements, instruments or documents set forth in Section 1.2(a) is accurate and shall not diminish the Company’s and the Company’s Shareholder’s
remedies hereunder if any of the foregoing documents is not accurate. 
 (c) No Material Adverse Effect. There shall not have
occurred a Material Adverse Effect with respect to the Parent or Purchaser. 
 (d) No Legal Proceedings. No Governmental Entity shall
have commenced any Legal Proceeding challenging or seeking the recovery of a material amount of damages in connection with the Share Purchase or seeking to prohibit or limit the exercise by Purchaser of any material right pertaining to ownership of
stock of the Company. No Governmental Entity shall have threatened to commence any material Legal Proceeding challenging or seeking the recovery of a material amount of damages in connection with the Share Purchase or seeking to prohibit or limit
the exercise by Purchaser of any material right pertaining to ownership of stock of the Company. 

  
 55 

 7.3 Additional Conditions to the Obligations of Purchaser. The obligations of Purchaser to
consummate the transactions contemplated hereby shall be subject to the satisfaction at or prior to the Closing of each of the following conditions (it being understood that each such condition is solely for the benefit of Purchaser and may be
waived by Purchaser in writing in its sole discretion without notice or Liability to any Person): 
 (a) Representations, Warranties and
Covenants. The representations and warranties of the Company and the Company Shareholder in this Agreement shall be true and correct in all material respects (except for such representations and warranties that are qualified by their terms by a
reference to materiality or Material Adverse Effect and the representations and warranties contained in Section 2.2, which representations and warranties shall be true and correct in all respects) on and as of the date hereof and on and
as of the Closing Date as though such representations and warranties were made on and as of such date (except for representations and warranties which address matters only as to a specified date, which representations and warranties shall be true
and correct with respect to such specified date). The Company and the Company Shareholder shall have each performed and complied in all material respects with all respective covenants, obligations and conditions of this Agreement required to be
performed and complied with by the Company or the Company Shareholder, as applicable, at or prior to the Closing. 
 (b) Receipt of
Closing Deliveries. Purchaser shall have received each of the agreements, instruments and other documents set forth in Section 1.2(b); provided, however, that such receipt shall not be deemed to be an agreement by Purchaser
that the amounts set forth on the Closing Expenses Certificate or the Spreadsheet or any of the other agreements, instruments or documents set forth in Section 1.2(b) is accurate and shall not diminish Purchaser’s remedies hereunder
if any of the foregoing documents is not accurate. 
 (c) Injunctions or Restraints on Conduct of Business. No temporary restraining
order, preliminary or permanent injunction or other order issued by any court of competent jurisdiction or other legal or regulatory restraint provision limiting or restricting Purchaser’s ownership, conduct or operation of the business of the
Company, following the Closing shall be in effect nor shall there be pending or threatened any Legal Proceeding seeking any of the foregoing, any Antitrust Restraint or any other injunction, restraint or material damages in connection with the Share
Purchase or the other transactions contemplated hereby. 
 (d) No Legal Proceedings. No Governmental Entity shall have commenced any
Legal Proceeding challenging or seeking the recovery of a material amount of damages in connection with the Share Purchase or seeking to prohibit or limit the exercise by Purchaser of any material right pertaining to ownership of stock of the
Company. No Governmental Entity shall have threatened to commence any material Legal Proceeding challenging or seeking the recovery of a material amount of damages in connection with the Share Purchase or seeking to prohibit or limit the exercise by
Purchaser of any material right pertaining to ownership of stock of the Company. 
 (e) No Material Adverse Effect. There shall not
have occurred a Material Adverse Effect with respect to the Company. 
 (f) No Outstanding Securities. Other than Company Ordinary
Shares issued and outstanding as of immediately prior to the Closing, there shall be no outstanding securities, warrants, options, commitments or agreements of the Company immediately prior to the Closing that purport to obligate the Company to
issue any Company Ordinary Shares, Company Options or any other securities under any circumstances. 

  
 56 

 (g) Company Securityholders. CBI shall be the sole Company Shareholder and there shall be
no Company Optionholders. 
 (h) Employees. All of the Company’s Designated Employees shall have remained continuously employed
with the Company from the date of this Agreement through the Closing and shall have signed each of the documents set forth in Section 1.2(b)(v), and no action shall have been taken by any such individual to rescind any such document.

 (i) Repurchase. The Company shall have repurchased all of the Company Ordinary Shares held by Teva in accordance with the terms of
the Teva Share Purchase Agreement. 
 (j) CBI Loan Amendment. The Company shall have obtain an executed CBI Loan Amendment from CBI
with respect to each of the CBI Loan Agreements. 
 (k) Financial Reporting. The Company shall have provided Purchaser with the
Required Financial Reports. 
 ARTICLE 8 

TERMINATION, AMENDMENT AND WAIVER 

8.1 Termination. At any time prior to the Closing, this Agreement may be terminated and the Share Purchase abandoned by authorized
action taken by the terminating party: 
 (a) by mutual written consent duly authorized by the Company’s Board of Directors and Parent;

 (b) by either Purchaser or the Company, if the Closing shall not have occurred on or before June 15, 2014, or such other date that
Purchaser and the Company may agree upon in writing (the “Termination Date”); provided, further, that the right to terminate this Agreement under this clause (b) of Section 8.1 shall not be available
to any party whose breach of any covenant or agreement hereunder will have been the principal cause of, or will have directly resulted in, the failure of the Closing to occur on or before the Termination Date; 

(c) by either Purchaser or the Company, if any permanent injunction or other order of a Governmental Entity of competent authority preventing
the consummation of the Share Purchase shall have become final and nonappealable; 
 (d) by Purchaser, if (i) the Company or the
Company Shareholder shall have breached any representation, warranty, covenant or agreement contained herein and such breach shall not have been cured within five Business Days after receipt by the Company or the Company Shareholder, as applicable,
of written notice of such breach (provided, however, that no such cure period shall be available or applicable to any such breach which by its nature cannot be cured) and if not cured within the timeframe above and at or prior to the Closing,
such breach would result in the failure of any of the conditions set forth in Section 7.1 or Section 7.3 to be satisfied, (ii) the Company shall have breached Section 6.1 or Section 6.2, or
(iii) there shall have been a Material Adverse Effect with respect to the Company; or 
 (e) by the Company, if Parent or Purchaser
shall have breached any representation, warranty, covenant or agreement contained herein and such breach shall not have been cured within five Business Days after receipt by Purchaser of written notice of such breach (provided, however, that
no such cure period shall be available or applicable to any such breach which by its nature cannot be cured) and if not cured within the timeframe above and at or prior to the Closing, such breach would result in the

  
 57 

 
failure of any of the conditions set forth in Section 7.1 or Section 7.2 to be satisfied, (ii) the Parent or Purchaser shall have materially breached
Section 6.2, or (iii) there shall have been a Material Adverse Effect with respect to the Parent or Purchaser. 
 8.2
Effect of Termination. In the event of termination of this Agreement as provided in Section 8.1, this Agreement shall forthwith become void and there shall be no liability or obligation on the part of Parent, Purchaser, the
Company or their respective officers, directors, shareholders or affiliates; provided, however, that (a) the provisions of this Section 8.2 (Effect of Termination), ARTICLE 10 (General Provisions) and any related definition
provisions and the Confidentiality Agreement shall remain in full force and effect and survive any termination of this Agreement and (b) nothing herein shall relieve any party hereto from liability in connection with any breach of such
party’s representations, warranties or covenants contained herein. 
 8.3 Amendment. Subject to the provisions of applicable
Legal Requirements, the parties hereto may amend this Agreement by authorized action pursuant to an instrument in writing signed on behalf of each of the parties hereto. To the extent permitted by applicable Legal Requirements, Purchaser and the
Company Shareholder may cause this Agreement to be amended at any time after the Closing by execution of an instrument in writing signed on behalf of Purchaser and the Company Shareholder. Notwithstanding the foregoing, in event that the Company
borrows additional money from CBI in accordance with Section 6.19, then Schedule A-1 and Schedule A-2 may be updated without the consent of the other parties hereto to add such additional loans. 

8.4 Extension; Waiver. At any time at or prior to the Closing, any party hereto may, to the extent legally allowed, (a) extend the
time for the performance of any of the obligations or other acts of the other parties hereto, (b) waive any inaccuracies in the representations and warranties made to such party contained herein or in any document delivered pursuant hereto, and
(c) waive compliance with any of the agreements or conditions for the benefit of such party contained herein. At any time after the Closing, the Company Shareholder and Purchaser may, to the extent legally allowed, (i) extend the time for
the performance of any of the obligations or other acts of the other, (ii) waive any inaccuracies in the representations and warranties made to such party contained herein or in any document delivered pursuant hereto, and (iii) waive
compliance with any of the agreements or conditions for the benefit of such Person contained herein. Any agreement on the part of a party hereto or the Company Shareholder to any such extension or waiver shall be valid only if set forth in an
instrument in writing signed on behalf of such party. Without limiting the generality or effect of the preceding sentence, no delay in exercising any right under this Agreement shall constitute a waiver of such right, and no waiver of any breach or
default shall be deemed a waiver of any other breach or default of the same or any other provision in this Agreement. 
 ARTICLE 9

 INDEMNIFICATION 

9.1 Unilateral Right of Set-Off. In accordance with Section 1.12(h), the obligation of Parent and/or Purchaser to make any
Contingent Payment shall be qualified by the right of Parent and/or Purchaser to reduce the amount of any one or more of the Milestone Payments or the Contingent Sales Payments, by the amount of any Indemnifiable Damages for which an Indemnified
Person may be entitled to indemnification pursuant to this ARTICLE 9. 
 9.2 Indemnification. Subject to the limitations set forth in
this ARTICLE 9, from and after the Closing, the Company Shareholder shall indemnify and hold harmless Parent, Purchaser and their officers, directors, agents and employees, and each Person, if any, who controls or may control Parent within the
meaning of the Securities Act (each of the foregoing being referred to individually as an “Indemnified Person” and collectively as “Indemnified Persons”) from and against any and all losses,
Liabilities, damages, fees, Tax, reductions in value, costs and expenses, including costs of investigation 

  
 58 

 
and defense and reasonable fees and reasonable expenses of lawyers, experts and other professionals, whether or not due to a third-party claim (collectively, “Indemnifiable
Damages”), incurred or accrued and arising out of, resulting from or in connection with (i) any failure of any representation or warranty made by the Company or a Company Shareholder in this Agreement or the Company Disclosure
Letter (including any exhibit or schedule to the Company Disclosure Letter) to be true and correct as of the Agreement Date and as of the Closing Date as though such representation or warranty were made as of the Closing Date (except in the case of
representations and warranties which by their terms speak only as of a specific date or dates, which representations and warranties shall be true and correct as of such date), (ii) any failure of any certification, representation or warranty
made by the Company in any certificate (other than the Spreadsheet and the Closing Expenses Certificate) delivered to Purchaser pursuant to any provision of this Agreement to be true and correct as of the date such certificate is delivered to
Purchaser, (iii) any breach of or default in connection with any of the covenants or agreements made by the Company in this Agreement, (iv) any matter set forth on Schedule 2.6 to the Company Disclosure Letter or that is or would be
an exception to the representations and warranties made on each date in Section 2.6 (Litigation), (v) any inaccuracies in the Spreadsheet, and (vi) any Indemnifiable Transaction Expenses or any inaccuracies in the Closing
Expenses Certificate. Materiality standards or qualifications, and qualifications by reference to the defined term “Material Adverse Effect” in any representation, warranty or covenant shall only be taken into account in determining
whether a breach of or default in connection with such representation, warranty or covenant (or failure of any representation or warranty to be true and correct) exists, and shall not be taken into account in determining the amount of any
Indemnifiable Damages with respect to such breach, default or failure to be true and correct. The Company Shareholder shall not have any right of contribution, indemnification or right of advancement from the Company, Parent or Purchaser with
respect to any Indemnifiable Damages claimed by an Indemnified Person. It is understood that neither the Company nor the Company Shareholder shall be liable to the Indemnified Persons for fraud or intentional misrepresentation with respect a
representation or warranty set forth in this Agreement, if and to the extent (and only if and to the extent) the alleged fraud or intentional misrepresentation is based on information or knowledge obtained by Parent or Purchaser prior to the
Closing. 
 9.3 Indemnifiable Damage Threshold; Other Limitations. 

(a) Notwithstanding anything contained herein to the contrary, except with regard to claims involving (i) fraud or intentional
misrepresentation by the Company or the Company Shareholder or (ii) any failure to be true and correct of any of the representations and warranties in Section 2.1 (Organization, Standing, Power and Subsidiaries), Section 2.2 (Capital
Structure), Section 2.3(a) (Authority), Section 2.13 (Taxes) (the “Tax Representation”), Section 3.1 (Power and Capacity), Section 3.2 Enforceability; Non-Contravention Section 3.3(Title to Share) and
Section 3.5 (Solvency); (the preceding eight sections, collectively, the “Special Representations”), no Indemnified Person may make a claim in respect of any claim for indemnification that may be made pursuant to clause
(i) or (ii) of the first sentence of Section 9.2 unless and until a Claim Certificate (as defined below) describing Indemnifiable Damages in an aggregate amount greater than $500,000 (the “Aggregate
Threshold”) has been delivered, in which case the Indemnified Person may make claims for indemnification and may exercise its Set-Off Rights for all Indemnifiable Damages (including the amount of the Aggregate Threshold). 

(b) Except with regard to (i) claims involving fraud or intentional misrepresentation by the Company Shareholder (for which there shall
be no maximum aggregate limit) and claims involving fraud or intentional misrepresentation by the Company (for which the limit is set forth in subsection (c) below), (ii) any failure of any of the Special Representations to be true and
correct as aforesaid (for which the limit is set forth in subsection (c) below) and (iii) any failure to be true and correct of any of the representations and warranties in Section 2.10 (Intellectual Property) (the “IP
Representation”) or Section 2.19 (Regulatory Matters) (the “Regulatory Representation”) (for which the limit is set forth in 

  
 59 

 
subsection (d) below), the maximum aggregate amount the Indemnified Persons may recover from the Company Shareholder pursuant to clauses (i), (ii), and (iv) of the first sentence of
Section 9.2 shall be an amount equal to 15% of the Total Consideration paid or due and payable pursuant to Section 1.3. 

(c) In the case of claims involving fraud or intentional misrepresentation by the Company or in the case of the failure of the Special
Representations to be true and correct as aforesaid, the maximum aggregate amount the Indemnified Persons may recover from the Company Shareholder pursuant to clauses (i), (ii), (iii), (v) and (vi) of the first sentence of
Section 9.2 shall be an amount equal to 100% of the Total Consideration paid or due and payable pursuant to Section 1.3. 

(d) In the case of the failure of the IP Representation or the Regulatory Representation to be true and correct as aforesaid, the maximum
aggregate amount the Indemnified Persons may recover from the Company Shareholder pursuant to clauses (i) and (ii) of the first sentence of Section 9.2 with respect a failure of the IP Representation or the Regulatory
Representation to be true and correct as aforesaid shall be an amount equal to 35% of the Total Consideration paid or due and payable pursuant to Section 1.3. 

(e) Indemnifiable Damages shall be calculated net of actual recoveries under existing insurance policies (net of any actual collection costs
and reserves); provided, however, that neither Parent nor Purchaser shall have no obligation to pursue any claims for insurance. In no event shall any party be indemnified under different provisions of this Agreement more than once for the same
dollar of Indemnifiable Damages. 
 (f) Notwithstanding any provision of this Agreement to the contrary, (i) except in the case of
fraud or intentional misrepresentation by the Company Shareholder Parent or the Purchaser, the indemnification obligations set forth in this Article 9 shall be the sole and exclusive remedies available to the parties hereto with respect to or in
connection with this Agreement or any agreement, document, certificate or instrument delivered hereunder, or any of the transactions contemplated hereunder or thereunder and (ii) except in the case of fraud or intentional misrepresentation by
the Company Shareholder, the Indemnified Persons right to indemnification from the Company Shareholder under this Agreement shall be exclusively by the Set-Off Rights; provided, however, that nothing in this provision shall limit any
equitable remedy, including injunctions and specific performance, that a party hereto may have pursuant to this Agreement. 
 (g)
Notwithstanding anything to the contrary contained herein, no party hereto shall be liable for any loss of profits or anticipated savings, loss of goodwill or injury to reputation, loss of business opportunity, punitive damages or any indirect,
consequential or special losses or damages. 
 9.4 Period for Claims . Except as set forth below, the period during which claims for
Indemnifiable Damages may be made (the “Claims Period”) for Indemnifiable Damages arising from or in connection with all of the matters listed in the first sentence of Section 9.2, shall commence at the Closing
and terminate the day after the date that is eighteen (18) months following the Closing Date (the “General Claims Period”). The Claims Period for Indemnifiable Damages arising out of, resulting from or in connection with
(x) any failure of the Tax Representation to be true and correct, or (y) any of the matters listed in clauses (iii) and (v) of the first sentence of Section 9.2, shall commence at the Closing and terminate upon the
expiration of the applicable statute of limitations (giving effect to any waiver, mitigation or extension thereof) for such claim. The Claims Period for Indemnifiable Damages arising out of, resulting from or in connection with any failure of the IP
Representation or the Regulatory Representation to be true and correct, shall commence at the Closing and terminate upon the day after the date that is twenty-four (24) months following the Closing Date. The Claims Period for Indemnifiable
Damages arising out of, resulting from or in connection with (i) fraud, willful breach or intentional misrepresentation by the Company or the Company Shareholder, and (ii) any failure of any of the Special

  
 60 

 
Representations to be true and correct, shall commence at the Closing and terminate upon the expiration of the applicable statute of limitations (giving effect to any waiver, mitigation or
extension thereof) for such claim. The indemnification obligations of the Indemnified Persons will be determined without regard to any right to indemnification that the Company Shareholder may have in its capacity as an agent of the Company and the
Company Shareholder will not be entitled to any indemnification from the Company for amounts paid for indemnification under this ARTICLE 9. 

9.5 Claims. 
 (a) On or
before the last day of the applicable Claims Period, Purchaser may deliver to the Company Shareholder a certificate signed by any officer of Purchaser (a “Claim Certificate”): 

(i) stating that an Indemnified Person has incurred or paid, or in good faith reasonably anticipates that it may incur or pay, Indemnifiable
Damages (or that with respect to any Tax matters, that any Tax Authority may raise such Tax Matter in audit of Purchaser or its subsidiaries, which could give rise to Indemnifiable Damages); 

(ii) stating the amount of such Indemnifiable Damages (which, in the case of Indemnifiable Damages not yet incurred or paid, may be the
maximum amount reasonably anticipated by Purchaser in good faith to be incurred or paid); and 
 (iii) specifying in reasonable detail
(based upon the information then possessed by Purchaser) the individual items of such Indemnifiable Damages included in the amount so stated and the nature of the claim to which such Indemnifiable Damages are related. 

No delay in providing such Claim Certificate within the Claims Period shall affect an Indemnified Person’s rights hereunder, unless (and
then only to the extent that) the Company Shareholder is materially prejudiced thereby. 
 9.6 Resolution of Objections to Claims.

 (a) If the Company Shareholder does not contest, by written notice to Purchaser, any claim or claims by Purchaser made in any Claim
Certificate within the 30-day period following receipt of such Claim Certificate pursuant to Section 9.5, then Purchaser shall retain from the Contingent Payments an amount equal to the amount of any Indemnifiable Damages corresponding
to such claim or claims as set forth in such Claim Certificate. 
 (b) If the Company Shareholder objects in writing to any claim or claims
by Purchaser made in any Claim Certificate within such 30-day period, Purchaser and the Company Shareholder shall attempt in good faith for 45 days after Purchaser’s receipt of such written objection to resolve such objection. If Purchaser and
the Company Shareholder shall so agree, a memorandum setting forth such agreement shall be prepared and signed by both parties. 
 (c) If no
such agreement can be reached during the 45-day period for good faith negotiation, upon the expiration of such 45-day period either Purchaser or the Company Shareholder may bring suit in the courts of the State of Delaware and the Federal courts of
the United States of America, in each case, located within the State of Delaware to resolve the matter. The decision of the trial court as to the validity and amount of any claim in such Claim Certificate shall be nonappealable, binding and
conclusive upon the parties to this Agreement and the parties shall be entitled to act in accordance with such decision. 

  
 61 

 9.7 Third-Party Claims. In the event Purchaser becomes aware of a third-party claim which
Purchaser believes may result in a claim for indemnification pursuant to this ARTICLE 9 by or on behalf of an Indemnified Person, Purchaser shall have the right in its sole discretion to conduct the defense of and to settle or resolve any such claim
(and the costs and expenses incurred by Purchaser in connection with such defense, settlement or resolution (including reasonable attorneys’ fees, other professionals’ and experts’ fees and court or arbitration costs) shall be
included in the Indemnifiable Damages for which Purchaser may seek indemnification pursuant to a claim made hereunder). The Company Shareholder shall have the right to receive copies of all pleadings, notices and communications with respect to the
third-party claim to the extent that receipt of such documents does not affect any privilege relating to any Indemnified Person and shall be entitled, at its expense, to participate in, but not to determine or conduct, any defense of the third-party
claim or settlement negotiations with respect to the third-party claim. However, except with the consent of the Company Shareholder, which consent shall not be unreasonably withheld, conditioned or delayed and which shall be deemed to have been
given unless the Company Shareholder shall have objected within 15 days after a written request for such consent by Purchaser, no settlement or resolution by Purchaser of any claim that gives rise to a claim by or on behalf of an Indemnified Person
shall be determinative of the existence of or amount of Indemnifiable Damages relating to such matter. In the event that the Company Shareholder has consented to any such settlement or resolution, the Company Shareholder shall not have any power or
authority to object under Section 9.5 or any other provision of this ARTICLE 9 to the amount of any claim by or on behalf of any Indemnified Persons for indemnity with respect to and in accordance with such consented settlement or
resolution. 
 9.8 Indemnification by Purchaser. From and after the Closing, Parent and Purchaser will indemnify, defend and hold
harmless the Company Shareholder and its officers, directors, agents and employees, and each Person, if any, who controls or may control the Company Shareholder within the meaning of the Securities Act (each of the foregoing being referred to
individually as an “Shareholder Indemnified Person” and collectively as “Shareholder Indemnified Persons”) from and against any and all Indemnifiable Damages, incurred or accrued and arising out of,
resulting from or in connection with (i) any failure of any representation or warranty made by the Parent or Purchaser in this Agreement (including any exhibit or schedule hereto) to be true and correct as of the Agreement Date and as of the
Closing Date as though such representation or warranty were made as of the Closing Date (except in the case of representations and warranties which by their terms speak only as of a specific date or dates, which representations and warranties shall
be true and correct as of such date), (ii) any failure of any certification, representation or warranty made by the Parent or Purchaser in any certificate delivered to Company Shareholder pursuant to any provision of this Agreement to be true
and correct as of the date such certificate is delivered to Company Shareholder, (iii) any breach of or default in connection with any of the covenants or agreements made by the Parent or Purchaser in this Agreement. Except as set forth below,
the period during which claims for Indemnifiable Damages may be made for Indemnifiable Damages arising from or in connection with all of the matters listed in this Section 9.8, shall commence at the Closing and terminate the day after
the date that is eighteen (18) months following the Closing Date. The Claims Period for Indemnifiable Damages arising out of, resulting from or in connection with (x) any failure of the representations and warranties in
Section 4.1 (Organization and Standing), Section 4.2 (Authority; Noncontravention), Section 4.3 (Capitalization), Section 4.7 (Solvency), Section 4.8 (Issuance of Shares), Section 4.9
(Financing), and the representations and warranties of the Parent and Purchaser contained in any certificate delivered to Company Shareholder regarding the same subject matter as those covered by such representations and warranties pursuant to any
provision of this Agreement to be true and correct or (y) any breach of or default in connection with any of the covenants or agreements made by the Parent and Purchaser in this Agreement and the other certificates contemplated hereby, shall
commence at the Closing or at such later time on which such covenant, agreement or certificate is to be performed or delivered, as the case may be, and terminate upon the expiration of the applicable statute of limitations (giving effect to any
waiver, mitigation or extension thereof) for such claim. 

  
 62 

 9.9 Treatment of Indemnification Payments. The Company Shareholder, the Company
Shareholder, Parent and Purchaser agree to treat any payment received pursuant to this ARTICLE 9 as adjustments to the Total Consideration for all Tax purposes, to the maximum extent permitted by Legal Requirements. 

9.10 Tail D&O Insurance. Prior to the Closing, the Company shall purchase a “tail” officers’ and directors’
liability and professional liability insurance policy (the “D&O Insurance”), which by its terms shall survive the Closing for not less than seven years for the benefit of the Company’s past and present
directors, officers and employees that are insured under the Company’s current directors’ and officers’ liability insurance policy in effect as of the date of this Agreement. The Company shall not be required to pay an annual premium
for the D&O Insurance in excess of $50,000 of the last annual premium paid prior to the date of this Agreement (it being understood and agreed that in the event such D&O Insurance cannot be obtained for $50,000 of such last annual premium or
less, in the aggregate, the Company shall provide the greatest D&O Insurance coverage as may be obtained for such amount). 
 ARTICLE
10 
 GENERAL PROVISIONS 

10.1 Survival of Representations and Warranties and Covenants. If the Share Purchase is consummated, the representations and warranties
and covenants of the Company and the Company Shareholder contained in this Agreement, the Company Disclosure Letter (including any exhibit or schedule to the Company Disclosure Letter), and the other certificates contemplated hereby shall survive
the Closing and remain in full force and effect, regardless of any investigation or disclosure made by or on behalf of any of the parties to this Agreement, until the date that is eighteen (18) months following the Closing Date;
provided, however, that the Special Representations and the representations and warranties of the Company contained in any certificate delivered to Purchaser regarding the same subject matter as those covered by the Special
Representations pursuant to any provision of this Agreement, will remain operative and in full force and effect, regardless of any investigation or disclosure made by or on behalf of any of the parties to this Agreement, until the expiration of the
applicable statute of limitations (giving effect to any waiver, mitigation or extension thereof) for claims against the Company Shareholder which seek recovery of Indemnifiable Damages arising out of an inaccuracy or breach of such representations
or warranties; provided, further, that the IP Representation and the Regulatory Representation and the representations and warranties of the Company contained in any certificate delivered to Purchaser regarding the same subject
matter as those covered by the IP Representation or the Regulatory Representation pursuant to any provision of this Agreement, will remain operative and in full force and effect, regardless of any investigation or disclosure made by or on behalf of
any of the parties to this Agreement, until the date that is twenty-four (24) months following the Closing Date for claims against the Company Shareholder which seek recovery of Indemnifiable Damages arising out of an inaccuracy or breach of
such representations or warranties; provided, further, that the Tax Representation and the representations and warranties of the Company contained in any certificate delivered to Purchaser regarding the same subject matter as
those covered by Tax Representation pursuant to any provision of this Agreement, will remain operative and in full force and effect, regardless of any investigation or disclosure made by or on behalf of any of the parties to this Agreement, until
the expiration of the applicable statute of limitations (giving effect to any waiver, mitigation or extension thereof) for such claim against the Company Shareholder which seek recovery of Indemnifiable Damages arising out of an inaccuracy or breach
of such representations or warranties; provided, further, that no right to indemnification pursuant to ARTICLE 9 in respect of any claim that is set forth in a Claim Certificate delivered to the Company Shareholder prior to the
expiration of the applicable Claims Period set forth above shall be affected by the expiration of such representations and warranties; and provided, further, that such expiration shall not affect the rights of any Indemnified Person to seek
recovery of Indemnifiable Damages arising out of any fraud, willful breach or intentional misrepresentation by the Company (subject to the limitations set forth in ARTICLE 9) or the Company Shareholder. If the Share

  
 63 

 
Purchase is consummated, the representations, warranties and covenants of Parent and Purchaser contained in this Agreement and the other certificates contemplated hereby shall survive the Closing
and remain operative and in full force and effect regardless of any investigation or disclosure made by or on behalf of any of the parties to this Agreement, until the date that is eighteen (18) months following the Closing Date;
provided, however, that the representations and warranties in Section 4.1 (Organization and Standing), Section 4.2 (Authority; Noncontravention), Section 4.3 (Capitalization),
Section 4.7 (Solvency), Section 4.8 (Issuance of Shares), Section 4.9 (Financing), and the representations and warranties of the Parent and Purchaser contained in any certificate delivered to Company and Company Shareholder
regarding the same subject matter as those covered by such representations and warranties pursuant to any provision of this Agreement, will remain operative and in full force and effect, regardless of any investigation or disclosure made by or on
behalf of any of the parties to this Agreement, until the expiration of the applicable statute of limitations (giving effect to any waiver, mitigation or extension thereof) for claims against the Parent and Purchaser which seek recovery of
Indemnifiable Damages arising out of an inaccuracy or breach of such representations or warranties; and provided further that the covenants of the Parent and Purchaser contained in this Agreement and the other certificates contemplated
hereby shall survive until the expiration of the applicable statute of limitations (giving effect to any waiver, mitigation or extension thereof) following the date such covenant was or is to be performed; provided, further; that no
right to indemnification pursuant to ARTICLE 9 in respect of any claim that is delivered to the Parent or Purchaser prior to the expiration of the applicable claims period set forth above shall be affected by the expiration of such representations
and warranties or covenants; and provided, further, that such expiration shall not affect the rights of any Shareholder Indemnified Person to seek recovery of Indemnifiable Damages arising out of any fraud, willful breach or
intentional misrepresentation by the Parent or Purchaser. If the Share Purchase is consummated, all covenants of the Company and the Company Shareholder (including the covenants set forth in ARTICLE 5 and ARTICLE 6) contained in this Agreement and
the other certificates contemplated hereby shall expire and be of no further force or effect as of the Closing, except to the extent such covenants provide that they are to be performed after the Closing; provided, however, that no right to
indemnification pursuant to ARTICLE 9 in respect of any claim based upon any breach of a covenant shall be affected by the expiration of such covenant. 

10.2 Release and Waiver. The Company Shareholder, for itself and on behalf of its heirs, legal representatives, successors and
assigns (collectively, the “Relevant Persons”), hereby irrevocably, unconditionally and forever acquits, releases, waives and discharges Parent, Purchaser, and the Company and each of their respective officers, directors,
employees, agents, Affiliates, representatives, successors and assigns (individually and collectively, the “Released Parties”) from any and all past, present and future debts, losses, costs, bonds, suits, actions, causes of
action, liabilities, contributions, attorneys’ fees, interest, damages, punitive damages, expenses, claims, potential claims, counterclaims, cross-claims, or demands, in law or in equity, asserted or unasserted, express or implied, known or
unknown, matured or unmatured, contingent or vested, liquidated or unliquidated, of any kind or nature or description whatsoever, that any of the Relevant Persons had, presently has or may hereafter have or claim or assert to have against any of the
Released Parties, except for such Relevant Person’s or Relevant Persons’, as applicable, rights under this Agreement and each agreement attached as an exhibit hereto (the “Shareholder Claims”). The Company
Shareholder further acknowledges and agrees that the Total Consideration is conclusive and binding on the Company Shareholder and such other Relevant Persons. The release is intended to be complete, global and all encompassing and specifically
includes claims that are known, unknown, fixed, contingent or conditional. With respect to such Shareholder Claims, the Company Shareholder hereby expressly waives any and all rights conferred upon it by any statute or rule of law which
provides that a release does not extend to claims which the claimant does not know or suspect to exist in its favor at the time of executing the release, which if known by him, her or it must have materially affected its settlement with the released
party. 

  
 64 

 10.3 Notices. All notices and other communications hereunder shall be in writing and shall
be deemed given if delivered personally or by commercial delivery service, or mailed by registered or certified mail (return receipt requested) or sent via facsimile (with confirmation of receipt) to the parties hereto at the following address (or
at such other address for a party as shall be specified by like notice): 
  

	 	(i)	if to Purchaser: 

 Hyperion Therapeutics Israel Holding Corp. Ltd. 

2000 Sierra Point Parkway, Suite 400 

Brisbane, California 94005 

Attention: Chief Executive Officer 

Facsimile No.: (650) 871-7029 

Telephone No.: (650) 745-7802 

with a copy (which shall not constitute notice) to: 

Fenwick & West LLP 

555 California Street 

12th Floor 

San Francisco, CA 94104 

Attention: Effie Toshav and Matthew Rossiter 

Facsimile No.: (415) 281-1350 

Telephone No.: (415) 875-2372 

and with a copy (which shall not constitute notice) to: 

Yigal Arnon & Co. 

22 Joseph Rivlin Street 

Jerusalem 94240 

Israel 

Attention: Barry P. Levenfeld and Ben Sandler, Advs. 

Facsimile No.: +972-2-623 9236 

Telephone No.: +972-2-6239200 

Email: barry@arnon.co.il; bens@arnon.co.il 

 

	 	(ii)	if to Parent: 

 Hyperion Therapeutics, Inc. 

2000 Sierra Point Parkway, Suite 400 

Brisbane, California 94005 

Attention: Chief Executive Officer 

Facsimile No.: (650) 871-7029 

Telephone No.: (650) 745-7802 

with a copy (which shall not constitute notice) to: 

Fenwick & West LLP 

555 California Street 

12th Floor 

San Francisco, CA 94104 

Attention: Effie Toshav and Matthew Rossiter 

Facsimile No.: (415) 281-1350 

Telephone No.: (415) 875-2372 

  
 65 

 and with a copy (which shall not constitute notice) to: 

Yigal Arnon & Co. 

22 Joseph Rivlin Street 

Jerusalem 94240 

Israel 

Attention: Barry P. Levenfeld and Ben Sandler, Advs. 

Facsimile No.: +972-2-623 9236 

Telephone No.: +972-2-6239200 

Email: barry@arnon.co.il; bens@arnon.co.il 
  

	 	(iii)	if to the Company, to: 

 Andromeda Biotech Ltd. 

42 Ha’Yarkon St., 

Yavne 8122745, Israel 

Attention: Shlomo Dagan, Ph.D. 

Facsimile No.: +972 8 940 7737 

Telephone No.: +972 8 938 7777 

with a copy (which shall not constitute notice) to: 

Meitar Liquornik Geva Leshem Tal, Law Offices 

16 Abba Hillel Road 

Ramat-Gan 5250608 

Israel 

Attention: Haim Gueta, Advocate 

Facsimile No.: 972-3-610-3731 

Telephone No.: +972-3-6103100 
  

	 	(iv)	if to the Company Shareholder, to: 

 Clal Biotechnology Industries Ltd. 

12 Abba Hillel Silver St., 

Ramat Gan 5250605, Israel 

Attention: Orit Lidor and Ofer Gonen 

Telephone No.: +972 3 6121616 

with a copy (which shall not constitute notice) to: 

Meitar Liquornik Geva Leshem Tal, Law Offices 

16 Abba Hillel Road 

Ramat-Gan 5250608 

Israel 

Attention: Haim Gueta, Advocate 

Facsimile No.: 972-3-610-3731 

Telephone No.: +972-3-6103100 

10.4 Interpretation. When a reference is made in this Agreement to Articles, Sections, Schedule or Exhibits, such reference shall be to
an Article or Section of, or a Schedule or an Exhibit to 

  
 66 

 
this Agreement unless otherwise indicated. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this
Agreement. The words “include,” “includes” and “including” when used herein shall be deemed in each case to be followed by the words “without limitation.” The phrases “provided to,” “furnished
to,” and phrases of similar import when used herein, unless the context otherwise requires, shall mean that a true, correct and complete paper copy of the information or material referred to has been made available to the party to whom such
information or material is to be provided. Unless the context of this Agreement otherwise requires: (i) words of any gender include each other gender; (ii) words using the singular or plural number also include the plural or singular
number, respectively; and (iii) the terms “hereof,” “herein,” “hereunder” and derivative or similar words refer to this entire Agreement. 

10.5 Counterparts. This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same
instrument and shall become effective when one or more counterparts have been signed by each of the parties hereto and delivered to the other parties hereto; it being understood that all parties hereto need not sign the same counterpart. 

10.6 Entire Agreement; Nonassignability; Parties in Interest. This Agreement and the documents and instruments and other agreements
specifically referred to herein or delivered pursuant hereto, including all the schedules and exhibits attached hereto, the Schedules, including the Company Disclosure Letter, (a) constitute the entire agreement among the parties hereto with
respect to the subject matter hereof and supersede all prior agreements and understandings, both written and oral, among the parties hereto with respect to the subject matter hereof, except for the Confidentiality Agreement, which shall continue in
full force and effect, and shall survive any termination of this Agreement, in accordance with its terms, (b) are not intended to confer, and shall not be construed as conferring, upon any Person other than the parties hereto any rights or
remedies hereunder (except that ARTICLE 9 is intended to benefit Indemnified Persons) and (c) shall not be assigned by operation of law or otherwise except as otherwise specifically provided herein. 

10.7 Assignment. Neither this Agreement nor any of the rights, interests or obligations under this Agreement may be assigned or
delegated, in whole or in part, by operation of law or otherwise by any of the parties hereto without the prior written consent of the other parties hereto, and any such assignment without such prior written consent shall be null and void, except
that Parent or Purchaser may assign this Agreement to any direct or indirect wholly owned subsidiary of Parent or, in the case of Purchaser, Parent, without the prior consent of the Company; provided, however, that Parent and Purchaser shall
remain liable for all of their obligations under this Agreement. Subject to the preceding sentence, this Agreement shall be binding upon, inure to the benefit of, and be enforceable by, the parties hereto and their respective successors and assigns,
and not to any third party. 
 10.8 Severability. In the event that any provision of this Agreement, or the application thereof,
becomes or is declared by a court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement shall continue in full force and effect and shall be interpreted so as reasonably necessary to effect the intent of the
parties hereto. The parties hereto shall use all reasonable efforts to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that shall achieve, to the extent possible, the economic, business and other
purposes of such void or unenforceable provision. 
 10.9 Remedies Cumulative. Except as otherwise provided herein, any and all
remedies herein expressly conferred upon a party hereto shall be deemed cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such party, and the exercise by a party hereto of any one remedy shall not
preclude the exercise of any other remedy and nothing in this Agreement shall be deemed a waiver by any party of any right to specific performance or injunctive relief. It is accordingly agreed that the parties shall be entitled to an injunction or
injunctions to prevent breaches of this 

  
 67 

 
Agreement and to enforce specifically the terms and provisions hereof, this being in addition to any other remedy to which they are entitled at law or in equity, and the parties hereby waive the
requirement of any posting of a bond in connection with the remedies described herein. 
 10.10 Governing Law; Submission to
Jurisdiction. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without reference to such state’s principles of conflicts of law. The parties hereto hereby irrevocably submit to the
exclusive jurisdiction of the courts of the State of Delaware and the Federal courts of the United States of America located within the District of Delaware, in respect of the interpretation and enforcement of the provisions of this Agreement and of
the documents referred to in this Agreement, and in respect of the transactions contemplated hereby and thereby (including resolution of disputes under Section 9.6), and hereby waive, and agree not to assert, as a defense in any action,
suit or proceeding for the interpretation or enforcement hereof or thereof, that it is not subject thereto or that such action, suit or proceeding may not be brought or is not maintainable in said courts or that the venue thereof may not be
appropriate or that this Agreement or any such document may not be enforced in or by such courts, and the parties hereto irrevocably agree that all claims with respect to such action or proceeding shall be heard and determined in such a Delaware
State or Federal court. The parties hereby consent to and grant any such court jurisdiction over the person of such parties and over the subject matter of such dispute and agree that mailing of process or other papers in connection with any such
action or proceeding in the manner provided in Section 10.3 or in such other manner as may be permitted by applicable Legal Requirements, shall be valid and sufficient service thereof. With respect to any particular action, suit or
proceeding, venue shall lie solely in the County of Newcastle, Delaware. 
 10.11 Rules of Construction. The parties hereto have been
represented by counsel during the negotiation, preparation and execution of this Agreement and, therefore, hereby waive, with respect to this Agreement, each Schedule and each Exhibit attached hereto, the application of any law, regulation, holding
or rule of construction providing that ambiguities in an agreement or other document shall be construed against the party drafting such agreement or document. 

10.12 Parent’s and Purchaser’s Due Diligence Investigation. Parent and Purchaser have, for the sole purpose of determining
whether to enter into and negotiate the transactions contemplated by this Agreement, conducted a review of information provided to it regarding the Company’s commercial, financial, legal and other affairs. The parties agree and acknowledge that
the representations and warranties of the Company set forth in this Agreement (and in the Company Disclosure Letter) shall in no way be limited, qualified, impaired or affected by Parent’s or Purchaser’s conduct of such investigation. 

10.13 WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING
OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT, OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE ACTIONS OF ANY PARTY HERETO IN NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT HEREOF. 

10.14 Waiver of Conflicts Regarding Representation. Recognizing that Meitar Liquornik Geva Leshem Tal
(“Meitar”) has acted as legal counsel to the Company and the Company Shareholder prior to the Closing, and that Meitar may act as legal counsel to the Company Shareholder of the Company after the Closing Date, each of the
Parent, Purchaser and Company hereby waives, on its own behalf and agrees to cause its subsidiaries to waive, any conflicts that may arise in connection with Meitar representing the Company Shareholder after the Closing Date. Following the Closing,
Parent and Purchaser agree that it will not request from Meitar or use or intentionally access any of the communications among Meitar, the Company and the Company Shareholder relating to the Share Purchase (the
“Communications”) in connection with any dispute arising under this Agreement; provided, however, that nothing contained herein shall prevent Parent or Purchaser from requesting, using

  
 68 

 
or accessing any Communications in connection with document production requests or discovery in any legal proceeding so long as such Communications would not be subject to an attorney-client
privilege if they were being requested in a legal proceeding by an unrelated third party and such Communications are produced or required to be produced in response to such document production requests or discovery 

[SIGNATURE PAGE NEXT] 

  
 69 

 IN WITNESS WHEREOF, Parent, Purchaser, the Company and the Company Shareholder have caused this
Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above. 
  

			
	PARENT:
	
	HYPERION THERAPEUTICS, INC.
		
	 By:
	 	 /s/ Donald J. Santel

	 Name:
	 	 Donald J. Santel

	 Title:
	 	 Chief Executive Officer

	
	PURCHASER:
	
	HYPERION THERAPEUTICS ISRAEL HOLDING CORP. LTD.
		
	 By:
	 	 /s/ Natalie Holles

	 Name:
	 	 Natalie Holles

	 Title:
	 	 Chief Executive Officer

 [SIGNATURE PAGE TO STOCK
PURCHASE AGREEMENT] 

 IN WITNESS WHEREOF, Parent, Purchaser, the Company and the Company Shareholder have caused this
Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above. 
  

					
	COMPANY:
	
	ANDROMEDA BIOTECH LTD.
			
	By:	 	/s/ Shlomo Dagan	 	/s/ Elder Chaim
	Name:	 	Shlomo Dagan	 	Elder Chaim
	Title:	 	CEO	 	CFO

 [SIGNATURE PAGE TO STOCK
PURCHASE AGREEMENT] 

 IN WITNESS WHEREOF, Parent, Purchaser, the Company and the Company Shareholder have caused this
Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above. 
  

					
	COMPANY SHAREHOLDER:
	
	CLAL BIOTECHNOLOGY INDUSTRIES LTD.
			
	 By:
	 	 /s/ Ofer Gonen
	 	 /s/ Ruben Krupik

	 Name:
	 	 Ofer Gonen
	 	 Ruben Krupik

	 Title:
	 	 Vice President
	 	 Chief Executive Officer

 [SIGNATURE PAGE TO STOCK
PURCHASE AGREEMENT] 

 EXHIBIT A 

Definitions 
 As used in
this Agreement, the following terms shall have the meanings indicated below. Unless indicated otherwise, all mathematical calculations contemplated hereby shall be rounded to the tenth decimal place. 

“Affiliate” has the meaning set forth in Rule 144 promulgated under the Securities Act. 

“Business” means the business of the Company as currently conducted and as currently proposed by the Company to be
conducted. 
 “Business Day” means a day (i) other than Friday, Saturday or Sunday and (ii) on which
commercial banks are open for business in San Francisco, California and in Israel. 
 “CBI” means Clal Biotechnology
Industries Ltd. 
 “CBI Cash Closing Amount” means an amount of cash equal to the difference between (i) the
Closing Cash Consideration, minus (ii) the Teva Cash Closing Amount. 
 “CBI Initial Loan Amount” means, an
amount equal to the aggregate outstanding principal and accrued and unpaid interest on all indebtedness of the Company to CBI incurred prior to January 1, 2013, which is outstanding as of immediately prior to the Closing and the conversion
contemplated by the CBI Loan Amendments, and as reflected on Schedule A-3 (as shall be updated by the Company prior to the Closing). 

“CBI Total Loan Amount” means, collectively, the CBI Initial Loan Amount and the CBI Recent Loan Amount. 

“CBI Loan Agreements” means those certain Loan Agreements by and among the Company and CBI identified on Schedule
A-1, as may be updated by the Company prior to the Closing. 
 “CBI Net New Funding Amount” means, as of the
date of determination, an amount equal to (x) the then outstanding CBI Recent Loan Amount, plus (y) the total amounts paid by CBI to the Company in consideration for any shares that were issued by the Company to CBI since
January 1, 2013 (including such consideration that was paid by way of a conversion of any indebtedness of the Company to CBI incurred since January 1, 2013), less (y) the product of (A) the quotient obtained by dividing
(i) the sum of clauses (x) and (y), by (ii) the CBI Total Loan Amount, multiplied by (B) the aggregate amounts that were paid until such date of determination to CBI pursuant to this Agreement in consideration for the shares
referred to in clause (y). 
 “CBI Ratio” means, as of the date of determination, a fraction (x) the numerator
of which is the then applicable CBI Net New Funding Amount and (y) the denominator of which is the sum of (i) clause (x), plus (ii) the then applicable Teva Net Funding Amount. 

 “CBI Recent Loan Amount” means an amount equal to the aggregate principal
and accrued and unpaid interest on all indebtedness of the Company to CBI incurred since January 1, 2013, which is outstanding as of immediately prior to the Closing and the conversion contemplated by the CBI Loan Amendments, and as reflected
on Schedule A-2 (as shall be updated by the Company prior to the Closing). 
 “Closing Cash Consideration”
means (A) $12,500,000, less (B) the sum of (1) the Transaction Expenses, plus (2) the Employee Closing Payment Amount. 

“Closing Expenses Certificate” means a certificate executed on behalf of the Company by the Chief Financial Officer of
the Company dated as of the Closing Date, certifying the amount of Transaction Expenses that are then outstanding or that were paid after April 1, 2014 (including an itemized list of each Transaction Expense with a description of the nature of
such expense and the Person to whom such expense was or is owed). The Closing Expenses Certificate shall include a representation of the Company, certified by the Chief Financial Officer of the Company on behalf of the Company, that such certificate
includes all of the Transaction Expenses of the sort described above, paid or payable at any time prior to, at or following the Closing Date, it being the expressed intent of the Company and Purchaser that to the maximum extent possible all the
Transaction Expenses be deducted in the calculation of the Closing Cash Consideration and that there be no Indemnifiable Transaction Expenses. 

“Closing Value” means the sum of (A) the Closing Cash Consideration, plus (B) $7,850,000. 

“Code” shall mean the Internal Revenue Code of 1986, as amended. 

“Company IP Rights” means (A) any and all Intellectual Property that is licensed by the Company which
Intellectual Property is used (x) in the conduct of the business of the Company as currently conducted by the Company or (y) in the design, development, manufacturing, reproduction, branding, marketing, advertising, promotion, licensing,
sale, offer for sale, importation, distribution, provision and/or use of any and all Company Products as currently conducted and as currently proposed by the Company to be conducted; and (B) Company-Owned IP Rights. 

“Company IP Rights Agreements” means any licenses, sublicenses, and other agreements, permissions, and understandings
of any kind or nature, under which the Company is (A) a licensee or otherwise is authorized to use or practice, or is otherwise granted any right or immunity with respect to, any Company IP Rights, or (B) a licensor or otherwise authorizes
the use or practice of, or otherwise grants any right or immunity with respect to any Company IP Rights. Company IP Rights Agreements include any license agreements, options, settlement agreements, coexistence agreements, consent agreements and
assignments governing Company IP Rights. 
 “Company Option Plan” means the Andromeda Biotech Ltd 2007 Share Option
Plan. 
 “Company Optionholders” means the holders of Company Options. 

“Company Options” means options to purchase Company Ordinary Shares. 

“Company Ordinary Shares” means the Ordinary Shares, nominal value of New Israeli Shekel 0.01 per share, of the
Company. 

  
 2 

 “Company-Owned IP Rights” means any and all Intellectual Property that is
owned by the Company. 
 “Company Product” means the peptide DiaPep277 consisting of the amino acid sequence
VLGGGVALLRVIPALDSLTPANED or any composition or formulation comprising this peptide. 
 “Company Proprietary
Specifications” means, collectively, any confidential manufacturing specifications or designs, any material portion or aspect of confidential manufacturing specifications or designs, or any material proprietary information contained in
or relating to any confidential manufacturing specifications or designs, of any Company-Owned IP Rights or Company Products. 

“Company Registered Intellectual Property” means all United States, Israeli, international and foreign:
(A) patents and patent applications (including provisional applications); (B) registered trademarks, applications to register trademarks or service marks, intent-to-use applications, or other registrations or applications related to
trademarks or service marks; (C) registered Internet domain names; (D) registered copyrights and applications for copyright registration; and (E) any other Intellectual Property that is the subject of an application, certificate,
filing, registration or other document issued, filed with, or recorded by any Governmental Entity, in each case, owned by or registered or filed in the name of, the Company. 

“Company Securityholders” means the Company Shareholder and Company Optionholders, collectively. 

“Company Shareholder” means the holder of outstanding Company Ordinary Shares as of the Closing Date. 

“Contract” means any written or oral legally binding contract, agreement, instrument, commitment or undertaking of any
nature (including leases, licenses, mortgages, notes, guarantees, sublicenses, subcontracts, letters of intent and purchase orders), including all amendments, supplements, exhibits and schedules thereto, as of the Agreement Date or as may hereafter
be in effect prior to Closing. 
 “Employee Closing Payment Amount” the aggregate payments at Closing to Company
employees under the Termination and Release agreements, as set forth in the Spreadsheet. 
 “Employee Contingent Payment
Amount” the maximum aggregate amount payable to the employees of the Company under the Termination and Release agreements contingent on the achievement of Milestones 1 through 5 and the payment of the Contingent Payments associated with
such Milestones in accordance with the provisions of the Section 1.11 and Section 1.12, as set forth in the Spreadsheet, which shall be reduced proportionally in the event of the exercise by Purchaser of its Set-Off Rights in
connection with any of such Contingent Payments. 
 “Encumbrance” means, with respect to any asset, any mortgage,
deed of trust, lien, pledge, charge, security interest, title retention device, conditional sale or other security arrangement, collateral assignment, claim, charge, adverse claim of title, ownership or right to use, restriction or other encumbrance
of any kind in respect of such asset (including any restriction on (i) the voting of any security or the transfer of any security or other asset, (ii) the receipt of any income derived from any asset, (iii) the use of any asset, and
(iv) the possession, exercise or transfer of any other attribute of ownership of any asset). 
 “Equity
Interests” means, with respect to any Person, any capital stock of, or other ownership, membership, partnership, joint venture or equity interest in, such Person or any indebtedness, 

  
 3 

 
securities, options, warrants, call, subscription or other rights of, or granted by, such Person or any of its Affiliates that are convertible into, or are exercisable or exchangeable for, or
giving any Person any right to acquire any such capital stock or other ownership, partnership, joint venture or equity interest, in all cases, whether vested or unvested. 

“Exchange Act” means the Securities Exchange Act of 1934, as amended. 

“FD&C Act” means the United States Federal Food, Drug, and Cosmetic Act, as amended. 

“Governmental Entity” means any supranational, national, state, municipal, local or foreign government, any court,
tribunal, arbitrator, administrative agency, commission or other governmental official, authority or instrumentality, in each case whether domestic or foreign, any stock exchange or similar self-regulatory organization or any quasi-governmental or
private body exercising any regulatory, Taxing or other governmental or quasi-governmental authority (including any governmental division, department, agency, commission, instrumentality, official, organization, unit, body or entity and any court or
other tribunal). 
 “Government Grant” means any pending and outstanding grants, incentives, exemptions and
subsidies from the Government of the State of Israel or any Governmental Entity thereof, or from any non-Israeli Governmental Entity, granted to (or transferred to, assigned to or purchased by) the Company. 

“HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. 

“Indemnifiable Transaction Expenses” means any Transaction Expenses that have not been taken into account in the
calculation of the Total Consideration. All Indemnifiable Transaction Expenses shall constitute “Indemnifiable Damages” for purposes of ARTICLE 9 without regard to the Aggregate Threshold. 

“Intellectual Property” means any and all industrial and intellectual property rights and all rights associated
therewith, throughout the world, including all patents and applications therefor and all reissues, divisions, renewals, extensions, provisionals, continuations and continuations-in-part thereof, all inventions (whether patentable or not), invention
disclosures, improvements, trade secrets, proprietary information, know how, technology, technical data, proprietary processes and formulae, algorithms, specifications, customer lists and supplier lists, all industrial designs and any registrations
and applications therefor, all trade names, logos, trade dress, trademarks and service marks, trademark and service mark registrations, trademark and service mark applications, and any and all goodwill associated with and symbolized by the foregoing
items, Internet domain name registrations, Internet and World Wide Web URLs or addresses, all copyrights, copyright registrations and applications therefor, all computer software, databases and data collections and all rights therein, all moral and
economic rights of authors and inventors, however denominated, and any similar or equivalent rights to any of the foregoing, and all tangible embodiments of the foregoing. 

“ITA” shall mean the Israeli Tax Authority. 

“ITO” shall mean the Israeli Income Tax Ordinance (New Version), 1961, as amended, and all rules and regulations
promulgated thereunder. 
 “knowledge” means, with respect to any fact, circumstance, event or other matter in
question, the knowledge of such fact, circumstance, event or other matter after reasonable inquiry of (i) an individual, if used in reference to an individual or (ii) with respect to any Person that is not an individual,

  
 4 

 
the executive officers of such Person, or in the case of the Company any of the directors of the Company and the following managers of the Company: Shlomo Dagan and Chaim Eldar with respect to
all matters and Rachel Eren for matters relating to Company development programs and regulatory affairs (the individuals specified in clause (ii) are collectively referred to herein as the “Entity Representatives”). Any
such individual or Entity Representative will be deemed to have knowledge of a particular fact, circumstance, event or other matter if (A) such fact, circumstance, event or other matter is reflected in one or more documents (whether written or
electronic, including electronic mails sent to or by such individual or Entity Representative) in, or that have been in, the possession of such individual or Entity Representative, including his or her personal files, (B) such fact,
circumstance, event or other matter is reflected in one or more documents (whether written or electronic) contained in books and records of such Person that would reasonably be expected to be reviewed by an individual who has the duties and
responsibilities of such individual or Entity Representative in the customary performance of such duties and responsibilities, or (C) such knowledge could be obtained from reasonable inquiry of the persons employed by such Person charged with
administrative or operational responsibility for such matters for such Person. With respect to any matters relating to Intellectual Property, “Knowledge” does not require the Company to conduct, have conducted, obtain, or have obtained any
freedom-to-operate opinions or similar opinions of counsel or any patent, trademark or other Intellectual Property Rights clearance searches and no knowledge of any third-party Patent rights, trademark rights,
or other intellectual property rights that could have been revealed by such inquiries, opinions, or searches will be imputed to the Company unless the Company has actually conducted or procured the conduct of such searches. 

“Legal Requirements” means any federal, state, foreign, local, municipal or other law, statute, constitution,
principle of common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Entity and any
orders, writs, injunctions, awards, judgments and decrees applicable to the Company or to any of their respective assets, properties or businesses. 

“Liabilities” means all debts, liabilities and obligations, whether accrued or fixed, absolute or contingent, matured
or unmatured, determined or determinable, asserted or unasserted, known or unknown, including those arising under any law, action or governmental order and those arising under any Legal Requirement, Legal Proceeding or Order of a Governmental Entity
and those arising under any Contract, regardless of whether such debt, liability or obligation would be required to be disclosed on a balance sheet prepared in accordance with IFRS. 

“Material Adverse Effect” with respect to any entity means any change, event, violation, inaccuracy, circumstance or
effect (each, an “Effect”) that, individually or taken together with all other Effects, and regardless of whether or not such Effect constitutes a breach of the representations or warranties made by such entity in this
Agreement, is, or would reasonably likely to, (i) be or become materially adverse in relation to the near-term or longer-term condition (financial or otherwise), properties, assets (including intangible assets), liabilities, business,
employees, operations or results of operations of such entity and its subsidiaries, taken as a whole, except to the extent that any such Effect directly results from (A) changes in general economic or political conditions, (B) changes
generally affecting the industry in which such entity and its subsidiaries operate, (C) changes in Legal Requirements or accounting requirements or principles (including GAAP), (D) any acts of terrorism, sabotage, armed hostilities,
military action or war, and (E) the impact of the negotiation, announcement or performance of this Agreement and the Share Purchase or any action taken by the Company at the written request of Purchaser; provided, however, that the
exceptions in clauses (A) through (D) shall not apply if such changes or acts disproportionately affect such entity and its subsidiaries, taken as a whole, as compared to other participants in such entity’s industry, or
(ii) materially impede such entity’s ability to consummate the transactions contemplated by this Agreement in accordance with its terms and applicable Legal Requirements. 

  
 5 

 “OCS” shall mean the Office of the Chief Scientist of Israeli Ministry of
the Economy. 
 “OCS Notice” shall mean the written notice to the OCS regarding the change in ownership of the
Company effected as a result of the Share Purchase, required to be submitted to the OCS in connection with the Share Purchase in accordance with the Israeli Encouragement of Industrial Research and Development Law, 1984, which may be submitted by
the Company at any time following the date hereof but not later than the Closing. 
 “Order” means any judgment,
writ, decree, stipulation, determination, decision, award, rule, preliminary or permanent injunction, temporary restraining order or other order of any Governmental Entity. 

“Permitted Encumbrances” means: (i) statutory liens for Taxes that are not yet due and payable or liens for Taxes
being contested in good faith by any appropriate proceedings for which adequate reserves have been established; and (ii) statutory liens to secure obligations to landlords, lessors or renters under leases or rental agreements. 

“Parent Common Stock” means the Common Stock, par value $0.0001 per share, of Parent. 

“Parent Stock Price” means the average of the daily closing sale prices of Parent Common Stock as quoted on the NASDAQ
Global Select Market for the fifteen consecutive trading days ending with the trading day that is three trading days prior to the date of this Agreement. 

“Person” means any natural person, company, corporation, limited liability company, general partnership, limited
partnership, limited liability partnership, trust, estate, proprietorship, joint venture, business organization or Governmental Entity. 

“PHSA” means the United States Public Health Service Act, as amended. 

“Regulatory Authority” means any applicable government regulatory authority, domestic or foreign, or any other
supranational (e.g., the European Commission, the Counsel of the European Union or the European Agency for the Evaluation of Medical Products), national, regional, federal state, provincial or local regulatory agency department, bureau, commission,
counsel, or other Governmental Entity, regulating or otherwise exercising authority over the research, development, clinical testing, manufacture, distribution, marketing, storage, transportation, use or sale of a pharmaceutical or biological
product or involved in granting approvals for the manufacturing, marketing, reimbursement and/or pricing of a pharmaceutical or biological product, and any successor Governmental Entity having substantially the same function. 

“RTPA” means the Israeli Restrictive Trade Practices Act, 1988, as amended. 

“Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

“SEC” means the Securities and Exchange Commission. 

“Securities Act” means the Securities Act of 1933, as amended. 

  
 6 

 “Share Consideration” means a number of shares of Parent Common Stock
equal to the quotient obtained by dividing $7,850,000 by the Parent Stock Price. 
 “Tax” (and, with correlative
meaning, “Taxes” and “Taxable”) means (i) any Israeli and/or U.S. federal, state, local or other foreign net income, alternative or add-on minimum tax, gross income, estimated, gross receipts,
sales, use, ad valorem, value added, transfer, franchise, fringe benefit, capital stock, profits, license, registration, withholding, payroll, social security (or equivalent), employment, unemployment, disability, excise, severance, stamp,
occupation, premium, property (real, tangible or intangible), environmental or windfall profit tax, custom duty or other tax, governmental fee or other like assessment or charge of any kind whatsoever including any interest or any penalty, addition
to tax, inflation linkage or additional amount (whether disputed or not) imposed by any Governmental Entity responsible for the imposition of any such tax (domestic or foreign), including the ITA (each, a “Tax Authority”),
(ii) any Liability for the payment of any amounts of the type described in clause (i) of this sentence as a result of being a member of an affiliated, consolidated, combined, unitary or aggregate group for any Taxable period, and
(iii) any Liability for the payment of any amounts of the type described in clause (i) or (ii) of this sentence as a result of being a transferee of or successor to any Person or as a result of any express or implied obligation to
assume such Taxes or to indemnify any other Person. 
 “Tax Return” means any return, statement, declaration, report
or form (including estimated Tax returns and reports, withholding Tax returns and reports, any schedule or attachment, and information returns and reports) filed or required to be filed with respect to Taxes. 

“Teva” means Teva Pharmaceutical Industries Ltd. 

“Teva Cash Closing Amount” means an amount of cash equal to the product of (i) the Closing Value, multiplied by
(ii) Fifty percent (50%). 
 “Teva Net Funding Amount” means, as of the date of determination, the sum of
(1) $36,210,545 minus (2) the aggregate amounts that were paid to Teva until such time in accordance with Sections 1.3 of this Agreement and Sections 4 and 5 of the Teva Share Purchase Agreement (without duplication). 

“Teva Ratio” means, as of the date of determination, a fraction (x) the numerator of which is the then applicable
Teva Net Funding Amount and (y) the denominator of which is the sum of (i) clause (x), plus (ii) the then applicable CBI Net New Funding Amount. 

“Teva Share Purchase Agreement” means that certain Share Purchase and Rights Agreement, dated as of February 13,
2014, by and among the Company and Teva. 
 “Third Party Intellectual Property Rights” means any Intellectual
Property owned by a third party. 
 “Total Consideration” means the consideration payable pursuant to
Section 1.3. 

  
 7 

 “Transaction Expenses” means all third party fees, costs, expenses,
payments, and expenditures, including any VAT payable in connection therewith, incurred by the Company in connection with the Share Purchase and this Agreement and the transactions contemplated hereby whether or not billed or accrued (including any
fees, costs expenses, payments, and expenditures of legal counsel and accountants, the maximum amount of fees costs, expenses, payments, and expenditures payable to financial advisors, investment bankers and brokers of the Company notwithstanding
any contingencies for earnouts, escrows, etc., and any such fees, costs, expenses, payments, and expenditures incurred by Company Securityholders paid for after April 1, 2014 by the Company). 

“Warning Letter” means a letter characterized by any Regulatory Authority as a warning letter, a notice of adverse
finding, observation of noncompliance or a similar letter or report in which any Regulatory Authority expresses the opinion that violations or non-compliance of law, regulation or guideline have occurred. 

Other capitalized terms defined elsewhere in this Agreement and not defined in this Exhibit A shall have the meanings assigned to such
terms in this Agreement. 

  
 8 

 EXHIBIT B 

Form of Termination and Release 

 EXHIBIT C 

Form of Instruction Letter 

 EXHIBIT D 

Form of Company Legal Opinion 

 EXHIBIT E 

Form of Investment Representation Letter and Lock-up Agreement 

 EXHIBIT F 

Form of Form of CBI Loan Amendment 

  
 ii 

 Schedule 1.2(b)(v) 

Key Employees 

  
 iii 

 Schedule 1.11(b) 

Reductions in Milestone Payments 

Reduction in Contingent Sales Payments 

  
 iv 

 Schedule 6.18 

  
 v 

 Schedule A-1 

CBI Loan Agreements 

  
 vi 

 Schedule A-2 

CBI Recent Loan Amount 

  
 vii 

 Schedule A-3 

CBI Initial Loan Amount 

  
 viiiEX-10.2

 Exhibit 10.2 

RESEARCH AND LICENCE AGREEMENT 

By and between: 
 YEDA
RESEARCH AND DEVELOPMENT COMPANY LTD., 
 a company duly incorporated and existing under the laws of the State of Israel, of P.O.
Box 29, Rehovot, 76100 Israel 
 (hereinafter “Yeda”) 

of the one part; 

and 
 PORTMAN
PHARMACEUTICALS, INC. 
 a corporation duly incorporated and existing under the laws of the State of Delaware, USA, of One Parker
Plaza, Fort Lee, New Jersey 07024, USA 
 (hereinafter “the Corporation”) 

of the other part; 
  

	WHEREAS	in the course of research conducted at the Weizmann Institute of Science, Rehovot (hereinafter “the Institute”), Professor Irun R. Cohen of the Department of Cell Biology at the Institute (hereinafter
“Prof. Cohen”) has developed certain technology constituting the subject matter of (1) US Patent Application no. [*] relating to the [*], (2) Israel Patent Applications nos. 98028 and 98298 relating to pharmaceutical compositions
for prevention and/or treatment of pathological processes involving induction of TNF-secretion, comprising a low dosage of a low molecular weight heparin and Israel Patent Application no. 79254 relating to compositions for treatment of autoimmune
diseases and prevention of graft rejection (the technology being the subject of the latter patent application in cooperation with scientists of Hadassah Medical Organization (“HMO”) of Jerusalem, Israel), and (3) Israel Patent
Application No. 102687 relating to the use of peptides in vaccine technology (“the Peptide Technology”) (hereinafter collectively “the Existing Technology”); and 

 

	WHEREAS	the Corporation is interested in the performance of additional research at the Institute under the supervision of Prof. Cohen in the fields of the Existing Technology as specified in the research program attached
hereto, marked “A” and forming an integral part hereof (hereinafter “the Research Program” and “the Research”); and 

  
 [*] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	WHEREAS	it is contemplated that the Research Program and the Research may be supplemented in the manner hereinafter provided; and 

  

	WHEREAS	in consideration of the Corporation’s undertakings hereunder and the fulfilment thereof, Yeda is willing, subject to and in accordance with the terms and conditions of this Agreement, to procure the performance of
the Research at the Institute as aforesaid; and 

  

	WHEREAS	the Corporation is willing, subject to and in accordance with the terms and conditions of this Agreement, to finance the performance of the Research; and 

 

	WHEREAS	it is contemplated that, to the extent that the efforts needed for the proper performance of the Research Program shall not in Prof. Cohen’s view thereby be diminished, Prof. Cohen may engage during the period of
the performance of the Research Program, in other research in the field of [*] and the use of peptides in vaccine technology (hereinafter collectively “the Field”), such research not being or becoming part of the Research Program
(as supplemented, if supplemented) and being outside the scope of the Existing Technology (hereinafter “the Further Research”); and 

  

	WHEREAS	the parties are the parties to a research and licence agreement dated as of March 6, 1992 (“the Original Agreement”) and this Agreement constitutes an amended and restated version of the Original
Agreement, substituting the Original Agreement with effect from the date hereof, except as otherwise provided herein; and 

  

	WHEREAS	it is agreed that the research performed in accordance with the Original Agreement shall be continued within the framework of this Agreement from the date hereof until December 31, 1993 and the term “Research”
hereinafter shall encompass the said research performed in that period; and 

  

	WHEREAS	pursuant to an agreement between the Institute of the first part, Yeda of the second part, and the Scientists employed by the Institute (including Prof. Cohen) of the third part and to a further agreement between Yeda,
of the one part and HMO, of the other part, all right, title and interest in the Existing Technology, in any results derived from the performance until the date hereof of the research pursuant to the Original Agreement (“the Past
Research”) and in any results deriving from the performance at the Institute of the Research and the Further Research vests and will vest in Yeda, subject, as to the results of the Further Research, to such licences which are or may be
granted with respect thereto to third parties funding such Further Research as hereinafter set forth; and 

  

	WHEREAS	 subject to and in accordance with the terms and conditions of this Agreement, the Corporation wishes to receive, and Yeda is willing to grant the
Corporation, (i) an exclusive licence for the use of the Existing Technology, of the results derived from the Past Research and of results deriving from the performance of the Research (as supplemented, if supplemented, as hereinafter provided) for
the 

  
 [*] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	 	manufacture and sale of the Products (as hereinafter defined), and (ii) subject to any obligations to third parties, the right of first opportunity to finance the performance of Further Research and/or to receive a
licence for the use of results deriving from the performance of Further Research on terms to be determined in the manner hereinafter specified; 

NOW THEREFORE IT IS AGREED BY THE PARTIES HERETO AS FOLLOWS: 
  

	1.	Status of Recitals 

 The recitals hereto form an integral part of this Agreement.

  

	2.	Performance of Research 

  

	 	(a)	In consideration of the sums to be paid by the Corporation pursuant to Paragraph 3 below and subject to the execution of such payments, Yeda undertakes to procure the performance of the Research (as supplemented - if
supplemented, pursuant to Paragraph 2(b) below) at the Institute under the supervision of Prof. Cohen during the period commencing on signature hereof and ending on December 31, 1996 (hereinafter “the Research Period”). By
agreement of the parties in writing, the Research Period may be extended by such period and upon such terms and conditions as the parties shall so agree. 

  

	 	(b)	Should it transpire at any time that not all the funds to be provided by the Corporation pursuant to Paragraph 3 below are required for the performance of the Research (as originally defined or as theretofore
supplemented in accordance with this subparagraph (b) below) whether because all the objects of the Research (as originally defined or as theretofore supplemented as aforesaid) have been achieved or whether as a result of the receipt by Prof.
Cohen of public giant funds earmarked for the performance of research forming part of the Research (as originally defined or as theretofore supplemented as aforesaid), then the funds from the Corporation falling free shall be devoted to funding the
performance of the supplementary research program or programs in the Field as Yeda may submit to the Corporation in writing from time to time, such supplementary research program or programs—if it or they do not relate to the Existing
Technology—to include a definition of the products and services to be licensed. Unless the funds to be provided by the Corporation have fallen free as a result of the receipt of public grant funds as aforesaid, the supplementary research
programs to be submitted as aforesaid shall relate to the Existing Technology exclusively, except to the extent the Corporation shall agree otherwise in writing. Upon submission of such supplementary research program or programs, it or they, as the
case may be, shall become an integral part of the Research Program and the research performed thereunder shall be deemed an integral part of the Research. For the removal of doubt, it is expressly agreed that Prof. Cohen shall not be entitled to
receive public grant funds, acceptance of which shall derogate in any way from the Corporation’s rights hereunder, unless the Corporation’s prior written approval thereof has been obtained. 

  
 2 

	 	(c)	(i) If Prof. Cohen shall cease to be available for the supervision of the performance of the Research, Yeda shall use its best efforts to find from amongst the staff of the Institute a replacement scientist acceptable
to the Corporation (such acceptance not to be unreasonably withheld) but no undertaking to find such replacement is given by Yeda. Should no such acceptable replacement scientist be found within 60 (sixty) days of Prof. Cohen becoming unavailable,
then the Research Period and the performance of Research hereunder shall cease at the end of a further period of 60 (sixty) days, but without prejudice to any licence already then granted pursuant to this Agreement and the terms and provisions
hereof relating thereto. 

  

	 	(ii)	Upon termination of the performance of the Research at the Institute pursuant to Paragraph 2(c)(i) above, the Corporation shall be free to perform itself or to procure the performance by a third party acceptable to Yeda
(such acceptance not to be unreasonably withheld) of the continuation of the Research, provided (unless otherwise agreed in writing by the parties hereto): 

  

	 	(aa)	that the results of such research shall be deemed to constitute Licensed Information (within the meaning of the expression as defined below); 

 

	 	(bb)	that the Corporation shall provide Yeda or shall procure that the said third party shall provide Yeda with written reports on the conduct of such research in the same way, mutatis mutandis, as that specified in
Paragraphs 4(a) and (c) below; 

  

	 	(cc)	such third party shall have signed an undertaking of confidentiality, similar to that pursuant to Paragraph 10 below, with respect to all information to be disclosed to it or to be generated by it in the performance of
such research and shall have confirmed to Yeda in writing that title to all such information vests or shall vest in Yeda and that it will make reports to Yeda as provided in subparagraph (bb) above. 

 

	3.	Funding of the Research 

  

	 	(a)	In consideration of Yeda’s undertaking pursuant to Paragraph 2(a) above, the Corporation undertakes to provide Yeda with $[*] ([*] United States Dollars) to be used for financing research in the instalments set out
in Attachment B hereto, it being agreed that the first instalment set out as aforesaid shall be partially in respect of Past Research performed in the period from July 1, 1993 to the date hereof and partially in respect of the
continuation of such research to be performed in the period from the date hereof and until December 31, 1993 and that all the subsequent instalments set out in Attachment B shall be used for financing the Research to be performed in the period
commencing on January 1, 1994. 

  
 [*] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	 	(b)	It is agreed that at the request from time to time of Prof. Cohen or either party hereto, the parties shall consult with a view to considering the advisability of variations in the Research Program and/or acceleration
in the schedule of payments pursuant to Paragraph 3(a) above. Such variations or accelerations approved by the parties in writing shall constitute amendments to this Agreement. For the removal of doubt, nothing herein contained shall be interpreted
as imposing on either party any obligation to agree to any such amendment. 

  

	 	(c)	Notwithstanding the provisions of Paragraph 3(a) above, in the event that the Corporation resolves that for scientific and/or commercial reasons, it is not feasible that the Research in all or any of the three areas of
technology identified and numbered 1, 2 and 3 respectively in the first recital hereto (hereinafter individually “an Area” and, collectively, “the Areas”), will lead to the development of Products (as defined in
clause 7 below), then the Corporation shall be entitled to terminate its funding of the Research in such Area or Areas and its funding thereof with effect from December 31, 1994 or from December 31, 1995, provided that: (i) the
scientific reasons relied upon are substantiated by the panel of scientists appointed by the Corporation to be its Scientific Advisory Board; (ii) written notice of such termination (“the Corporation’s Notice”) shall be
served on Yeda no later than 90 days prior to December 31, 1994 or no later than 90 days prior December 31, 1995, as the case may be; and (iii) notwithstanding such termination of funding, the Corporation shall continue to be liable
for all costs and expenses falling within the scope of the budget attached to the Research Program and relating to the terminated Area or the terminated Areas, as the case may be, which are payable by Yeda during the period from such termination and
until the date 12 months after receipt by Yeda of the Corporation’s Notice, pursuant to obligations already undertaken by Yeda prior to receipt of the Corporation’s Notice and which cannot lawfully be cancelled. Payment by the Corporation
to Yeda of such costs and expenses shall be made at the commencement of the calendar quarter in which such costs and expenses are payable in accordance with the said budget. Simultaneously with the termination of Research in an Area or Areas, as
aforesaid, the Licence granted hereunder shall also terminate as to such Area or Areas and if the Research is terminated with respect to all 3 Areas, then the Licence granted hereunder shall terminate in its entirety. 

 

	4.	Reporting by Yeda 

  

	 	(a)	Yeda will procure the submission by Prof. Cohen to the Corporation of an interim written report on the progress of the Research in each 6 month period during the Research Period, within 30 days of the end of each such 6
month period, and of a written report summarising the results of the Research within 60 days of the end of the Research Period. It is agreed that the Corporation shall be entitled to delay the making of any payment due to Yeda under Paragraph 3
above until all reports pursuant to this Paragraph 4(a) and due by the date on which payment is due, have been made. 

  

	 	(b)	 Further, Yeda shall submit to the Corporation, with respect to each 3 (three) month period of the Research Period, a financial report setting forth
the monies received 

	 	
and expended in connection with the Research during such 3 (three) month period. Each report as aforesaid shall be submitted to the Corporation not later than 45 (forty-five) days after the end
of the period covered by such report. Procedures for charges in respect of Research expenditures shall be made in accordance with the procedures prevailing at the Institute for charging research expenditures to individual projects of applied
research. 

  

	 	(c)	In addition to the reports to be submitted pursuant to Paragraph 4(a) above, Yeda will procure the submission by Prof. Cohen to the Corporation of reports of any significant findings in the Research promptly upon such
findings being made. 

  

	5.	Title 

 It is hereby agreed and recorded that all right, title and interest, in
and to the Existing Technology and any products, materials, methods, processes, techniques, knowhow, data, information and other results which are discovered or which accrue in the course of, or which arise or stem from the performance of the
Research or the Further Research by or under the supervision of Prof. Cohen (or his substitute) at the Institute, or which were discovered or accrued in the course of, or which arose or stemmed from, or will arise or stem from, the performance of
the Past Research and all right, title and interest in and to any drawings, plans, diagrams, specifications and other documents in any way embodying the Existing Technology, or the aforesaid products, materials, methods, processes, techniques,
knowhow, data, information or other results (hereinafter “the Licensed Information”), shall vest in Yeda exclusively, subject to any licence granted to the Corporation in terms hereof and subject, as to that portion of the Licensed
Information deriving from the Further Research, to any licences which are or may be granted with respect thereto to third parties funding such Further Research as hereinafter set forth. 

 

	6.	Patents  

  

	 	(a)	At the initiative of either party, the parties shall consult with one another regarding the filing of patent applications in respect of any portion of the Licensed Information licensed to the Corporation hereunder
including, but without limitation, the jurisdictions in which such applications should be filed, the timing of the filing of such applications and the contents thereof. Following such consultations, Yeda shall, at the Corporation’s written
request, file and prosecute applications as aforesaid. The parties agree that their joint policy will be to seek comprehensive patent protection for all Licensed Information licensed to the Corporation hereunder. 

 

	 	(b)	(i) All patent applications to be filed by Yeda in terms of subparagraph (a) above, shall be filed in the name of Yeda or should the law of the relevant jurisdiction so require, in the name of the inventor and then
assigned to Yeda. 

 The Corporation shall bear all costs and fees incurred by Yeda in the preparation, filing,
prosecution, maintenance and the like of all patent applications filed in accordance with the provisions of subparagraph (a) above (including the patent applications filed prior to the date hereof pursuant to the provisions of Paragraph 6(a) of
the Original Agreement) and in the maintenance, protection and the like of all patents issuing therefrom. It is agreed that the Corporation shall not be obliged to reimburse Yeda for any costs and fees incurred by Yeda until the date of the Original
Agreement in connection with the filing, prosecution, maintenance and the like of the patent applications and patents listed in Attachment “C” hereto (hereinafter “the Existing Patents” and “the Existing
Applications”) but shall be liable for and shall bear all costs incurred by Yeda after the date of the Original Agreement in the further prosecution, maintenance and the like of the Existing Applications and in the maintenance, protection
and the like of all patents issuing therefrom and of the Existing Patents (it being recorded that some of such costs and fees have been reimbursed to Yeda by the Corporation prior to the date hereof pursuant to the Original Agreement). 

 

	 	(ii)	At the request of the Corporation (or on Yeda’s own initiative), Yeda shall take or, at its discretion, authorise the Corporation to take, such action as shall be reasonably available to protect or to sue for
infringement of any Existing Patent or of any patent which shall have issued from any of the patent applications referred to in (b)(i) above. Should Yeda authorise the Corporation to take action as aforesaid, counsel for such action shall be
selected by the Corporation, subject to Yeda’s approval (such approval not to be unreasonably withheld). All costs involved in any action taken by Yeda at the Corporation’s request or by the Corporation, (including, inter alia,
legal costs and other sums awarded to the counter-party in such action) shall be borne by the Corporation exclusively. Any recovery in any such actions financed by the Corporation shall first be applied to cover costs and thereafter divided [*]%
([*] percent) to the Corporation and [*]% ([*] percent) to Yeda (save that if the recovery is in the form of the payment of royalties in respect of sales of the infringer (or alleged infringer) of such patent (“infringer”), then the
Corporation shall pay to Yeda, after deduction of the costs of such action, the lower of (i) [*]% ([*] percent) of such recovery and (ii) [*]% ([*] percent) of those sales of such infringer (or [*]% ([*] percent) where the sales are of
products in the Area of Peptide Technology) in respect of which such royalties are payable by the infringer). All costs involved in any such action taken by Yeda without the Corporation’s request, including any costs or other sums awarded to
the counter-party, shall be borne by Yeda exclusively and any recovery in any such action shall be retained by Yeda in full. The Corporation shall cooperate with Yeda in pursuing any actions undertaken under this subparagraph (b)(ii).

  
 [*] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	 	(c)	The provisions of subparagraph (a) above shall not prevent Yeda from filing patent applications with respect to any portion of the Licensed Information licensed to the Corporation hereunder (or any other Licensed
Information) in addition to those filed by it at the Corporation’s written request pursuant to subparagraph (a) above, it being agreed: 

  

	 	(aa)	that at least 60 (sixty) days before filing any such patent application relating to Licensed Information licensed to the Corporation hereunder, Yeda shall send the Corporation written notice of its intention to do so;

  

	 	(bb)	that all costs and fees incurred in connection with the preparation, filing, maintenance, prosecution, protection and the like of such patent applications and patents issuing therefrom shall be borne by Yeda
exclusively; and 

  

	 	(cc)	that the Corporation shall not be entitled to cause Yeda to take any action whatsoever for the protection of or for infringement of patents issuing on such patent applications, the taking of any such action shall be
entirely within Yeda’s discretion, the costs of any such action, as well as any costs and other sums awarded to any counter-party in such action, shall be paid by Yeda exclusively and any recovery in any such action shall be retained by Yeda.

  

	 	(d)	The Corporation agrees to pay any amount due to Yeda pursuant to subparagraph (b) above within 30 (thirty) days of Yeda’s first written request supported by invoice or other appropriate document.

  

	 	(e)	Nothing herein contained shall be deemed to be a warranty by Yeda that the Existing Applications or any of them or any patent applications relating to the Licensed Information or any portion thereof will be granted, or
that the Existing Patents or any patents obtained on any of the said patent applications, if obtained, are or will be valid or will afford proper protection. 

  

	7.	Licensing 

  

	 	(a)	Subject to the terms and conditions hereinafter set forth, Yeda hereby grants the Corporation and the Corporation accepts, an exclusive worldwide licence (“the Licence”) to use that part of the Licensed
Information being Existing Technology or derived from the Past Research or deriving from the Research and under the Licensed Patents (as hereinafter defined) (if any), for the manufacture and sale of the products and services covered by the Existing
Patents and/or the Existing Applications and, if the Research Program shall be supplemented as provided in Paragraph 2(b) above, then also, the products and services listed in the supplementary research program or programs becoming part of the
Research Program pursuant to Paragraph 2(b) above (all the said products and services being referred to hereinafter collectively as “the Products”). 

	 	(b)	(i) In this Agreement: 

 the term “Licensed Patents” shall mean the Existing
Patents and the patents issuing on the Existing Applications or on patent applications filed by Yeda in accordance with the Corporation’s written request pursuant to Paragraph 6(a) above or (as to patent applications relating to Licensed
Information licensed to the Corporation hereunder) by Yeda pursuant to Paragraph 6(c) above. 
  

	 	(ii)	The Licence shall remain in force with respect to any of the Products in any country (if not previously terminated according to the provisions of this Agreement) as follows: 

 

	 	(aa)	in a country where a Licensed Patent or Patents issues relating to such Product, until the date of expiry of the last of the Licensed Patents covering such Product in such country to expire or until the expiry of the
period 15 (fifteen) years commencing on the first commercial sale by the Corporation (or a permitted sublicensee) of the Product in such country, whichever is the longer; 

 

	 	(bb)	in any other country, the date of expiry of a period of 10 (ten) years commencing on the first commercial sale by the Corporation (or a permitted sub-licensee) of the Product in such country. 

The Corporation shall notify Yeda in writing immediately upon the entering into of each such first commercial transaction, specifying its
date. 
  

	 	(c)	(i) Except as provided in subparagraph (c)(ii) below, no sublicence under the Licence may be granted by the Corporation without Yeda’s prior written consent, such consent not to be unreasonably withheld and Yeda
agreeing to react to the Corporation’s written request for consent within 30 (thirty) days of receipt thereof. It is agreed that Yeda’s consent may not be sought unless the proposed sublicence is for monetary consideration exclusively in a
bona fide arms-length commercial transaction, is made by written agreement, the provisions of which are consistent with the terms of the Licence and contain, inter alia, the following terms and conditions: 

 

	 	(aa)	the sublicence shall expire automatically on the termination of the Licence for any reason; 

  

	 	(bb)	the party receiving the sublicence (hereinafter “the Sublicensee”) shall be bound by provisions substantially similar to those in Paragraph 10 below binding the Corporation (the obligations of the
Sublicensee so arising being addressed also to Yeda directly); 

  

	 	(cc)	all terms necessary to enable performance by the Corporation of its obligations hereunder; 

	 	(dd)	that any act or omission by the Sublicensee which would have constituted a breach of this Agreement by the Corporation had it been the act or omission of the Corporation, shall constitute a breach of the sublicence
agreement with the Corporation entitling the Corporation to terminate the sublicence, and the Corporation hereby undertakes to inform Yeda forthwith upon receipt of knowledge by the Corporation of such breach and, at the written request of Yeda, to
exercise such right of termination; 

  

	 	(ee)	that the sublicence shall not be assignable or further sublicenseable; 

  

	 	(ff)	that a copy of the agreement granting the sublicence shall be made available to Yeda, promptly upon its execution. 

  

	 	(ii)	Sublicences under the Licence may be granted by the Corporation to wholly-owned subsidiaries of the Corporation, provided: 

  

	 	(aa)	prior written notice of such grant, together with a copy of the proposed sublicence, shall have been submitted to Yeda at least 15 days before the grant; 

 

	 	(bb)	on grant of such sublicence and at all times during the currency thereof, Yeda shall have the same rights regarding representation on the Board of Directors of the subsidiary and the quorum for meetings thereof and
regarding representation on subcommittees of such Board as those (if any) that it has at such time regarding representation on the Board of Directors of the Corporation and the quorum for meetings thereof and regarding representation of any
subcommittees of such Board; 

  

	 	(cc)	the sublicence shall expire automatically if the sublicensee ceases to be wholly-owned by the Corporation and/or if the provisions of subparagraph (bb) above are not fulfilled; 

 

	 	(dd)	the sublicence agreement shall be in writing, shall be consistent with the terms of the Licence and shall contain, inter alia, the terms and conditions set out in subparagraphs (c)(i)(aa), (bb), (cc), (ee) and
(ff) above; 

  

	 	(ee)	that any act or omission by the subsidiary which would have constituted a breach of this Agreement by the Corporation had it been the act or omission of the Corporation, shall be deemed a breach of this Agreement by the
Corporation. 

	 	(d)	(i) In this Agreement, the term “Net Sales” shall mean the total amount actually received by the Corporation or permitted Sublicensees from the sale of Products by it or by permitted Sublicensees,
provided that as to sales other than at arms-length, the term “Net Sales” shall mean the total amount that would have been due in an arms-length sale, according to the then current conditions for such sale or—in the absence of
such current conditions—according to reasonable conditions for such sale, in all cases after deduction of: 

  

	 	(aa)	sales taxes (including value added taxes) to the extent applicable to such sale and not collected separately from the counter-party to the sale; and 

 

	 	(bb)	credits or allowances, if any, actually granted on account of price adjustments, recalls, rejections or return of Products previously sold; 

and provided further as to sales by the Corporation or permitted Sublicensees to an entity affiliated, directly or indirectly, to the
Corporation or to such Sublicensees, that the term “Net Sales” shall mean the higher of (x) “Net Sales”, as defined above, with respect to sales other than at arms-length; and (y) the total amount actually
received by the affiliated entity on resale to an independent third party purchaser after the deductions specified in subparagraphs (aa) and (bb) above, to the extent applicable. 

 

	 	(ii)	In consideration for the Licence, the Corporation shall pay Yeda a royalty of [*]% ([*] percent) of all Net Sales (except on Net Sales relating to Products in the Area of Peptide Technology, in respect of which the
Corporation shall pay Yeda a royalty of [*]% ([*] percent)) and [*]% ([*] percent) of all amounts received by the Corporation for or from the grant of sublicences and/or pursuant thereto, except amounts so received and calculated on the basis of
sales made by such Sublicensees (hereinafter “Sublicensing Receipts”). 

  

	 	(iii)	(aa) Amounts payable to Yeda in terms of this Paragraph 7(d) shall be paid to Yeda on a quarterly basis and no later than 30 (thirty) days after the end of each calendar quarter, commencing with the first calendar
quarter in which any Net Sales or Sublicensing Receipts are received. 

  

	 	(bb)	The Corporation shall, within a period of 30 (thirty) days from the end of each calendar quarter commencing with the first calendar quarter in which any Net Sales or Sublicensing Receipts are received, submit to Yeda a
full and detailed report, setting out all amounts owing to Yeda in respect of the quarter to which the report refers, and with full details (1) of payments received by the Corporation and Sublicensees constituting Net Sales or Sublicensing
Receipts including, without derogating from the generality of the aforegoing, a breakdown of Net Sales according to country and identity of seller, a breakdown of Sublicensing Receipts according to countries, the currency of the payments and date of
receipt thereof; and (2) of any other matter necessary to enable the determination of the amounts payable hereunder. 

  
 [*] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	 	(cc)	The Corporation shall keep and shall cause Sublicensees to keep complete and correct books of account and records consistent with sound business and accounting principles and practices and in such form and in such
details as to enable the determination of the amounts due to Yeda in terms hereof. The Corporation shall supply Yeda at the end of each year, commencing with the first year in which any amount is payable under this Paragraph 7(d), a report certified
by a Chartered Public Accountant in respect of the amounts due to Yeda pursuant to this Paragraph 7(d) in respect of the year covered by the said report. 

  

	 	(dd)	Yeda or its authorised representatives shall have the right during normal business hours to inspect the Corporation’s and Sublicensees’ books of accounts, records and other documentation to the extent relevant
or necessary in or for the ascertaining or verification of the amounts due to Yeda under this Paragraph 7(d). 

  

	8.	Additional Research, Development and Commercialization 

  

	 	(a)	It is understood and agreed that should any additional research be required (beyond that to be funded pursuant to Paragraph 3 above) with respect to any Product in order to enable the Corporation to commence development
of such Product to commercialization, then such additional research shall be performed at the Institute under the supervision of Prof. Cohen, in the event he is willing and able to undertake such research, in accordance with a research program and
budget to be agreed between the parties, and failing such agreement, to be determined by the Expert pursuant to Paragraph 15 below as to the research program and by the President of the Institute, as to the budget therefor. The provisions
hereinbefore relating to the performance of the Research (including the provisions of Paragraph 2(c) above, in the event Prof. Cohen is not able or willing as aforesaid), shall apply, mutatis mutandis, to the performance of the additional
research contemplated by this Paragraph 8(a). Should there be a dispute between the parties as to whether any such additional research relating to any Product is required as aforesaid, such dispute shall likewise be resolved by the Expert, pursuant
to Paragraph 15 below. Should the Corporation not agree to fund any additional research necessary regarding a certain Product as agreed by the parties or determined by the Expert within 60 (sixty) days of said agreement or determination, then such
Product shall thereupon be excluded from the Licence. 

  

	 	(b)	The Corporation undertakes to take all necessary steps to expedite the commencement of commercial sale of the Products. For such purpose and without derogating from the generality of the aforegoing, the Corporation
shall carry out all activities necessary to develop the Products to commercialization, including the performance of toxicological tests, pharmacological and efficacy tests, pre-clinical tests, clinical trials, any steps required for obtaining
regulatory approvals from the US Food and Drug Administration and other regulatory authorities and the development of procedures and facilities for large-scale commercial production of the Products. The Corporation further undertakes to commence
such commercialization as soon as practicable and continue therewith diligently throughout the period of the Licence. 

	 	(c)	Should Yeda be of the opinion that the Corporation is in breach of its obligations pursuant to Paragraph 8(b) above with respect to the development and commercialization of any Product or Products (it being understood
and agreed that the Corporation shall not be obliged to engage in the development and commercialization of any Product or Products which would compete with a Product or Products already developed and commercialized by the Corporation or already
under such development and commercialization by the Corporation), it may so advise the Corporation and notify the Corporation that unless certain steps are taken by the Corporation as specified in the said notice, the Licence with respect to such
Product or Products shall lapse. Should the Corporation accept the terms of such notice and not take the said specified steps, the said Product or Products shall upon further written notice from Yeda be excluded from the Licence. Should the
Corporation not accept the terms of the said notice, then the dispute shall be resolved by the Expert pursuant to Paragraph 15 below, the Expert being entitled to specify the steps to be taken by the Corporation as a condition for the continuation
of the Licence with respect to the Product or Products in question. 

  

	 	(d)	The Corporation will provide Yeda with written reports on the progress and results of the tests and trials conducted and all other actions taken by the Corporation pursuant to subparagraph (b) above, such reports
to be made at least once every 6 (six) months. 

  

	9.	Right of First Opportunity 

  

	 	(a)	Should Yeda, at the request of Prof. Cohen, resolve to seek third party financing (other than public grant funding) for the performance of Further Research during the Research Period (in addition to the Research to be
funded by the Corporation as hereinbefore provided) and/or to grant a licence to a third party for the commercialization of the results of Further Research conducted by Prof. Cohen during the Research Period (other than the Research to be funded by
the Corporation as hereinafter provided), then, provided that the Corporation shall have complied fully with all its obligations hereunder until that time and subject to any then existing conflicting contractual obligation to a third party
undertaken by Yeda without violation of the provisions of this Agreement, Yeda shall advise the Corporation in writing of the details of such contemplated research and/or licensing project and the terms and conditions upon which Yeda is willing to
enter into a contractual arrangement with a third party with respect to such project. It is agreed that Yeda shall have full discretion with respect to the determination of the details to be provided and the terms and conditions to be proposed as
aforesaid. 

  

	 	(b)	Should the Corporation advise Yeda, within 30 (thirty) days of receipt of such proposal, that it wishes to undertake the proposed project, then the parties shall negotiate a detailed contract based on the terms proposed
by Yeda and accepted by the Corporation as aforesaid. 

	 	(c)	Should the Corporation not have advised Yeda within the said 30 (thirty) days that it wishes to undertake the said project or, if the Corporation shall have advised Yeda within the said 30 (thirty) days that it wishes
to undertake the said project but a detailed contract shall not be signed, for whatever reason, within the period of 90 (ninety) days commencing on date of receipt by Yeda of the Corporation’s said notice, then Yeda shall be free, during the
period of one year commencing at the end of the said period of 30 (thirty) days, to enter into an agreement with a third party on the proposed project, on terms and conditions not substantially better (from the point of view of the third party),
than those offered to the Corporation by Yeda as aforesaid. If no such agreement with a third party is reached during the said period of one year, then the provisions of subparagraphs (a) and (b) above and of this subparagraph
(c) shall apply again with respect to such project. 

  

	10.	Confidentiality 

  

	 	(a)	The Corporation shall maintain in confidence the Licensed Information, except and to the extent that it is in the public domain at the date of the signing hereof or becomes part of the public domain thereafter other
than through a violation by the Corporation of this obligation of confidentiality and except that the Corporation shall be released from its obligation of confidentiality with regard to that portion of the Licensed Information expressly released
therefrom by Yeda by notice in writing. Notwithstanding the foregoing, the Corporation may disclose to its personnel and other third parties (including permitted Sublicensees) confidential Licensed Information to the extent necessary for the
exercise by it of its rights hereunder or in the fulfilment of its obligations hereunder, provided that it shall bind such personnel and other third parties with a similar undertaking of confidentiality in writing. 

 

	 	(b)	In addition to and without derogating from the aforegoing, the Corporation undertakes not to make mention of the names of Yeda, the Institute or any scientists of the Institute in any manner or for any purpose
whatsoever in relation to this Agreement, its subject matter and any matter arising from this Agreement, unless the prior written approval of Yeda thereto has been obtained (such approval not to be unreasonably withheld). 

 

	 	(c)	For the removal of doubt, nothing in subparagraphs (a) or (b) above contained shall be deemed to prevent the Corporation from mentioning the names of Yeda and/or the Institute or to prevent the Corporation
from disclosing any information where such mention or disclosure is to competent authorities for the purposes of obtaining approval or permission for the exercise of the Licence or is in the fulfilment of any legal duty owed to any competent
authority. 

  

	 	(d)	Yeda shall maintain in confidence the Licensed Information, except and to the extent that it is in the public domain at the date of the signing hereof or becomes part of the public domain thereafter other than through a
violation by Yeda of this obligation of confidentiality. Notwithstanding the aforegoing, it is agreed: 

	 	(i)	that Yeda may disclose to its and the Institute’s personnel and other third parties such confidential information as shall be necessary for the exercise by Yeda of any rights in and to the use of the Licensed
Information not exclusively licensed or no longer exclusively licensed hereunder to the Corporation, provided that it shall bind such personnel and other third parties with a similar undertaking of confidentiality in writing; and 

 

	 	(ii)	that Yeda shall have the right to allow Prof. Cohen to publish articles relating to the Licensed Information in scientific publications, provided that the publication of any such article shall not take place unless the
text thereof has been submitted to the Corporation at least 30 days prior to intended date of submission of the article for publication, so as to give the Corporation a reasonable opportunity to request the filing of a patent application relating to
the subject-matter of the article. 

  

	 	(e)	No termination of this Agreement, for whatever reason, shall release the Corporation from any of its obligations under this Paragraph 10 and such obligations shall survive termination as aforesaid. Yeda’s
obligation of confidentiality pursuant to Paragraph 10(d) above shall lapse upon termination of this Agreement. 

  

	11.	No Warranty 

 For the avoidance of doubt, it is agreed that nothing in this
Agreement constitutes or shall constitute a warranty or representation by Yeda that any results will be achieved by the Research, that any Further Research will be conducted, that any proposal relating to Further Research will be made to the
Corporation, that the Existing Technology or any results achieved by Past Research or by the Research or the Further Research (if any) are or will be commercially exploitable or of any other value. 

 

	12.	No Assignment 

 The Corporation may not assign all or any of its rights or
obligations under this Agreement or arising therefrom without the prior written consent of Yeda. 
  

	13.	Indemnification 

 The Corporation shall indemnify and hold harmless Yeda and the
Institute and the officers and employees of them from and against any loss, damage, liability and expense (including attorney fees and legal costs) arising out of or resulting from the exercise of the Licence or any sublicences and/or from the use
of the Licensed Information or any part thereof, including without limitation, product liability claims and/or claims arising out of the development activities of the Corporation pursuant to this Agreement or in connection therewith. 

 This obligation shall survive the termination of this Agreement for any reason. 

 

	14.	Term and Termination  

  

	 	(a)	(i) Unless previously terminated in accordance with the provisions hereof, this Agreement terminates when the Licence hereunder is no longer in force in any country whatsoever. 

 

	 	(ii)	For the avoidance of doubt, it is hereby recorded and agreed that following the expiry by passage of time pursuant to Paragraph 7(b)(ii) above of the Licence hereunder in any country with respect to any Product
(“the said country” and “the said Product”) and notwithstanding such expiry and as long as this Agreement is in force and even thereafter if this Agreement has expired upon expiry of the Licence hereunder as a
consequence of its expiry by passage of time in the country in which the Licence has last expired, the Corporation (and, at its option, its then permitted Sublicensees) shall be entitled to continue to manufacture and/or sell the said Product in the
said country without having to pay royalties to Yeda in respect of such activities subsequent to such expiry date and Yeda shall not grant any third party a licence to manufacture and/or sell the said Products in the said country. 

 

	 	(b)	Without derogating from the parties’ rights hereunder or by law to any other or additional remedy or relief, it is agreed that: 

 

	 	(i)	(aa) If within [*] of the [*], neither [*] nor [*] shall have been filed in acceptable form with [*] or [*]; or 

  

	 	(bb)	having filed such [*] and such [*] having been accepted for such Product, the Corporation shall not [*] and [*] or [*], as the case may be, [*] from the [*] as referred to in (aa) above; or 

 

	 	(cc)	such [*] or [*] having been obtained for such Product, [*] shall not have been [*] (except as a result of force majeure, in which case the period of [*] shall be extended by the period reasonably attributable to the
force majeure); or 

  

	 	(dd)	[*] of such Product having commenced, there shall be a period of [*] ([*]) [*] or more during which [*] (except as result of force majeure or other factors essentially beyond the control of the Corporation),

 then Yeda shall be entitled to terminate the Licence hereunder with respect to the said Product or, unless another Product
in the said Area is under development at such time and Yeda’s right of termination of the Licence with respect thereto pursuant to this subparagraph 14(b)(i) above shall not yet have arisen, to terminate the Licence hereunder with respect to
the said Area as a whole; 

  
 [*] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	 	(ii)	the provisions of subparagraph (i) above shall apply separately to each of the Areas. 

  

	 	(iii)	either Yeda or the Corporation may terminate this Agreement and the Licence hereunder by serving a written notice to that effect on the other, upon or after the winding-up or insolvency of the other, or upon or after
the commitment of a material breach hereof by the other (which breach cannot be cured or, if curable, has not been cured by the party in breach within 45 (forty-five) days (or, in the case of failure by the Corporation to pay Research funding on or
before due date, 30 (thirty) days) after receipt of a written notice from the other party in respect of such breach); and in such event this Agreement and the Licence hereunder shall be terminated forthwith upon receipt of notice as aforesaid. For
the purposes of this Paragraph 14(b)(iii), “material breach” shall not include the breaches governed by subparagraphs (i) or (ii) above, but shall include—without limitation—default in any payment payable
hereunder to Yeda; 

  

	 	(iv)	any amount payable hereunder by one of the parties to the other, which has not been paid by its due date of payment, shall bear interest from its due date of payment until the date of actual payment, at the rate of 3%
(three percent) per annum in excess of the average LIBOR rate for US Dollar deposits for a period of 3 (three) months prevailing from time to time during the period of arrears, 

 

	 	(c)	If all three Areas shall be excluded from the Licence pursuant to subparagraph (b)(i) above, then the Licence hereunder as a whole shall thereupon terminate. 

 

	 	(d)	Upon the termination of this Agreement for whatever reason, the Corporation shall deliver to Yeda all tables, graphs, diagrams, specifications and other documentation in the Corporation’s possession containing the
Licensed Information and shall further deliver to Yeda, without consideration, all documentation, including health regulatory documentation relating to the Products, owned or controlled by the Corporation at the time. Notwithstanding the aforegoing,
the Corporation may retain one copy of all such documentation relating to any development and other work performed by the Corporation in connection with the Products (hereinafter “the Corporation’s Information”), provided
(i) that such documentation may be used by the Corporation for the sole purpose of defending itself in any future claims relating to the exercise by the Corporation (prior to termination) of its rights hereunder; (ii) that the Corporation
shall otherwise maintain such documentation in strict confidence as long as the obligation of confidentiality under Paragraph 10 shall continue to apply thereto and (iii) (without derogating from Paragraph 14(a)(ii) above), that the retention
of such documentation shall in no way be deemed to establish any right to the further exercise of the Licence or of the Licensed Information or to derogate in any way from the provisions of Paragraph 14(f) below. 

 

	 	(e)	The termination of this Agreement for any reason shall not relieve the parties of any obligations to make payments thereunder which shall have accrued prior to such termination. 

	 	(f)	It is agreed, subject to Paragraph 14(a)(ii) above, that upon termination of this Agreement and the Licence thereunder, all rights in the Licensed Information vested in the Corporation shall revert to Yeda and the
Corporation shall not thereafter be entitled to make any use of the Licensed Information. 

  

	 	(g)	The provisions of subparagraphs (d), (e) and (f) above shall apply, mutatis mutandis, in the event of exclusion from the Licence of an Area or Areas or Product or Products, pursuant to subparagraph 14(b)(i)
above, Paragraph 3(c) above or Paragraphs 8(a) or 8(c) above. 

  

	 	(h)	(i) In the event that performance of the Research shall terminate pursuant to Paragraph 2(c)(i) above, the Corporation may elect within 30 (thirty) days of such termination, to terminate the Licence and this Agreement
(except the provisions of this Paragraph 14(h)) by service of written notice to such effect on Yeda, whereupon if during a period of [*] years from the date of termination of the Agreement as aforesaid, Yeda shall enter into an agreement with a
third party for grant of a licence (exclusive or otherwise) to use the Licensed Information for the purpose of the development of the Products, [(or any of them], then, subject to subparagraphs (ii) and (iii) below, Yeda shall pay the
Corporation [*]% ([*] percent) of all [*] received by Yeda from such third party in respect of the grant of such licence, within 30 (thirty) days of receipt thereof from time to time, until such time as the Corporation shall have received a total
amount equivalent to [*]% ([*] percent) of the amount (in US Dollars) paid to Yeda by the Corporation for funding the Research (“the Corporation’s Research Funding”). 

 

	 	(ii)	 In the event that this Agreement and the Licence shall be terminated by the Corporation pursuant to sub-paragraph (i) above, or in the event that
the Corporation shall terminate the performance of the Research in all three Areas pursuant to clause 3(c) above, with the resultant termination of the Agreement and the Licence, then notwithstanding such termination, this Paragraph 14(h) shall
survive, and if Yeda should enter, during the period of [*] years from the date of termination of the Agreement as aforesaid into an agreement granting a third party a licence (exclusive or otherwise) to use the Corporation’s Information (or
part thereof) for the purpose of the development of the Products (or some of them), then subject to subparagraph (i) above and subparagraph (iii) below, Yeda shall pay to the Corporation [*]% ([*] percent) of all [*] received by Yeda from
such third party in respect of the grant of such licence, within 30 days of the receipt thereof from time to time, until such time as the Corporation shall have received a total amount equivalent to [*]% ([*] percent) of the costs incurred by the
Corporation (in US Dollars), (such costs having been reported to and approved by the Chief Scientist of the Israel Ministry of Industry and Trade (“the Chief Scientist”) or being costs of the type that would have met the criteria of
the Chief Scientist had matching funds therefor been sought) in obtaining that part of the Corporation’s Information licensed to the third party (“the Corporation’s Development Funding”), provided that, if Yeda shall be
obliged to pay to the Corporation on the same receipts pursuant both to 

  
 [*] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	 	
subparagraph (i) above and to this subparagraph (ii), Yeda shall pay the Corporation an aggregate of [*]% ([*] per cent) of such receipts, the amount paid to be applied in reduction of the
outstanding balances of the Corporation’s Research Funding and the Corporation’s Development Funding in proportion to respective amounts of the said outstanding balances. 

 

	 	(iii)	Notwithstanding anything to the contrary contained in this subparagraph (h), in the event that the Corporation shall have utilized public grant funding (including, without limitation, funding from the Chief Scientist)
to finance the Corporation’s Research Funding or the Corporation’s Development Funding, and Yeda and/or any third party licensee of Yeda as referred to in (i) or (ii) above shall be obliged to remit any amount to the public
grantor, from out of Yeda’s receipts from the grant of a licence to a third party in respect of the Licenced Information and/or the Corporation’s Information, such amount shall be deemed payment to the Corporation in reduction of
Yeda’s liability to the Corporation pursuant to subparagraphs (i) and/or (ii) above, as the case may be. 

  

	15.	Expert 

 The parties agree that Prof. Michael Sela shall be the Expert mentioned
in this Agreement hereinbefore or, if he should be unable or unwilling to act or continue to act in that capacity, then the Expert shall be Prof. Ruth Arnon of the Institute, unless the parties shall have agreed on another substitute for Prof. Sela
within 21 (twenty-one) days of Prof. Sela having become unable or unwilling to act or to continue to act, in which latter case the said substitute shall be the Expert. Should no such substitute have been agreed as aforesaid and should Prof. Arnon be
unable or unwilling to act or continue to act as the Expert, then the Expert shall be the person appointed, at the request of either party, by the President of the Hebrew University for the time being. The Expert shall act as such and not as an
arbitrator and shall not be subject to the law relating to arbitration. The Expert shall consult with the parties and otherwise reach his decision in such manner as he shall deem fit in his absolute discretion and his decision shall bind the parties
fully and finally. 
  

	16.	Consultancy Agreement 

 For the removal of doubt, Yeda confirms that Prof. Cohen
may enter into a consultancy agreement with the Corporation, provided that the terms thereof shall not conflict with the terms and conditions of this Agreement and with the policies prevailing at the Institute in this respect. The parties record
that a consultancy agreement between the Corporation and Prof. Cohen has been signed. 

  
 [*] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	17.	Governing Law 

 This Agreement shall be governed by the laws of Israel. Subject to
the provisions of Paragraph 15 above, the courts of Israel shall have exclusive jurisdiction over any disputes arising thereunder, except that Yeda may bring suit against the Corporation also in the jurisdiction outside Israel in which the
Corporation has its principal place of business. 
  

	18.	Entire Agreement and Effective Date 

 This Agreement is an amended and restated
version of the Original Agreement (signed as of March 6, 1992) and substitutes it as of the effective date hereof with respect to the period subsequent to the effective date, except as otherwise expressly provided herein. The Original Agreement
shall continue to govern with respect to the period until the effective date hereof, except as otherwise expressly provided herein. The active date of this Agreement is the date stated at the foot of this Agreement. This Agreement and the Original
Agreement constitute together, in the manner hereinbefore specified, the entire agreement between the parties. Any addition or amendment thereto shall not be effective unless in writing signed by the authorized signatories of both parties. 

 

	19.	Notices 

  

	 	(a)	Notices to be given hereunder shall be given if available by telex or telecopier or, if neither of these is available, as required by Paragraph 19(b). If notice is sent by telex or telecopier, it shall be deemed to have
been served 24 hours after transmission. All notices given by telex or telecopier shall be confirmed by letter despatched in the manner appearing in Paragraph 19(b) within 24 hours after transmission. 

 

	 	(b)	Any other notices to be given hereunder shall be served on a party by prepaid express registered letter (or nearest equivalent) to its address given herein or such other address as may from time to time be notified for
this purpose and any notice so served shall be deemed to have been served 7 (seven) days after the time at which it was posted and in proving such service it shall be sufficient to prove that the notice was properly addressed and posted.

 IN WITNESS WHEREOF the parties hereto have set their signatures as of this 12th day of January 1994. 

 

									
	for YEDA RESEARCH AND DEVELOPMENT COMPANY LTD.	 		 	for PORTMAN PHARMACEUTICALS, INC.
					
	By:	 	 [illegible]
	 		 	By:	 	 [illegible]

	Title:	 	President	 		 	Title:	 	Vice President

 C 

COMPOSITION FOR PREVENTION OF GRAFT REJECTION 
 (Our ref: T/665)

  

									
	 Country
	  	Filing/Grant - date	 	  	Application/Patent - No.	 
	 Israel
	  	 	26.06.06	  	  	 	79254	  
	 Australia
	  	 	10.09.91-	  	  	 	608,228	  
	 Canada
	  	 	01.06.93-	  	  	 	1,318,591-	  
	 Denmark
	  	 	26.06.87	  	  	 	3312/87	  
	 EPO11
	  	 	19.11.92-	  	  	 	251134-	  
	 Japan
	  	 	26.06.87	  	  	 	159514/07	  
	 United States
	  	 	27.04.93-	  	  	 	5,206,223-	  

  

	1 	European Patent Office designating - Austria, Belgium, France, Greece, Italy, Luxembourg, Netherlands, Spain, Sweden, Switzerland, United Kingdom and West Germany. 

CONJUGATES OF POORLY IMMUNOGENIC ANTIGENS AND SYNTHETIC PEPTIDE CARRIERS AND VACCINES COMPRISING THEM. 

(Our ref: 48-92) 
  

									
	 Country
	  	Filing date	 	  	Application/Patent - No.	 
	 Israel
	  	 	30.07.92	  	  	 	102687	  
	 PCT1
	  	 	28.07.93	  	  	 	PCT/US93/07096	  

  

	1 	Patent Cooperation Treaty International Application designating all PCT countries, including EPO. 

 A 

November 7. 1993 
 Outline of Research
Program for Portman 
  

	1.	Delta Project (see Delta Row chart) 

 The aim of this project is to [*]. 

Candidate drugs are: 
 [*] 

[*] 
 [*] 

Candidates [*] will have priority and the most effective molecule will be chosen as the drug for testing and trials. 

The [*] class of candidates will have a lower priority but will be used in comparison with the first priority molecules to learn whether
molecules with other activities can be obtained and to close off the competition. 
 [*] This does not have a high priority but might worthwhile if it can
be done easily. 
 Model applications include: 
  

	 	(i)	[*] 

  

	 	(ii)	[*] 

  

	 	(iii)	[*] 

  

	 	(iv)	[*] 

  

	 	(v)	[*] 

 Mechanisms of Delta effects. 

 

	 	(i)	[*] 

  

	 	(ii)	[*] 

  
 [*] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	 	(iii)	[*] 

  

	 	(iv)	[*] 

  

	 	(v)	[*] 

 The results obtained from the above studies will help decide which molecules will be
developed and for which clinical applications. 

  
 [*] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

			
	 RESEARCH PROGRAM
	  	November 1993
	 Delta Flow Chart
	  	

  

	
	

  
 [*] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 RESEARCH PROGRAM 

Delta Flow Chart 
  

	2.	1DDM Project (see 1DDM Flow chart) 

 The aim of this project is [*] 

The detection of [*]. 
 [*] 

The immune response [*] will continue to be investigated as a rationale for diagnosis and therapy, 

Therapy using [*] will continue as the basis for human trials. 

The role of [*] will continue to be studied. Toxicity testing and clinical trials will be supported by the research program. 

  
 [*] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

			
	 RESEARCH PROGRAM
	  	November 1993
	 Delta Flow Chart
	  	
	
	

 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions. 

  
 26 

 AGREEMENT 

Made and entered into on this 11th day of June 1996 

By and Between: 
 YEDA RESEARCH
AND DEVELOPMENT COMPANY LTD. 
 a company organised and existing under the laws of the State of Israel and having an address for the
purposes of this Agreement at P.O. Box 29, Rehovot 76100, ISRAEL; 
 (hereinafter “Yeda”) 

And 
 PORTMAN PHARMACEUTICALS,
INC. 
 a company organised under the laws of the State of Delaware, U.S.A. and having an address for the purposes of this Agreement at
One Parker Plaza, Fort Lee, New Jersey 07024, U.S.A. 
 (hereinafter “Portman US”) 

And 
 PORTMAN PHARMACEUTICAL
INDUSTRIES LTD. 
 a company organised and existing under the laws of the State of Israel and having an address for the purposes of this
Agreement at Migdal Hakanyoter, 53 Ha’Irusim St., Nes Ziona 70400, Israel 
 (hereinafter “Portman Israel”) 

And 
 TEVA PHARMACEUTICAL
INDUSTRIES LTD. 
 a company organised and existing under the laws of the State of Israel and having an address for the purposes of this
Agreement at 5 Basel Street, Petah Tikvah, Israel; 
 (hereinafter “Teva”) 

(Yeda, Portman US, Portman Israel and Teva are sometimes collectively referred to hereunder as “the Parties”) 

 NOW, THEREFORE, in consideration of the mutual covenants and obligations herein made and
undertaken, the Parties hereto do hereby agree as follows: 
 1. Yeda and Portman US agree that the amounts to be provided by Portman US for the
funding of the Research pursuant to the R&L Agreement in the years 1995 and 1996 are hereby reduced and shall be, in the aggregate, one million four hundred thousand US Dollars (US $1,400,000) for the year 1995 and one million US Dollars (US
$1,000,000) for the year 1996, to be paid as follows: 
 1.1 For the year 1995: 

 

	 	1.1.1	for the first quarter of 1995: the sum of four hundred thousand US Dollars (US $400,000); 

  

	 	1.1.2	for the second quarter of 1995: the sum of four hundred thousand US Dollars (US $400,000); 

  

	 	1.1.3	for the third quarter of 1995: the sum of three hundred and fifty thousand US Dollars (US $350,000); 

  

	 	1.1.4	for the fourth quarter of 1995: the sum of two hundred and fifty thousand US Dollars (US $250,000). 

1.2 For the year 1996: 
  

	 	1.2.1	for the first quarter of 1996: the sum of two hundred and fifty thousand US Dollars (US $250,000); 

  

	 	1.2.2	for the second quarter of 1996: the sum of two hundred and fifty thousand US Dollars (US $250,000); 

  

	 	1.2.3	for the third quarter of 1996: the sum of two hundred and fifty thousand US Dollars (US $250,000); 

  

	 	1.2.4	for the fourth quarter of 1996: the sum of two hundred and fifty thousand US Dollars (US $250,000). 

The payments due under Sections 1.1 and 1.2 above (and not paid on or before the date hereof) shall be made in advance of the relevant
quarter. 
  

	2	Agreed Deductions. Yeda hereby agrees that each of the amounts set forth in Sections 1.1 and 1.2 above may be reduced by an amount of approximately forty thousand US Dollars (US $40,000), representing direct
labor costs incurred in the performance of the Research and paid for directly by Portman, provided 

	 	2.1	as to deductions from amounts due under Section 1.1, that prior to signature hereof such costs have been authorised by Yeda in writing and proof satisfactory to Yeda evidencing actual payment of such costs has been
presented by Portman to Yeda; and 

  

	 	2.2	as to deduction from amounts due under Section 1.2, that such costs have been authorised by Yeda in advance and in writing and proof satisfactory to Yeda evidencing actual payment of such costs has been presented
by Portman to Yeda prior to such deduction. 

 Subject to prior agreement in writing between Yeda and Portman US, any other
costs relating to the Research, whether conducted by or through Yeda, may be paid for directly by Portman and subsequently deducted from the amounts set forth in Section 1.2 above, subject to presentation by Portman, prior to such deduction, of
proof satisfactory to Yeda evidencing such payments. 
  

	3	Additional Research. 

 3.1 Subject to the occurrence of a Determining
Event (as that term is hereinafter defined) by no later than December 31, 1998, Portman US agrees, if Yeda should so request in writing, to finance the continuation of the Research at the Institute, under the supervision of Prof. Cohen, in the
amount of $[*], for the additional period specified below, commencing on January 1, 1997, if the Determining Event has occurred on or before December 1, 1996 or commencing 1 (one) month after the Determining Event, if the Determining Event
has occurred after December 1, 1996. “Determining Event” herein shall mean: (1) the receipt by Portman US or Portman Israel (hereinafter in this Section—“Portman”), of funds aggregating $[*] or more
against issue of shares or other securities issued by Portman, whether following an offer or offers to the public, by private placement(s) or otherwise howsoever or (2) the acquisition of a controlling interest in Portman by Teva or any
person(s) and/or entity(ies) not presently being stockholders in Portman or (3) the merger or amalgamation of Portman into or with any other entity (other than an entity in which Portman holds 75% or more of the voting rights and of the rights
to dividends) or (4) the acquisition by any person(s) and/or entity(ies) of all or a major part of the assets of Portman or (5) any other event having substantially the same effect as the events listed in (2), (3) or (4) above.

  
 [*] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 It is expressly agreed that the provision of bridging finance to Portman by way of
shareholder’s loan by the existing shareholders in Portman or any of them in an aggregate amount of up to $1,250,000 in the period ending on December 31, 1996, shall not be taken into account in considering whether a Determining Event has
occurred. The details of the research programme for such additional period and the budget breakdown therefor shall be agreed by Portman US and Yeda, after consultation with Prof. Cohen, or failing agreement within 30 days of Portman US or Yeda first
proposing such research programme, as determined by the Expert referred to in Section 12 of the R&L Agreement. The additional period of research to be financed by Portman as aforesaid shall be [*], unless the Determining Event which has
occurred is the event specified in (1) above and the aggregate amount of funds received by Portman pursuant to such event is less than $[*], in which case the additional period of research shall be [*]. It is agreed, for the removal of doubt,
that should the aggregate amount so received by Portman by a certain date be $[*] or more but less than $[*] and by Portman be increased later (but prior to December 31, 1998), to $[*] or more, then the additional period of research shall be
[*]. Payment of the funds for any year in such additional period shall be made quarterly in advance in four equal instalments of US $[*]. 

3.2 Portman shell be entitled to terminate the financing of Research financed pursuant to Section 3.1 above, with effect
from the end of the first year of such Research or the end of the second year of such Research, on the same terms, mutatis mutandis, as those laid down in Section 3(c) of the R&L Agreement including the provisos in subparagraphs (i),
(ii) and (iii) of that Section 3(c), mutatis mutandis, provided only that in the event of such termination with effect from the end of such second year, the Licence granted under the R&L Agreement shall not terminate
(notwithstanding the provisions of the said Section 3(c)). 
  

	4	 Effect on Cooperation Agreement. The Parties agree that references in the Cooperation Agreement to the R&L Agreement shall be deemed
references to the R&L Agreement as amended hereby and in that sense the Cooperation Agreement shall be deemed amended hereby. For the removal of doubt, it is expressly agreed that payments by Teva to Portman pursuant to the Cooperation Agreement
for financing the Research shall be made without 

  
 [*] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
taking into account any deductions made from the payments due to Yeda from Portman as contemplated in Section 2 above. It is also recorded, for the further removal of doubt, that non-payment
by Teva to Portman of any payment shall not relieve Portman of its obligations to make the payments due to Yeda under the R&L Agreement (as amended herein). 
  

	5	Duly Executed Amendment. The Parties hereby consent and acknowledge (to the extent such consent and acknowledgment is required) that this Agreement constitutes an amendment to the R&L Agreement and to the
Cooperation Agreement (in the sense specified above) executed in proper form and manner and pursuant to all relevant provisions thereof. 

  

	6	Prior Instalments Paid. Yeda confirms that before signature hereof, all instalments due to Yeda under the R&L Agreement for funding the Research in the year 1995 and the instalment due to Yeda under the’
R&L Agreement for funding the Research in the first quarter of 1996 have been duly paid. 

  

	7	Agreements to Remain in Effect in all Other Respects. For the purpose of removing any doubt, it is hereby confirmed and certified that any and all agreements existing between all and/or some of the Parties shall
remain in full force and effect, as amended, to the extent amended, by this Agreement. In the event of any conflict between this Agreement and any other Agreement, this Agreement will prevail. 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their
respective duly authorised representatives as set forth below. 
  

									
	  
	  		  	  

	YEDA RESEARCH AND DEVELOPMENT	  		  	PORTMAN PHARMACEUTICALS, INC.
	COMPANY LIMITED	  		  	
					
	By:	  	 [illegible]
	  		  	By:	  	 [illegible]

	Title:	  	President	  		  	Title:	  	Vice President
	Date:	  	3/26/1996	  		  	Date:	  	4/9/1996
			
	  
	  		  	  

	PORTMAN PHARMACEUTICAL	  		  	TEVA PHARMACEUTICAL
	INDUSTRIES LTD.	  		  	INDUSTRIES LTD.
					
	By:	  	 [illegible]
	  		  	By:	  	 [illegible]

	Title:	  	Director	  		  	Title:	  	CFO
	Date:	  	4/9/1996	  		  	Date:	  	6/11/1996

 AGREEMENT 

Entered into this 29 day of April, 1998, by and between YEDA RESEARCH AND DEVELOPMENT COMPANY LTD. (“Yeda”) and PEPTOR
LTD. (“Peptor”). 
 WITNESSETH 

WHEREAS Yeda is party to the Research and License Agreement with Portman Pharmaceuical Inc. (“Portman US”) and Portman
Pharmaceucials Ltd. (“Portman Israel”) (Porman U.S. and Portman Israel are hereinafter referred to collectively as “Porman”) dated January 12, 1994, including amendments thereto (the “R&L
Agreement”); and 
 WHEREAS upon the Closing (the “Closing”) of the Merger Agreement dated
February 25, 1998 (the “Merger Agreement”) between Peptor and Portman US, Peptor shall acquire all the issued and outstanding shares of Portman US. 

NOW THEREFORE IT IS HEREBY AGREED 
  

	1	R&L Agreement. At time of the Closing Peptor shall replace Portman as a party to the R&L Agreement, and as such there, all of the right and obligations of Portman under the R&L Agreement shall
become the rights and obligations of Peptor. 

  

	2	Deferral of Payments. 

  

	 	2.1	Yeda hereby agrees to defer all payments owed and due to it by Portman. Portman’s debts to Yeda as of the Closing date (the “Debt”) shall be paid to Yeda by Peptor in accordance with the following payment
schedule: 

  

	 	2.1.1	$200,000 shall be paid by Peptor to Yeda upon the Closing. 

  

	 	2.1.2	$150,000 shall be paid by Peptor to yeda within 90 days following the Closing. 

  

	 	2.1.3	The balance of the Debt to Yeda shall be paid by Peptor to Yeda following successful completion of the next round of financing of Peptor. 

 

	 	2.2	Peptor shall be responsible for the continuance of the Research (as defined in the R&L Agreement) in Prof. Irum Cohen’s laboratory and for the payments due in respect of such Research in accordance with the
R&L Agreeement, as of the date of the Closing. Such payments are a part of the Debt described in Section 2.1 above. 

  

	3	Effect of the Agreement. This Agreement constitutes the entire agreement between the parties with respect to its subject matter and supersedes all prior agreements, arrangements, dealings or writings
between the parties with regard to such subject matter. This Agreement may not be varied except in writing signed by the parties’ authorized representatives. 

	4	Notices. 

  

	 	4.1	All notice provisions remain the same except that the following shall be added: 

  

			
	Peptor:	  	Kiryat Weizmann, Rehovot, Israel
		  	Attention: Yoram Karmon
		  	Telephone: 972 (08) 940-1232
		  	Facsimile: 972 (08) 940-7737

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above
written. 
  

			
	YEDA RESEARCH & DEVELOPMENT LTD.
		
	By:	 	 /s/ Shlomo Harel

		 	President /title
	
	PEPTOR LTD.
		
	By:	 	 /s/ Yoram Karmon

		 	CEO /title

 May 3, 2000 

Ref. :09-1688-00-666 
 No. :26520

 By facsimile: 
 08 9407737 

Dr. Yoram Karmon 
 President and CEO 

Peptor Limited 
 Kiryat Weizmann 

Rehovot 76326 
 Dear Dr. Karmon, 

We acknowledge receipt of your letter to Mr. Shlomo Harel dated December 13, 1999. Hence, the Agreement between Yeda Research and
Development Co. Ltd. and Portman Pharmaceuticals Inc. dated January 12, 1994, supplemented in June 1996 (“the Agreements”) in respect of pharmaceutical compositions for prevention and/or treatment of pathological processes involving
induction of TNF-secretion, comprising a low dosage of a low molecular weight heparin, patent applications listed in Appendix 1 attached hereto and of compositions for the treatment of autoimmune diseases and prevention of graft rejection, patent
applications listed in Appendix 2 attached hereto (“the Areas”), terminated as of December 31, 1999 on terms and conditions of the Agreement, in respect thereof. 

 

					
	 [illegible]
	  		  	 /s/ Yorm Karmon

	YEDA RESEARCH AND	  		  	PEPTOR LTD.
	DEVELOPMENT CO. LTD.	  		  	

 ADDENDUM 

Entered into this 26 day of September 2000, by and between Yeda Research and Development Company Ltd. (“Yeda”) and Peptor
Ltd. (“Peptor”). 
 WHEREAS, Yeda and Portman Pharmaceuticals, Inc. and Portman Pharmaceutical Industries Ltd. (collectively
“Portman”) have executed a certain Research and Licence Agreement dated as of January 12, 1994 and amended on June 11, 1996 (the “R&L Agreement” and the “Amendment” respectively); and 

WHEREAS, Peptor and Portman have executed a Merger Agreement dated as of February 25, 1998 (the “Merger Agreement”); and 

WHEREAS, Peptor and Yeda have entered into an agreement dated as of April 29, 1998, in accordance with which Peptor replaced Portman as a
party to the R&L Agreement (the “Peptor-Yeda Agreement”); and 
 WHEREAS, the Additional Research period as defined and in
accordance with Section 8 of the R&L Agreement and Section 3 of the Amendment was concluded on December 31, 1999; and 
 WHEREAS,
the parties hereto wish to extend such research period in accordance with Section 2(a) of the R&L Agreement for an additional period of one (1) year (“the 2000 Research and 2000 Research Period”) all in accordance with
the terms and conditions set out below; 
 NOW, THEREFORE, in consideration of the mutual covenants and obligations herein made and undertaken, the
parties hereto do hereby agree as follows: 
  

	1	Interpretation and Definitions 

 Any terms which have not been defined in this
addendum (the “Addendum”) shall have the meanings attributed to them in the R&L Agreement and the Amendment. This Addendum and the R&L Agreement, and the Amendment shall be read as one and shall represent the complete current
understanding between the Parties with respect to the 2000 Research Period. Subject to the modification contained herein, the provisions of the R&L Agreement and the Amendment shall remain unaltered and in full force and effect. 

 All appendices attached hereto shall form an integral part of this Agreement. 

 

	2	Performance of Research 

  

	 	2.1	Yeda undertakes to procure the performance of additional research at the Institute under the supervision of Prof. Cohen in the fields of [*], and the use of peptides in vaccine technology (the
“Research”), all in accordance with the 2000 Research Programme attached hereto as Appendix —3, during a period of twelve (12) months, commencing on January 1, 2000 (“the 2000 Research Period”).

  

	 	2.2	The parties hereto may, however extend the term of this Addendum for two (2) additional periods of one (1) year under mutually agreeable written Research Programme and Research Budget.

  

	3.	Funding of the Research 

 In consideration of Yeda’s undertaking pursuant to
Section 2 above, Peptor undertakes to provide Yeda with US$ [*] ([*] United States Dollars) to be used for the financing of the Research in the installments set out in Exhibit B hereto. 

  
 [*] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 IN WITNESS HEREOF, the parties hereto have caused this Addendum to be executed by their respective duly
authorized representatives as set forth below. 
 Notwithstanding the date of signing hereof, this Agreement shall be valid and effective as of
January 1, 2000. 
  

									
	YEDA RESEARCH AND	 		 	PEPTOR LTD.
	DEVELOPMENT COMPANY, LTD	 		 	
					
	By:	 	 [illegible]
	 		 	By:	  	 /s/ Yoram Karmon

	Title:	 	Chairman	 		 	Title:	  	CEO

 SECOND ADDENDUM 

Entered into this 4th day of April 2001, by and between Yeda Research and Development Company Ltd. (“Yeda”) and Peptor
Ltd. (“Peptor”). 
 WHEREAS, Yeda and Portman Pharmaceuticals, Inc. and Portman Pharmaceutical Industries Ltd. (collectively
“Portman”) have executed a certain Research and Licence Agreement dated as of January 12, 1994 and amended on June 11, 1996 (the “R&L Agreement” and the “Amendment” respectively); and 

WHEREAS, Peptor and Portman have executed a Merger Agreement dated as of February 25, 1998 (the “Merger Agreement”); and 

WHEREAS, Peptor and Yeda have entered into an agreement dated as of April 29, 1998, in accordance with which Peptor replaced Portman as a
party to the R&L Agreement and the Amendment (the “Peptor-Yeda Agreement”); and 

WHEREAS, the Additional Research period as defined and in accordance with Section 8 of the R&L Agreement and Section 3 of the Amendment
was concluded on December 31, 1999; and 
 WHEREAS, the parties have extended the original research period in an Addendum signed on
September 26, 2000 (the “First Addendum”); and 
 WHEREAS, the parties hereto wish to extend such research period in accordance with
Section 2(a) of the R&L Agreement and Article 2.2 of the first Addendum for an additional period of one (1) year to extend until January 1, 2002 (“the 2001 Research and 2001 Research Period”) and in accordance with the
terms and conditions set out below;  

 NOW, THEREFORE, in consideration of the mutual covenants and obligations herein made and undertaken, the
parties hereto do hereby agree as follows: 
  

	1	Interpretation and Definitions 

 Any terms which have not been defined in this
addendum (the “Second Addendum”) shall have the meanings attributed to them in the R&L Agreement and the Amendment. This Second Addendum, the R&L Agreement, the Amendment and the First Addendum shall be read as one and shall
represent the complete current understanding between the Parties with respect to the 2001 Research Period. Subject to the modification contained herein, the provisions of the R&L Agreement, the Amendment and the First Addendum shall remain
unaltered and in full force and effect. 
 All appendices attached hereto shall form an integral part of this Agreement. 

 

	2	Performance of Research 

  

	 	2.1	Yeda undertakes to procure the performance of additional research at the Institute under the supervision of Prof. Cohen in the fields of [*], and the use of peptides in vaccine technology (the
“Research”), all in accordance with the 2001 Research Programme attached hereto as Exhibit A, during a period of twelve (12) months, commencing on January 1, 2001 (“the 2001 Research Period”).

  

	 	2.2	The parties hereto may, however extend the term of this Second Addendum for two (2) additional periods of one (1) year under mutually agreeable written Research Programme and Research Budget.

  

	3	Funding of the Research 

 In consideration of Yeda’s undertaking pursuant to
Section 2 above, Peptor undertakes to provide Yeda with US$ [*] ([*] United States Dollars) to be used for the financing of the Research in the installments set out in Exhibit B hereto. 

  
 [*] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 IN WITNESS HEREOF, the parties hereto have caused this Second Addendum to be executed by their respective duly
authorized representatives as set forth below. 
 Notwithstanding the date of signing hereof, this Agreement shall be valid and effective as of
January 1, 2001. 
  

									
	YEDA RESEARCH AND	 		  	PEPTOR LTD.
	DEVELOPMENT COMPANY, LTD	 		  		  	
					
	By:	 	 /s/ Dr. Issac Shariv
	 		  	By:	  	 /s/ Yoram Karmon

	Title:	 	CEO	 		  	Title:	  	CEO

 Exhibit A 

 September 21, 2004 

Ref. :09-1688-04-868 
 No. :58088

 Mr. Shaun Marcus 
 CEO 

DeveloGen Israel Ltd. (formerly Peptor Ltd) 
 Kiryat Weizmann 

Rehovot 76326 
 Dear Mr. Marcus, 

We acknowledge receipt of your letter to Dr. Shariv dated June 17, 2004. Hence, the Research and License Agreement between Yeda
Research and Development Co. Ltd. and Portman Pharmaceuticals Inc. (“Portman”) dated January 12, 1994 (the “R&L Agreement”), supplemented in June 1996, the Peptor Ltd. (“Peptor”) - Yeda Agreement dated
April 29, 1998 (according to which Peptor replaced Portman as a party to the R&L Agreement) and the addendums to the R&L Agreement dated September 26, 2000 and April 4, 2001 (Collectively the “Agreements”) in respect
only of the subject-matter specified in paragraph (3) to the first recital to the R&L Agreement “the Peptide Technology” (WO 94/03208 and WO 95/31994, Yeda References: 9248 and 9439; Peptor References: IC/005 and IC/006), as more
fully detailed in the patent and patent applications listed in Appendix 1 attached hereto (the “Area 3 Subject Matter”), is hereby terminated as of the date of this letter. Notwithstanding the aforesaid, the relevant terms and conditions
of the Agreements surviving termination of the Area 3 Subject Matter shall continue to apply in respect to the Area 3 Subject Matter. 
  

	
	 /s/ Dr. Isaac Shariv, CEO; /s/ Prof. Haim Garty, Chairman

	
	YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD.

 Agreed to and Accepted: 
  

	
	 /s/ Shawn Marcus, General Manager; [illegible], Director

	
	DEVELOGEN ISRAEL, LTD. (formerly Peptor Ltd.)

  

 Appendix 1 

PATENT CARD 
 9248

  

	Title:	CONJUGATES OF POORLY IMMUNOGENIC ANTIGENS AND SYNTHETIC PEPTIDE CARRIERS
AND VACCINES COMPRISING THEM 

  

	Inventors:	COHEN Irun R., FRIDKIN Matityahu, KONEN-WAISMAN Stephanie 

  

																	
	 Country
	  	 Application
	 	  	 Publication
	 	  	 Grant
	 	  	 Status
	 
	 ISRAEL
	  	 	30/07/1992 - 102687	  	  	 	10/06/1997 - 102687	  	  	 	11/09/1997 - 102687	  	  	 	Granted	  
	 PATENT COOPERATION TREATY
	  	 	28/07/1993 - PCT/US93/07096	  	  	 	17/02/1994 - WO 94/03208	  	  	 	—  	  	  	 	Published	  
	 AUSTRALIA
	  	 	28/07/1993 - 47900/93	  	  				  	 	05/03/1998 - 683421	  	  	 	Granted	  
	 BELGIUM
	  	 	28/07/1993 - 93918458.6	  	  	 	—  	  	  	 	12/01/2000 - 0 658 120	  	  	 	Granted	  
	 CANADA
	  	 	28/07/1993 - 2,141,454	  	  	 	—  	  	  	 	—  	  	  	 	Pending	  
	 EUROPEAN PATENT OFFICE
	  	 	28/07/1993 - 93918458.6	  	  	 	—  	  	  	 	12/01/2000 - 0 658 120	  	  	 	Granted	  
	 FRANCE
	  	 	28/07/1993 - 93918458.6	  	  	 	—  	  	  	 	12/01/2000 - 0 658 120	  	  	 	Granted	  
	 GERMANY
	  	 	28/07/1993 - 93918458.6	  	  	 	—  	  	  	 	12/01/2000 - 0 658 120	  	  	 	Granted	  
	 HUNGARY
	  	 	28/07/1993 - P9500270	  	  	 	28/11/1995 - P9500270	  	  	 	02/11/2000 - 218 425	  	  	 	Granted	  
	 IRELAND
	  	 	28/07/1993 - 93918458.6	  	  	 	—  	  	  	 	12/01/2000 - 0 658 120	  	  	 	Granted	  
	 ITALY
	  	 	28/07/1993 - 93918458.6	  	  	 	—  	  	  	 	12/01/2000 - 0 658 120	  	  	 	Granted	  
	 JAPAN
	  	 	28/07/1993 - 06-505410	  	  	 	—  	  	  	 	—  	  	  	 	Published	  
	 KOREA
	  	 	28/07/1993 - 700401/95	  	  	 	—  	  	  	 	05/03/2001 - 0290632	  	  	 	Granted	  
	 NEW ZEALAND
	  	 	28/07/1993 - 255143	  	  	 	—  	  	  	 	03/07/1996 - 255143	  	  	 	Granted	  
	 POLAND
	  	 	28/07/1993 - 307297	  	  	 	—  	  	  	 	15/10/1998 - 174082	  	  	 	Granted	  
	 RUSSIAN FEDERATION
	  	 	28/07/1993 - 95105991.00	  	  	 	27/02/1997 - 95105991/14	  	  	 	10/12/1999 - 2142291	  	  	 	Granted	  
	 SWITZERLAND
	  	 	28/07/1993 - 93918458.6	  	  	 	—  	  	  	 	12/01/2000 - 0 658 120	  	  	 	Granted	  
	 THE NETHERLANDS
	  	 	28/07/1993 - 93918458.6	  	  	 	—  	  	  	 	12/01/2000 - 0 658 120	  	  	 	Granted	  
	 U.S.A
	  	 	28/07/1993 - 08/379,613	  	  	 	—  	  	  	 	07/04/1998 - 5,736,146	  	  	 	Granted	  
	 UNITED KINGDOM
	  	 	28/07/1993 - 93918458.6	  	  	 	—  	  	  	 	12/01/2000 - 0 658 120	  	  	 	Granted	  

 PATENT CARD 

9439 
  

	Title:	PEPTIDES USED AS CARRIERS IN IMMUNOGENIC CONSTRUCTS SUITABLE FOR
DEVELOPMENT OF SYNTHETIC VACCINES 

  

	Inventors:	COHEN Irun R., FRIDKIN Matityahu, KONEN-WAISMAN Stephanie 

  

																	
	 Country
	  	 Application
	 	  	 Publication
	 	  	 Grant
	 	  	 Status
	 
	 ISRAEL
	  	 	25/05/1994 - 109790	  	  	 	—  	  	  	 	—  	  	  	 	Pending	  
	 PATENT COOPERATION TREATY
	  	 	25/05/1994 - PCT/US95/06575	  	  	 	30/11/1195 – WO 95/31994	  	  	 	—  	  	  	 	Published	  
	 AUSTRALIA
	  	 	25/05/1994 - 26027/95	  	  	 	—  	  	  	 	02/04/1998 - 684369	  	  	 	Granted	  
	 CANADA
	  	 	25/05/1994 - 2,191,202	  	  	 	—  	  	  	 	—  	  	  	 	Pending	  
	 EUROPEAN PATENT OFFICE
	  	 	25/05/1994 - 95920641.8	  	  	 	—  	  	  	 	—  	  	  	 	Pending	  
	 JAPAN
	  	 	25/05/1994 - 7-530530	  	  	 	—  	  	  	 	—  	  	  	 	Pending	  
	 U.S.A.
	  	 	25/11/1996 - 08/774,325	  	  				  	 
 	09/02/1999 –
5,869,058	  
  	  	 	Granted	  

 November 25, 2004 

Ref. :09-1688-04-880 
 No. :61739

 Mr. Shaun Marcus 
 CEO 

DeveloGen Israel Ltd. (formerly Peptor Ltd) 
 Kiryat
Weizmann 
 Rehovot 76326 
 Dear Mr. Marcus, 

We acknowledge receipt of Vered Hornik’s letter to Dr. Granoth dated October 27, 2004 informing us that Develogen Israel Ltd.
(“Develogen”) has decided to relinquish its license to the invention entitled: “METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE” (WO 02/16549, Yeda Reference: 2000-060; Develogen
Reference: IC/018), as more fully detailed in the patent applications listed in Appendix 1 attached hereto (the “Invention”). Hence, the Research and License Agreement between Yeda Research and Development Co. Ltd. and Portman
Pharmaceuticals Inc. (“Portman”) dated January 12, 1994 (the R&L Agreement”), supplemented in June 1996, the Peptor Ltd (“Peptor”) – Yeda Agreement dated April 29, 1998 (according to which Peptor replaced
Portman as a Party to the R&L Agreement) and the addendums to the R&L Agreement dated September 26, 2000 and April 4, 2001 (Collectively the “Agreements”) in respect only of the Invention and the enclosed patent
applications, is hereby terminated as of the date of this letter. Notwithstanding the aforesaid, the relevant terms and conditions of the Agreement surviving termination shall continue to apply in respect of the Invention. 

 

			
	 /s/ Dr. Isaac Shariv, CEO; /s/ Prof. Haim Garty, Chairman

	
	YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD.

 Agreed to and Accepted: 
  

			
	 /s/ Dr. Dana Elias, Vice President; /s/ Shawn Marcus, S.M.

	
	DEVELOGEN ISRAEL, LTD. (formerly Peptor Ltd.)

 APPENDIX 1 

PATENT CARD 

2000-060 
  

	Title:	METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE 

 

	Inventors:	COHEN Irun R., QUINTANA Francisco 

  

													
	 Country
	  	 Application
	  	 Publication
	  	
        Grant        
	 	  	
        Status        
	 
	 U.S.A
	  	25/08/2000 - 60/227,853	  	—  	  	 	—  	  	  	 	Expired	  
	 PATENT COOPERATION TREATY
	  	23/08/2001 - PCT/IL01/00790	  	28/02/2002 - WO 02/16549	  	 	—  	  	  	 	Published	  
	 AUSTRALIA
	  	23/08/2001 - 2001282475	  	—  	  	 	—  	  	  	 	Pending	  
	 CANADA
	  	23/08/2001 - 2,420,499	  	—  	  	 	—  	  	  	 	Pending	  
	 EUROPEAN PATENT OFFICE
	  	23/08/2001 - 01961097.1	  	—  	  	 	—  	  	  	 	Pending	  
	 ISRAEL
	  	23/08/2001 - 154557	  	—  	  	 	—  	  	  	 	Pending	  
	 JAPAN
	  	23/08/2001 - 521625/02	  	—  	  	 	—  	  	  	 	Pending	  
	 U.S.A
	  	23/08/2001 - 10/371,116	  	08/01/2004 - US-2004-0005588	  	 	—  	  	  	 	Published	  

 AMENDMENT TO RESEARCH AND LICENSE AGREEMENT 

This Amendment to Research and License Agreement (this “Amendment”) is entered into this 30th day of October, 2007 by and between
Yeda Research and Development Company Ltd. (“Yeda”) and Andromeda Biotech Ltd. (“Andromeda”). 
 WHEREAS, Yeda and
Andromeda are parties to a certain Research and License Agreement, dated January 12, 1994, as amended (the “R&L Agreement”); and 

WHEREAS, Yeda and Andromeda wish to amend the R&L Agreement, as set forth below: 

NOW, THEREFORE, it is agreed between the parties hereto as follows: 

1. The preamble to this Amendment constitutes an integral part hereof. 

2. All capitalized terms used herein and not otherwise defined shall have the dentitions given to them in the R&L Agreement. 

3. Section 7(d)(ii) of R&L Agreement shall be replaced in its entirety with the following: 

“In consideration for the License, the Corporation shall pay Yeda a royalty of [*]% ([*] percent) of all Net Sales (except on Net Sales
relating to Products in the Area of Peptide Technology, in respect of which the Corporation shall pay Yeda a royalty of [*]% ([*] percent)) and shall pay Yeda the Sublicense Royalty (as defined below) on all amounts received by the Corporation for
or from the grant of sublicenses and/or pursuant thereto except amounts so received and calculated on the basis of sales made by such Sublicenses (hereinafter “Sublicensing Receipts”). 

As used in this Section 7(d)(ii) the term “Sublicense Royalty” shall mean: 

(i) [*]% ([*] percent) effective immediately from the signature on this amendment. 

(ii) [*]% ([*] percent) if the sublicense is granted after the later of: (a) [*], or (b) the completion of [*]. 

 

	4.	All other terms and conditions of the R&L Agreement shall remain unchanged and in full force and effect. 

  
 [*] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first set forth above. 

 

									
	YEDA RESEARCH AND	  		  	PEPTOR LTD.
	DEVELOPMENT COMPANY, LTD	  		  	
					
	By:	  	 /s/ A. Narberg
	  		  	By:	  	 /s/ Shlomo Dagan

	Title:	  	CEO	  		  	Title:	  	CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]